Are you over 18 and want to see adult content?
More Annotations
A complete backup of greenwithindy.com
Are you over 18 and want to see adult content?
A complete backup of orkneyferries.co.uk
Are you over 18 and want to see adult content?
A complete backup of jovannysaul.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of jewishledger.com
Are you over 18 and want to see adult content?
A complete backup of en-eva-lopez.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of completecase.com
Are you over 18 and want to see adult content?
A complete backup of migliorpellet.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of machinerypark.com
Are you over 18 and want to see adult content?
A complete backup of huaweicentral.com
Are you over 18 and want to see adult content?
Text
months
GLYCOSYLATION AND ITS ROLE IN SARS-COV-2 VIRAL Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis Author: Meg Baker, PhD N-Glycosylation and COVID19 Glycobiology N-linked glycosylation (NLG) is a complex biosynthetic process that regulates proper folding of proteins through and intracellular transport of proteins to the secretory pathway. This co- and post-translational modification occurs by a series of enzymatic reactions, which MECHANISM OF THROMBOSIS WITH ASTRAZENECA AND J & J Mechanism of thrombosis with AstraZeneca and J & J vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD UPDATED on 4/15/2021 Atul Gawande@Atul_Gawande·15h Why wait for more info? A new case of cerebral sinus venus thrombosis was reported in a 25 year old man who became critically ill from a cerebral NATIONAL RESILIENCE, INC. IS A FIRST-OF-ITS-KIND National Resilience, Inc. is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption - the Acquisition of Two Premier Biologics Manufacturing Facilities: Boston and in Ontario, Canada Reporter: Aviva Lev-Ari, PhD, RN Resilience's new facility, located at 500 Soldiers Field DRUG DELIVERY PLATFORM TECHNOLOGY Dr. Hertz established the Radioactive Isotope Research Institute, in September, 1946 with a major focus on the use of fission products for the treatment of thyroid cancer, goiter, and other malignant tumors. Dr Samuel Seidlin was the Associate Director and managed the New YorkCity facilities.
MICROBIOME | LEADERS IN PHARMACEUTICAL BUSINESS Collectively, these microbes, known as the microbiome, outnumber the body’s human cells by about 10 to 1 and include more than 1,000 species of microorganisms and several million genes residing in the skin, respiratory system, urogenital, and gastrointestinal tracts. PHASE 1 CLINICAL TRIAL FAILURE What was the drug in Clinical Trial Tragedy In France Jan 2016. BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. The drug was developed to relieve pain, to ease mood and anxiety problems, and to improve movement coordination linked to ALVEOLAR-CAPILLARY INTERFACE Authors describe it as “a “lung-on-a-chip” that reconstituted the alveolar-capillary interface of the human lung and exposed it to physiological mechanical deformation and flow; in other words, it breathed rhythmically much like a living lung”. The model was developed by Hu et al and reported earlier in the journal Science in2010.
EVOLUTION OF MYOGLOBIN AND HEMOGLOBIN Evolution of Myoglobin / Hemoglobin Proteins. Primitive Globin – Very primitive animals had only a myoglobin-like, single-chain ancestral globin for oxygen storage and were so small that they did not require a transport protein. Roughly 500 million years ago the ancestral myoglobin gene was duplicated. CARDIOTOXICITY AND CARDIOMYOPATHY RELATED TO DRUGS ADVERSE Cardiotoxicity and Cardiomyopathy Related to Drugs Adverse Effects Curator: Larry H Bernstein, MD, FCAP Introduction This is the second part of a series on toxicities of therapeutic medications, the first being on the impact on drug development of early phase failure to identify toxicities that are found in late stage trials and result inwithdrawal.
APRIL | 2021 | LEADERS IN PHARMACEUTICAL BUSINESS Results. A total of 927,884 eligible echocardiograms were identified during the study period among 519,967 patients. Application of the final NLP algorithm classified 104,090 (11.2%) echocardiograms with any AS (mean age 75.2 years, 52% women), with only 67,297 (64.6%) having a diagnosis code for AS between 14 days before and up to 6months
GLYCOSYLATION AND ITS ROLE IN SARS-COV-2 VIRAL Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis Author: Meg Baker, PhD N-Glycosylation and COVID19 Glycobiology N-linked glycosylation (NLG) is a complex biosynthetic process that regulates proper folding of proteins through and intracellular transport of proteins to the secretory pathway. This co- and post-translational modification occurs by a series of enzymatic reactions, which MECHANISM OF THROMBOSIS WITH ASTRAZENECA AND J & J Mechanism of thrombosis with AstraZeneca and J & J vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD UPDATED on 4/15/2021 Atul Gawande@Atul_Gawande·15h Why wait for more info? A new case of cerebral sinus venus thrombosis was reported in a 25 year old man who became critically ill from a cerebral NATIONAL RESILIENCE, INC. IS A FIRST-OF-ITS-KIND National Resilience, Inc. is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption - the Acquisition of Two Premier Biologics Manufacturing Facilities: Boston and in Ontario, Canada Reporter: Aviva Lev-Ari, PhD, RN Resilience's new facility, located at 500 Soldiers Field DRUG DELIVERY PLATFORM TECHNOLOGY Dr. Hertz established the Radioactive Isotope Research Institute, in September, 1946 with a major focus on the use of fission products for the treatment of thyroid cancer, goiter, and other malignant tumors. Dr Samuel Seidlin was the Associate Director and managed the New YorkCity facilities.
MICROBIOME | LEADERS IN PHARMACEUTICAL BUSINESS Collectively, these microbes, known as the microbiome, outnumber the body’s human cells by about 10 to 1 and include more than 1,000 species of microorganisms and several million genes residing in the skin, respiratory system, urogenital, and gastrointestinal tracts. PHASE 1 CLINICAL TRIAL FAILURE What was the drug in Clinical Trial Tragedy In France Jan 2016. BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. The drug was developed to relieve pain, to ease mood and anxiety problems, and to improve movement coordination linked to ALVEOLAR-CAPILLARY INTERFACE Authors describe it as “a “lung-on-a-chip” that reconstituted the alveolar-capillary interface of the human lung and exposed it to physiological mechanical deformation and flow; in other words, it breathed rhythmically much like a living lung”. The model was developed by Hu et al and reported earlier in the journal Science in2010.
EVOLUTION OF MYOGLOBIN AND HEMOGLOBIN Evolution of Myoglobin / Hemoglobin Proteins. Primitive Globin – Very primitive animals had only a myoglobin-like, single-chain ancestral globin for oxygen storage and were so small that they did not require a transport protein. Roughly 500 million years ago the ancestral myoglobin gene was duplicated. CARDIOTOXICITY AND CARDIOMYOPATHY RELATED TO DRUGS ADVERSE Cardiotoxicity and Cardiomyopathy Related to Drugs Adverse Effects Curator: Larry H Bernstein, MD, FCAP Introduction This is the second part of a series on toxicities of therapeutic medications, the first being on the impact on drug development of early phase failure to identify toxicities that are found in late stage trials and result inwithdrawal.
2021 EMTECH NEXT
2021 EmTech Next AGENDA for June 19, 2021 Thursday, June 1011:30 AM EDT Reporter: Aviva Lev-Ari, PhD, RN HELP DESKHelp Desk OfficeHours11:30 AM –
DESPITE HEATED DISCUSSION OVER WHETHER IT WORKS, THE FDA Despite heated discussion over whether it works, the FDA has approved Aduhelm, bringing a new ray of hope to the Alzheimer's patients. Curator and Reporter: Dr. Premalata Pati, Ph.D., Postdoc On Monday, 7th June 2021, a controversial new Alzheimer's Disease treatment was licensed in the United States for the first time in nearly 20 years, CRYO-EM DISCLOSED HOW THE D614G MUTATION CHANGES SARS-COV Cryo-EM disclosed how the D614G mutation changes SARS-CoV-2 spike protein structure. Reporter: Dr. Premalata Pati, Ph.D., Postdoc SARS-CoV-2, the virus that causes COVID-19, has had a major impact on human health globally; infecting a massive quantity of people around 136,046,262 (John Hopkins University); causing severe disease and associated long-term health sequelae; resulting in SARS-COV2 HIJACKING THE COMPLEMENT AND COAGULATION SYSTEMS Emergence of a new SARS-CoV-2 variant from GR clade with a novel S glycoprotein mutation V1230L in West Bengal, India. Authors: Rakesh Sarkar, Ritubrita Saha, Pratik Mallick, Ranjana Sharma, Amandeep Kaur, Shanta Dutta, Mamta Chawla-Sarkar Reporter and Original Article Co-Author: Amandeep Kaur, B.Sc. , M.Sc. COMMENTS ON: EMERGENCE OF A NEW SARS-COV-2 VARIANT FROM GR Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal - http://PharmaceuticalIntelligence.com DRUG DELIVERY PLATFORM TECHNOLOGY Dr. Hertz established the Radioactive Isotope Research Institute, in September, 1946 with a major focus on the use of fission products for the treatment of thyroid cancer, goiter, and other malignant tumors. Dr Samuel Seidlin was the Associate Director and managed the New YorkCity facilities.
MICROBIOME | LEADERS IN PHARMACEUTICAL BUSINESS Collectively, these microbes, known as the microbiome, outnumber the body’s human cells by about 10 to 1 and include more than 1,000 species of microorganisms and several million genes residing in the skin, respiratory system, urogenital, and gastrointestinal tracts. BRADYKININ HYPOTHESIS: POTENTIAL EXPLANATION FOR COVID-19 Bradykinin Hypothesis: Potential Explanation for COVID-19 Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 9/14/2020 First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients BRACE CORONA trial presented in a Hot Line Session at ESC Congress 2020 September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin ALVEOLAR-CAPILLARY INTERFACE A revolutionary microchip-based human disease model for testing drugs. Reporter: Ritu Saxena, Ph.D. Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, have developed lung-on-a-microfluid chip and shown that it mimic human lung function in response to Interluekin-2 (IL-2) and mechanical strain.Authors describe it as “a “lung-on-a-chip STEROIDS, INFLAMMATION, AND CAR-T THERAPY Steroids, Inflammation, and CAR-T Therapy (UPDATED) Reporter: Stephen J. Williams, Ph.D. UPDATED: 08/31/2020 (CRISPR edited CAR-T clinical trials) Corticosteroids have been used as anticancer agents since the 1940s, with activity reported in a wide variety of solid tumors, including breast and prostate cancer, and the lymphoid hematologic malignancies. APRIL | 2021 | LEADERS IN PHARMACEUTICAL BUSINESS Results. A total of 927,884 eligible echocardiograms were identified during the study period among 519,967 patients. Application of the final NLP algorithm classified 104,090 (11.2%) echocardiograms with any AS (mean age 75.2 years, 52% women), with only 67,297 (64.6%) having a diagnosis code for AS between 14 days before and up to 6months
GLYCOSYLATION AND ITS ROLE IN SARS-COV-2 VIRAL Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis Author: Meg Baker, PhD N-Glycosylation and COVID19 Glycobiology N-linked glycosylation (NLG) is a complex biosynthetic process that regulates proper folding of proteins through and intracellular transport of proteins to the secretory pathway. This co- and post-translational modification occurs by a series of enzymatic reactions, which MECHANISM OF THROMBOSIS WITH ASTRAZENECA AND J & J Mechanism of thrombosis with AstraZeneca and J & J vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD UPDATED on 4/15/2021 Atul Gawande@Atul_Gawande·15h Why wait for more info? A new case of cerebral sinus venus thrombosis was reported in a 25 year old man who became critically ill from a cerebral BRADYKININ HYPOTHESIS: POTENTIAL EXPLANATION FOR COVID-19 Bradykinin Hypothesis: Potential Explanation for COVID-19 Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 9/14/2020 First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients BRACE CORONA trial presented in a Hot Line Session at ESC Congress 2020 September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin PHASE 1 CLINICAL TRIAL FAILURE What was the drug in Clinical Trial Tragedy In France Jan 2016. BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. The drug was developed to relieve pain, to ease mood and anxiety problems, and to improve movement coordination linked to EVOLUTION OF MYOGLOBIN AND HEMOGLOBIN Evolution of Myoglobin / Hemoglobin Proteins. Primitive Globin – Very primitive animals had only a myoglobin-like, single-chain ancestral globin for oxygen storage and were so small that they did not require a transport protein. Roughly 500 million years ago the ancestral myoglobin gene was duplicated. HALSTEDIAN MODEL OF CANCER PROGRESSION Halstedian model of cancer progression Writer and Curator: Larry H. Bernstein, MD, FCAP The Halstedian model of cancer progression is attributed to the meticulous care that William Halsted, Chairman of Surgery at the founding of the Johns Hopkins Medical School who in 1894 introduced “radical mastectomy” (1-3). This would be thestandard of care
CLINICALLY STUDIED, CONTINUOUS RELEASE AND ABSORPTION Novel delivery system in REMfresh mimics the way the body naturally releases and maintains melatonin over a 7-hour period Real-world evidence confirms previous clinical data on improved sleep duration and sleep quality with REMfresh Reporter: Gail S. Thornton, M.A. Chronic disorders of sleep and wakefulness affect an estimated 50-70 million adults in the United States. The PACEMAKERS, IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD The ‘Can‘ (metal box that contains all the circuitry and battery), is buried under the skin on the outside of the ribs. Put your arms down by your sides, the device would go where your ribs meet the middle of your bicep. A lead is then run under the skin to the centre of your chest where its is anchored and then north, under the skin again until the tip of the lead is roughly at the top of HELPING PHYSICIANS IDENTIFY GENE-DRUG INTERACTIONS FOR Reporter: Aviva Lev-Ari, PhD, RN Personalized Medicine Takes A Giant Step Forward At The Mount Sinai Medical Center New ‘CLIPMERGE’ program helps physicians identify gene-drug interactions to improve treatment decisions. NEW YORK – April 5, 2013 /Press Release/ –– Physicians and researchers at The Mount Sinai Medical Center will soon be utilizing a potentially revolutionary new APRIL | 2021 | LEADERS IN PHARMACEUTICAL BUSINESS Results. A total of 927,884 eligible echocardiograms were identified during the study period among 519,967 patients. Application of the final NLP algorithm classified 104,090 (11.2%) echocardiograms with any AS (mean age 75.2 years, 52% women), with only 67,297 (64.6%) having a diagnosis code for AS between 14 days before and up to 6months
GLYCOSYLATION AND ITS ROLE IN SARS-COV-2 VIRAL Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis Author: Meg Baker, PhD N-Glycosylation and COVID19 Glycobiology N-linked glycosylation (NLG) is a complex biosynthetic process that regulates proper folding of proteins through and intracellular transport of proteins to the secretory pathway. This co- and post-translational modification occurs by a series of enzymatic reactions, which MECHANISM OF THROMBOSIS WITH ASTRAZENECA AND J & J Mechanism of thrombosis with AstraZeneca and J & J vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD UPDATED on 4/15/2021 Atul Gawande@Atul_Gawande·15h Why wait for more info? A new case of cerebral sinus venus thrombosis was reported in a 25 year old man who became critically ill from a cerebral BRADYKININ HYPOTHESIS: POTENTIAL EXPLANATION FOR COVID-19 Bradykinin Hypothesis: Potential Explanation for COVID-19 Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 9/14/2020 First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients BRACE CORONA trial presented in a Hot Line Session at ESC Congress 2020 September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin PHASE 1 CLINICAL TRIAL FAILURE What was the drug in Clinical Trial Tragedy In France Jan 2016. BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. The drug was developed to relieve pain, to ease mood and anxiety problems, and to improve movement coordination linked to EVOLUTION OF MYOGLOBIN AND HEMOGLOBIN Evolution of Myoglobin / Hemoglobin Proteins. Primitive Globin – Very primitive animals had only a myoglobin-like, single-chain ancestral globin for oxygen storage and were so small that they did not require a transport protein. Roughly 500 million years ago the ancestral myoglobin gene was duplicated. HALSTEDIAN MODEL OF CANCER PROGRESSION Halstedian model of cancer progression Writer and Curator: Larry H. Bernstein, MD, FCAP The Halstedian model of cancer progression is attributed to the meticulous care that William Halsted, Chairman of Surgery at the founding of the Johns Hopkins Medical School who in 1894 introduced “radical mastectomy” (1-3). This would be thestandard of care
CLINICALLY STUDIED, CONTINUOUS RELEASE AND ABSORPTION Novel delivery system in REMfresh mimics the way the body naturally releases and maintains melatonin over a 7-hour period Real-world evidence confirms previous clinical data on improved sleep duration and sleep quality with REMfresh Reporter: Gail S. Thornton, M.A. Chronic disorders of sleep and wakefulness affect an estimated 50-70 million adults in the United States. The PACEMAKERS, IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD The ‘Can‘ (metal box that contains all the circuitry and battery), is buried under the skin on the outside of the ribs. Put your arms down by your sides, the device would go where your ribs meet the middle of your bicep. A lead is then run under the skin to the centre of your chest where its is anchored and then north, under the skin again until the tip of the lead is roughly at the top of HELPING PHYSICIANS IDENTIFY GENE-DRUG INTERACTIONS FOR Reporter: Aviva Lev-Ari, PhD, RN Personalized Medicine Takes A Giant Step Forward At The Mount Sinai Medical Center New ‘CLIPMERGE’ program helps physicians identify gene-drug interactions to improve treatment decisions. NEW YORK – April 5, 2013 /Press Release/ –– Physicians and researchers at The Mount Sinai Medical Center will soon be utilizing a potentially revolutionary new2021 EMTECH NEXT
2021 EmTech Next AGENDA for June 19, 2021 Thursday, June 1011:30 AM EDT Reporter: Aviva Lev-Ari, PhD, RN HELP DESKHelp Desk OfficeHours11:30 AM –
DESPITE HEATED DISCUSSION OVER WHETHER IT WORKS, THE FDA Despite heated discussion over whether it works, the FDA has approved Aduhelm, bringing a new ray of hope to the Alzheimer's patients. Curator and Reporter: Dr. Premalata Pati, Ph.D., Postdoc On Monday, 7th June 2021, a controversial new Alzheimer's Disease treatment was licensed in the United States for the first time in nearly 20 years, COMMENTS ON: EMERGENCE OF A NEW SARS-COV-2 VARIANT FROM GR Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal - http://PharmaceuticalIntelligence.com SARS-COV2 HIJACKING THE COMPLEMENT AND COAGULATION SYSTEMS Emergence of a new SARS-CoV-2 variant from GR clade with a novel S glycoprotein mutation V1230L in West Bengal, India. Authors: Rakesh Sarkar, Ritubrita Saha, Pratik Mallick, Ranjana Sharma, Amandeep Kaur, Shanta Dutta, Mamta Chawla-Sarkar Reporter and Original Article Co-Author: Amandeep Kaur, B.Sc. , M.Sc. BRADYKININ HYPOTHESIS: POTENTIAL EXPLANATION FOR COVID-19 Bradykinin Hypothesis: Potential Explanation for COVID-19 Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 9/14/2020 First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients BRACE CORONA trial presented in a Hot Line Session at ESC Congress 2020 September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin DRUG DELIVERY PLATFORM TECHNOLOGY Dr. Hertz established the Radioactive Isotope Research Institute, in September, 1946 with a major focus on the use of fission products for the treatment of thyroid cancer, goiter, and other malignant tumors. Dr Samuel Seidlin was the Associate Director and managed the New YorkCity facilities.
NAD-NADP TRANSHYDROGENASE Pentose Shunt, Electron Transfer, Galactose, more Lipids in brief. Reviewer and Curator: Larry H. Bernstein, MD, FCAP. Pentose Shunt, Electron Transfer, Galactose, and other Lipids in brief This is a continuation of the series of articles that spans the horizon of thegenetic
STEROIDS, INFLAMMATION, AND CAR-T THERAPY Steroids, Inflammation, and CAR-T Therapy (UPDATED) Reporter: Stephen J. Williams, Ph.D. UPDATED: 08/31/2020 (CRISPR edited CAR-T clinical trials) Corticosteroids have been used as anticancer agents since the 1940s, with activity reported in a wide variety of solid tumors, including breast and prostate cancer, and the lymphoid hematologic malignancies. CYTOSKELETON AND CELL MEMBRANE PHYSIOLOGY Cytoskeleton and Cell Membrane Physiology Curator: Larry H Bernstein, MD, FCAP Definition and Function The cytoskeleton is a series of intercellular proteins that help a cell with shape, support, and movement. Cytoskeleton has three main structural components: microfilaments, intermediate filaments, and movement The cytoskeleton mediates movement by helping the cell move CARDIOTOXICITY AND CARDIOMYOPATHY RELATED TO DRUGS ADVERSE Cardiotoxicity and Cardiomyopathy Related to Drugs Adverse Effects Curator: Larry H Bernstein, MD, FCAP Introduction This is the second part of a series on toxicities of therapeutic medications, the first being on the impact on drug development of early phase failure to identify toxicities that are found in late stage trials and result inwithdrawal.
APRIL | 2021 | LEADERS IN PHARMACEUTICAL BUSINESS Results. A total of 927,884 eligible echocardiograms were identified during the study period among 519,967 patients. Application of the final NLP algorithm classified 104,090 (11.2%) echocardiograms with any AS (mean age 75.2 years, 52% women), with only 67,297 (64.6%) having a diagnosis code for AS between 14 days before and up to 6months
GLYCOSYLATION AND ITS ROLE IN SARS-COV-2 VIRAL Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis Author: Meg Baker, PhD N-Glycosylation and COVID19 Glycobiology N-linked glycosylation (NLG) is a complex biosynthetic process that regulates proper folding of proteins through and intracellular transport of proteins to the secretory pathway. This co- and post-translational modification occurs by a series of enzymatic reactions, which MECHANISM OF THROMBOSIS WITH ASTRAZENECA AND J & J Mechanism of thrombosis with AstraZeneca and J & J vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD UPDATED on 4/15/2021 Atul Gawande@Atul_Gawande·15h Why wait for more info? A new case of cerebral sinus venus thrombosis was reported in a 25 year old man who became critically ill from a cerebral BRADYKININ HYPOTHESIS: POTENTIAL EXPLANATION FOR COVID-19 Bradykinin Hypothesis: Potential Explanation for COVID-19 Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 9/14/2020 First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients BRACE CORONA trial presented in a Hot Line Session at ESC Congress 2020 September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin PHASE 1 CLINICAL TRIAL FAILURE What was the drug in Clinical Trial Tragedy In France Jan 2016. BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. The drug was developed to relieve pain, to ease mood and anxiety problems, and to improve movement coordination linked to HALSTEDIAN MODEL OF CANCER PROGRESSION Halstedian model of cancer progression Writer and Curator: Larry H. Bernstein, MD, FCAP The Halstedian model of cancer progression is attributed to the meticulous care that William Halsted, Chairman of Surgery at the founding of the Johns Hopkins Medical School who in 1894 introduced “radical mastectomy” (1-3). This would be thestandard of care
STEROIDS, INFLAMMATION, AND CAR-T THERAPY Steroids, Inflammation, and CAR-T Therapy (UPDATED) Reporter: Stephen J. Williams, Ph.D. UPDATED: 08/31/2020 (CRISPR edited CAR-T clinical trials) Corticosteroids have been used as anticancer agents since the 1940s, with activity reported in a wide variety of solid tumors, including breast and prostate cancer, and the lymphoid hematologic malignancies. CLINICALLY STUDIED, CONTINUOUS RELEASE AND ABSORPTION Novel delivery system in REMfresh mimics the way the body naturally releases and maintains melatonin over a 7-hour period Real-world evidence confirms previous clinical data on improved sleep duration and sleep quality with REMfresh Reporter: Gail S. Thornton, M.A. Chronic disorders of sleep and wakefulness affect an estimated 50-70 million adults in the United States. The PACEMAKERS, IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD The ‘Can‘ (metal box that contains all the circuitry and battery), is buried under the skin on the outside of the ribs. Put your arms down by your sides, the device would go where your ribs meet the middle of your bicep. A lead is then run under the skin to the centre of your chest where its is anchored and then north, under the skin again until the tip of the lead is roughly at the top of HELPING PHYSICIANS IDENTIFY GENE-DRUG INTERACTIONS FOR Reporter: Aviva Lev-Ari, PhD, RN Personalized Medicine Takes A Giant Step Forward At The Mount Sinai Medical Center New ‘CLIPMERGE’ program helps physicians identify gene-drug interactions to improve treatment decisions. NEW YORK – April 5, 2013 /Press Release/ –– Physicians and researchers at The Mount Sinai Medical Center will soon be utilizing a potentially revolutionary new APRIL | 2021 | LEADERS IN PHARMACEUTICAL BUSINESS Results. A total of 927,884 eligible echocardiograms were identified during the study period among 519,967 patients. Application of the final NLP algorithm classified 104,090 (11.2%) echocardiograms with any AS (mean age 75.2 years, 52% women), with only 67,297 (64.6%) having a diagnosis code for AS between 14 days before and up to 6months
GLYCOSYLATION AND ITS ROLE IN SARS-COV-2 VIRAL Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis Author: Meg Baker, PhD N-Glycosylation and COVID19 Glycobiology N-linked glycosylation (NLG) is a complex biosynthetic process that regulates proper folding of proteins through and intracellular transport of proteins to the secretory pathway. This co- and post-translational modification occurs by a series of enzymatic reactions, which MECHANISM OF THROMBOSIS WITH ASTRAZENECA AND J & J Mechanism of thrombosis with AstraZeneca and J & J vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD UPDATED on 4/15/2021 Atul Gawande@Atul_Gawande·15h Why wait for more info? A new case of cerebral sinus venus thrombosis was reported in a 25 year old man who became critically ill from a cerebral BRADYKININ HYPOTHESIS: POTENTIAL EXPLANATION FOR COVID-19 Bradykinin Hypothesis: Potential Explanation for COVID-19 Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 9/14/2020 First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients BRACE CORONA trial presented in a Hot Line Session at ESC Congress 2020 September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin PHASE 1 CLINICAL TRIAL FAILURE What was the drug in Clinical Trial Tragedy In France Jan 2016. BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. The drug was developed to relieve pain, to ease mood and anxiety problems, and to improve movement coordination linked to HALSTEDIAN MODEL OF CANCER PROGRESSION Halstedian model of cancer progression Writer and Curator: Larry H. Bernstein, MD, FCAP The Halstedian model of cancer progression is attributed to the meticulous care that William Halsted, Chairman of Surgery at the founding of the Johns Hopkins Medical School who in 1894 introduced “radical mastectomy” (1-3). This would be thestandard of care
STEROIDS, INFLAMMATION, AND CAR-T THERAPY Steroids, Inflammation, and CAR-T Therapy (UPDATED) Reporter: Stephen J. Williams, Ph.D. UPDATED: 08/31/2020 (CRISPR edited CAR-T clinical trials) Corticosteroids have been used as anticancer agents since the 1940s, with activity reported in a wide variety of solid tumors, including breast and prostate cancer, and the lymphoid hematologic malignancies. CLINICALLY STUDIED, CONTINUOUS RELEASE AND ABSORPTION Novel delivery system in REMfresh mimics the way the body naturally releases and maintains melatonin over a 7-hour period Real-world evidence confirms previous clinical data on improved sleep duration and sleep quality with REMfresh Reporter: Gail S. Thornton, M.A. Chronic disorders of sleep and wakefulness affect an estimated 50-70 million adults in the United States. The PACEMAKERS, IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD The ‘Can‘ (metal box that contains all the circuitry and battery), is buried under the skin on the outside of the ribs. Put your arms down by your sides, the device would go where your ribs meet the middle of your bicep. A lead is then run under the skin to the centre of your chest where its is anchored and then north, under the skin again until the tip of the lead is roughly at the top of HELPING PHYSICIANS IDENTIFY GENE-DRUG INTERACTIONS FOR Reporter: Aviva Lev-Ari, PhD, RN Personalized Medicine Takes A Giant Step Forward At The Mount Sinai Medical Center New ‘CLIPMERGE’ program helps physicians identify gene-drug interactions to improve treatment decisions. NEW YORK – April 5, 2013 /Press Release/ –– Physicians and researchers at The Mount Sinai Medical Center will soon be utilizing a potentially revolutionary new2021 EMTECH NEXT
2021 EmTech Next AGENDA for June 19, 2021 Thursday, June 1011:30 AM EDT Reporter: Aviva Lev-Ari, PhD, RN HELP DESKHelp Desk OfficeHours11:30 AM –
DESPITE HEATED DISCUSSION OVER WHETHER IT WORKS, THE FDA Despite heated discussion over whether it works, the FDA has approved Aduhelm, bringing a new ray of hope to the Alzheimer's patients. Curator and Reporter: Dr. Premalata Pati, Ph.D., Postdoc On Monday, 7th June 2021, a controversial new Alzheimer's Disease treatment was licensed in the United States for the first time in nearly 20 years, FDA | LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE The Food and Drug Administration (FDA or Agency) plays a critical role in protecting the United States (U.S.) from threats including emerging infectious diseases, such as the Coronavirus Disease 2019 (COVID-19) pandemic. FDA is committed to providing timely guidance to support response efforts to this pandemic. COMMENTS ON: EMERGENCE OF A NEW SARS-COV-2 VARIANT FROM GR Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal - http://PharmaceuticalIntelligence.com SARS-COV2 HIJACKING THE COMPLEMENT AND COAGULATION SYSTEMS Emergence of a new SARS-CoV-2 variant from GR clade with a novel S glycoprotein mutation V1230L in West Bengal, India. Authors: Rakesh Sarkar, Ritubrita Saha, Pratik Mallick, Ranjana Sharma, Amandeep Kaur, Shanta Dutta, Mamta Chawla-Sarkar Reporter and Original Article Co-Author: Amandeep Kaur, B.Sc. , M.Sc. BRADYKININ HYPOTHESIS: POTENTIAL EXPLANATION FOR COVID-19 Bradykinin Hypothesis: Potential Explanation for COVID-19 Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 9/14/2020 First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients BRACE CORONA trial presented in a Hot Line Session at ESC Congress 2020 September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin DRUG DELIVERY PLATFORM TECHNOLOGY Dr. Hertz established the Radioactive Isotope Research Institute, in September, 1946 with a major focus on the use of fission products for the treatment of thyroid cancer, goiter, and other malignant tumors. Dr Samuel Seidlin was the Associate Director and managed the New YorkCity facilities.
NAD-NADP TRANSHYDROGENASE Pentose Shunt, Electron Transfer, Galactose, more Lipids in brief. Reviewer and Curator: Larry H. Bernstein, MD, FCAP. Pentose Shunt, Electron Transfer, Galactose, and other Lipids in brief This is a continuation of the series of articles that spans the horizon of thegenetic
EVOLUTION OF MYOGLOBIN AND HEMOGLOBIN Evolution of Myoglobin / Hemoglobin Proteins. Primitive Globin – Very primitive animals had only a myoglobin-like, single-chain ancestral globin for oxygen storage and were so small that they did not require a transport protein. Roughly 500 million years ago the ancestral myoglobin gene was duplicated. CARDIOTOXICITY AND CARDIOMYOPATHY RELATED TO DRUGS ADVERSE Cardiotoxicity and Cardiomyopathy Related to Drugs Adverse Effects Curator: Larry H Bernstein, MD, FCAP Introduction This is the second part of a series on toxicities of therapeutic medications, the first being on the impact on drug development of early phase failure to identify toxicities that are found in late stage trials and result inwithdrawal.
APRIL | 2021 | LEADERS IN PHARMACEUTICAL BUSINESS Linking Thrombotic Thrombocytopenia to ChAdOx1 nCov-19 Vaccination, AstraZeneca. Reporter: Aviva Lev-Ari, PhD, RN. UPDATED on 4/13/2021 “Right now, these adverse events appear to be extremely rare,” Anne Schuchat, MD, principal deputy director of the CDC, and Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research, said in a joint statement from the GLYCOSYLATION AND ITS ROLE IN SARS-COV-2 VIRAL Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis Author: Meg Baker, PhD N-Glycosylation and COVID19 Glycobiology N-linked glycosylation (NLG) is a complex biosynthetic process that regulates proper folding of proteins through and intracellular transport of proteins to the secretory pathway. This co- and post-translational modification occurs by a series of enzymatic reactions, which MECHANISM OF THROMBOSIS WITH ASTRAZENECA AND J & J Mechanism of thrombosis with AstraZeneca and J & J vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD UPDATED on 4/15/2021 Atul Gawande@Atul_Gawande·15h Why wait for more info? A new case of cerebral sinus venus thrombosis was reported in a 25 year old man who became critically ill from a cerebral BRADYKININ HYPOTHESIS: POTENTIAL EXPLANATION FOR COVID-19 Bradykinin Hypothesis: Potential Explanation for COVID-19 Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 9/14/2020 First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients BRACE CORONA trial presented in a Hot Line Session at ESC Congress 2020 September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin PHASE 1 CLINICAL TRIAL FAILUREBIA 10-2474.
3-(1-(cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-yl)pyridine 1-oxide. BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA.The drug was developed to relieve pain, to ease mood and anxiety problems, and to improve movement coordination linked to neurodegenerative illnesses. MANUFACTURING AND CONTROLS (CMC) Source: IMS Health (Midas). Biosimilars Drugs by US Sales – not included in the Top 100 Drug List Recombinate $2.9 1998 — Antihemophilic Factor VIII (Recombinant) by Baxter 5.7 Billion in 2012. Cerezyme $1.5 1994 — Gaucher disease and Fabrazyme for Fabry disease by Genzyme 200 millions in sales. TYSABRI(R) (natalizumab) revenues were $280 million, in-line with the second quarter of 2011 HALSTEDIAN MODEL OF CANCER PROGRESSION Halstedian model of cancer progression Writer and Curator: Larry H. Bernstein, MD, FCAP The Halstedian model of cancer progression is attributed to the meticulous care that William Halsted, Chairman of Surgery at the founding of the Johns Hopkins Medical School who in 1894 introduced “radical mastectomy” (1-3). This would be thestandard of care
STEROIDS, INFLAMMATION, AND CAR-T THERAPY Steroids, Inflammation, and CAR-T Therapy (UPDATED) Reporter: Stephen J. Williams, Ph.D. UPDATED: 08/31/2020 (CRISPR edited CAR-T clinical trials) Corticosteroids have been used as anticancer agents since the 1940s, with activity reported in a wide variety of solid tumors, including breast and prostate cancer, and the lymphoid hematologic malignancies. CLINICALLY STUDIED, CONTINUOUS RELEASE AND ABSORPTION Novel delivery system in REMfresh mimics the way the body naturally releases and maintains melatonin over a 7-hour period Real-world evidence confirms previous clinical data on improved sleep duration and sleep quality with REMfresh Reporter: Gail S. Thornton, M.A. Chronic disorders of sleep and wakefulness affect an estimated 50-70 million adults in the United States. The HELPING PHYSICIANS IDENTIFY GENE-DRUG INTERACTIONS FOR Reporter: Aviva Lev-Ari, PhD, RN Personalized Medicine Takes A Giant Step Forward At The Mount Sinai Medical Center New ‘CLIPMERGE’ program helps physicians identify gene-drug interactions to improve treatment decisions. NEW YORK – April 5, 2013 /Press Release/ –– Physicians and researchers at The Mount Sinai Medical Center will soon be utilizing a potentially revolutionary new APRIL | 2021 | LEADERS IN PHARMACEUTICAL BUSINESS Linking Thrombotic Thrombocytopenia to ChAdOx1 nCov-19 Vaccination, AstraZeneca. Reporter: Aviva Lev-Ari, PhD, RN. UPDATED on 4/13/2021 “Right now, these adverse events appear to be extremely rare,” Anne Schuchat, MD, principal deputy director of the CDC, and Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research, said in a joint statement from the GLYCOSYLATION AND ITS ROLE IN SARS-COV-2 VIRAL Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis Author: Meg Baker, PhD N-Glycosylation and COVID19 Glycobiology N-linked glycosylation (NLG) is a complex biosynthetic process that regulates proper folding of proteins through and intracellular transport of proteins to the secretory pathway. This co- and post-translational modification occurs by a series of enzymatic reactions, which MECHANISM OF THROMBOSIS WITH ASTRAZENECA AND J & J Mechanism of thrombosis with AstraZeneca and J & J vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD UPDATED on 4/15/2021 Atul Gawande@Atul_Gawande·15h Why wait for more info? A new case of cerebral sinus venus thrombosis was reported in a 25 year old man who became critically ill from a cerebral BRADYKININ HYPOTHESIS: POTENTIAL EXPLANATION FOR COVID-19 Bradykinin Hypothesis: Potential Explanation for COVID-19 Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 9/14/2020 First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients BRACE CORONA trial presented in a Hot Line Session at ESC Congress 2020 September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin PHASE 1 CLINICAL TRIAL FAILUREBIA 10-2474.
3-(1-(cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-yl)pyridine 1-oxide. BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA.The drug was developed to relieve pain, to ease mood and anxiety problems, and to improve movement coordination linked to neurodegenerative illnesses. MANUFACTURING AND CONTROLS (CMC) Source: IMS Health (Midas). Biosimilars Drugs by US Sales – not included in the Top 100 Drug List Recombinate $2.9 1998 — Antihemophilic Factor VIII (Recombinant) by Baxter 5.7 Billion in 2012. Cerezyme $1.5 1994 — Gaucher disease and Fabrazyme for Fabry disease by Genzyme 200 millions in sales. TYSABRI(R) (natalizumab) revenues were $280 million, in-line with the second quarter of 2011 HALSTEDIAN MODEL OF CANCER PROGRESSION Halstedian model of cancer progression Writer and Curator: Larry H. Bernstein, MD, FCAP The Halstedian model of cancer progression is attributed to the meticulous care that William Halsted, Chairman of Surgery at the founding of the Johns Hopkins Medical School who in 1894 introduced “radical mastectomy” (1-3). This would be thestandard of care
STEROIDS, INFLAMMATION, AND CAR-T THERAPY Steroids, Inflammation, and CAR-T Therapy (UPDATED) Reporter: Stephen J. Williams, Ph.D. UPDATED: 08/31/2020 (CRISPR edited CAR-T clinical trials) Corticosteroids have been used as anticancer agents since the 1940s, with activity reported in a wide variety of solid tumors, including breast and prostate cancer, and the lymphoid hematologic malignancies. CLINICALLY STUDIED, CONTINUOUS RELEASE AND ABSORPTION Novel delivery system in REMfresh mimics the way the body naturally releases and maintains melatonin over a 7-hour period Real-world evidence confirms previous clinical data on improved sleep duration and sleep quality with REMfresh Reporter: Gail S. Thornton, M.A. Chronic disorders of sleep and wakefulness affect an estimated 50-70 million adults in the United States. The HELPING PHYSICIANS IDENTIFY GENE-DRUG INTERACTIONS FOR Reporter: Aviva Lev-Ari, PhD, RN Personalized Medicine Takes A Giant Step Forward At The Mount Sinai Medical Center New ‘CLIPMERGE’ program helps physicians identify gene-drug interactions to improve treatment decisions. NEW YORK – April 5, 2013 /Press Release/ –– Physicians and researchers at The Mount Sinai Medical Center will soon be utilizing a potentially revolutionary new EMERGENCE OF A NEW SARS-COV-2 VARIANT FROM GR CLADE WITH A Emergence of a new SARS-CoV-2 variant from GR clade with a novel S glycoprotein mutation V1230L in West Bengal, India Authors: Rakesh Sarkar, Ritubrita Saha, Pratik Mallick, Ranjana Sharma, Amandeep Kaur, Shanta Dutta, Mamta Chawla-Sarkar Reporter: Amandeep Kaur, B.Sc. , M.Sc. AbstractSince its inception in late 2019, SARS-CoV-2 has evolved resulting in emergence of various PHARMACEUTICAL INNOVATION Recent Posts. Developing Machine Learning Models for Prediction of Onset of Type-2 Diabetes May 29, 2021; Renal tumor macrophages linked to recurrence are identified using single-cell protein activity analysis May 27, 2021; The collaboration between National Center for Advancing Translational Sciences (NCATS) at NIH and BurstIQ May 26, 2021; C.D.C. Reviewing Cases of Heart E-PROCEEDINGS FOR 2021 WORLD MEDICAL INNOVATION FORUM 2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021 The 2021 Virtual World Medical Innovation Forum will focus on the growing impact of gene and cell therapy. Senior healthcare leaders from all over look to shape and debate the area of gene and cell therapy. Our shared DRUG DELIVERY PLATFORM TECHNOLOGY EAW Name: Deepak Thassu, Category OWNER, Investigator Initiated Research Category Degree: M.Pharma, Ph.D (Phamaceutics) & MBA Specialty: Nanotechnology Drug Delivery, Pharmaceuticals, Medical Devices and Biologics E-Mail: drthassu@gmail.com Tel.Phone:585-820-9679 Affiliation: DrugDeliveryParticles Consultingand PharmaNova Inc
2021 MEDICAL TEXT ANALYSIS (NLP) The Eleuther project makes use of distributed computing resources, donated by cloud company CoreWeave as well as Google, through the TensorFlow Research Cloud, an initiative that makes spare computer power available, according to members of the project. To ease access to computer power, the Eleuther team created a way to split AI computations across multiple machines. CONFERENCE COVERAGE WITH SOCIAL MEDIA Posts about Conference Coverage with Social Media written by2012pharmaceutical
MANUFACTURING AND CONTROLS (CMC) 09/24/2010 – Drug-makers Amgen and Johnson & Johnson () are voluntarily recalling two brandsof an injectable anemia medication because vials containing the drug may have tiny glass flakes.The drug, Epoetin alfa, is marketed under the brand names Epogen and Procrit.Known as lamellae, the glass fragments are created by the interaction of the drug with glass vials during storage, Amgen said in STEROIDS, INFLAMMATION, AND CAR-T THERAPY Steroids, Inflammation, and CAR-T Therapy (UPDATED) Reporter: Stephen J. Williams, Ph.D. UPDATED: 08/31/2020 (CRISPR edited CAR-T clinical trials) Corticosteroids have been used as anticancer agents since the 1940s, with activity reported in a wide variety of solid tumors, including breast and prostate cancer, and the lymphoid hematologic malignancies. EVOLUTION OF MYOGLOBIN AND HEMOGLOBIN A history of duplication and divergence in multigene families makes it important to distinguish between two classes of related loci: those that represent the same locus in different species and between which divergence is a result of species divergence are orthologs. PRESERVED VS REDUCED EJECTION FRACTION: AVAILABLE AND Preserved vs Reduced Ejection Fraction: Available and Needed Therapies Reporter: Aviva Lev-Ari, PhD, RN Ejection Fraction Heart Failure Measurement Updated:Jul 9,2013 The ejection fraction (EF) is an important measurement in determining how well your heart is pumping out blood and in diagnosing and tracking heart failure. A significant proportion of patients with heart failure APRIL | 2021 | LEADERS IN PHARMACEUTICAL BUSINESS Results. A total of 927,884 eligible echocardiograms were identified during the study period among 519,967 patients. Application of the final NLP algorithm classified 104,090 (11.2%) echocardiograms with any AS (mean age 75.2 years, 52% women), with only 67,297 (64.6%) having a diagnosis code for AS between 14 days before and up to 6months
FDA | LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE The Food and Drug Administration (FDA or Agency) plays a critical role in protecting the United States (U.S.) from threats including emerging infectious diseases, such as the Coronavirus Disease 2019 (COVID-19) pandemic. FDA is committed to providing timely guidance to support response efforts to this pandemic. PHARMACEUTICAL INNOVATION Advinus Therapeutics, a research-based pharmaceutical company founded by globally experienced industry executives and promoted by the TATA Group, announced that it has successfully completed a 14-day POC study in 60 Type II diabetic patients on its lead molecule, GKM-001, a glucokinase activator.PLANT EXTRACT
Item Level of Evidence Available and Included in This Paper Recommendations for Patients Dietary pattern with added fats, fried food, eggs, organ and processed meats, and sugar-sweetened beverages (Southern diet pattern) Prospective studies Avoid Dietary cholesterol RCTs and prospective studies along with meta-analyses Limit Canola oil RCT meta-analyses show improvement in lipids but no MICROBIOME | LEADERS IN PHARMACEUTICAL BUSINESS Collectively, these microbes, known as the microbiome, outnumber the body’s human cells by about 10 to 1 and include more than 1,000 species of microorganisms and several million genes residing in the skin, respiratory system, urogenital, and gastrointestinal tracts. MANUFACTURING AND CONTROLS (CMC) Second-quarter net income surged 34 percent to $386.8 million, or $1.61 a share, from $288 million, or $1.18, a year earlier, the Weston, Massachusetts-based company said today in a statement. Earnings excluding some items of $1.82 topped by 26 cents the average of 21 analysts’ estimates ( PHASE 1 CLINICAL TRIAL FAILURE What was the drug in Clinical Trial Tragedy In France Jan 2016. BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. The drug was developed to relieve pain, to ease mood and anxiety problems, and to improve movement coordination linked to HALSTEDIAN MODEL OF CANCER PROGRESSION Halstedian model of cancer progression Writer and Curator: Larry H. Bernstein, MD, FCAP The Halstedian model of cancer progression is attributed to the meticulous care that William Halsted, Chairman of Surgery at the founding of the Johns Hopkins Medical School who in 1894 introduced “radical mastectomy” (1-3). This would be thestandard of care
STEROIDS, INFLAMMATION, AND CAR-T THERAPY Steroids, Inflammation, and CAR-T Therapy (UPDATED) Reporter: Stephen J. Williams, Ph.D. UPDATED: 08/31/2020 (CRISPR edited CAR-T clinical trials) Corticosteroids have been used as anticancer agents since the 1940s, with activity reported in a wide variety of solid tumors, including breast and prostate cancer, and the lymphoid hematologic malignancies. PACEMAKERS, IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD The ‘Can‘ (metal box that contains all the circuitry and battery), is buried under the skin on the outside of the ribs. Put your arms down by your sides, the device would go where your ribs meet the middle of your bicep. A lead is then run under the skin to the centre of your chest where its is anchored and then north, under the skin again until the tip of the lead is roughly at the top of APRIL | 2021 | LEADERS IN PHARMACEUTICAL BUSINESS Results. A total of 927,884 eligible echocardiograms were identified during the study period among 519,967 patients. Application of the final NLP algorithm classified 104,090 (11.2%) echocardiograms with any AS (mean age 75.2 years, 52% women), with only 67,297 (64.6%) having a diagnosis code for AS between 14 days before and up to 6months
FDA | LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE The Food and Drug Administration (FDA or Agency) plays a critical role in protecting the United States (U.S.) from threats including emerging infectious diseases, such as the Coronavirus Disease 2019 (COVID-19) pandemic. FDA is committed to providing timely guidance to support response efforts to this pandemic. PHARMACEUTICAL INNOVATION Advinus Therapeutics, a research-based pharmaceutical company founded by globally experienced industry executives and promoted by the TATA Group, announced that it has successfully completed a 14-day POC study in 60 Type II diabetic patients on its lead molecule, GKM-001, a glucokinase activator.PLANT EXTRACT
Item Level of Evidence Available and Included in This Paper Recommendations for Patients Dietary pattern with added fats, fried food, eggs, organ and processed meats, and sugar-sweetened beverages (Southern diet pattern) Prospective studies Avoid Dietary cholesterol RCTs and prospective studies along with meta-analyses Limit Canola oil RCT meta-analyses show improvement in lipids but no MICROBIOME | LEADERS IN PHARMACEUTICAL BUSINESS Collectively, these microbes, known as the microbiome, outnumber the body’s human cells by about 10 to 1 and include more than 1,000 species of microorganisms and several million genes residing in the skin, respiratory system, urogenital, and gastrointestinal tracts. MANUFACTURING AND CONTROLS (CMC) Second-quarter net income surged 34 percent to $386.8 million, or $1.61 a share, from $288 million, or $1.18, a year earlier, the Weston, Massachusetts-based company said today in a statement. Earnings excluding some items of $1.82 topped by 26 cents the average of 21 analysts’ estimates ( PHASE 1 CLINICAL TRIAL FAILURE What was the drug in Clinical Trial Tragedy In France Jan 2016. BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. The drug was developed to relieve pain, to ease mood and anxiety problems, and to improve movement coordination linked to HALSTEDIAN MODEL OF CANCER PROGRESSION Halstedian model of cancer progression Writer and Curator: Larry H. Bernstein, MD, FCAP The Halstedian model of cancer progression is attributed to the meticulous care that William Halsted, Chairman of Surgery at the founding of the Johns Hopkins Medical School who in 1894 introduced “radical mastectomy” (1-3). This would be thestandard of care
STEROIDS, INFLAMMATION, AND CAR-T THERAPY Steroids, Inflammation, and CAR-T Therapy (UPDATED) Reporter: Stephen J. Williams, Ph.D. UPDATED: 08/31/2020 (CRISPR edited CAR-T clinical trials) Corticosteroids have been used as anticancer agents since the 1940s, with activity reported in a wide variety of solid tumors, including breast and prostate cancer, and the lymphoid hematologic malignancies. PACEMAKERS, IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD The ‘Can‘ (metal box that contains all the circuitry and battery), is buried under the skin on the outside of the ribs. Put your arms down by your sides, the device would go where your ribs meet the middle of your bicep. A lead is then run under the skin to the centre of your chest where its is anchored and then north, under the skin again until the tip of the lead is roughly at the top of LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE (LPBI Developing Machine Learning Models for Prediction of Onset of Type-2 Diabetes. Reporter: Amandeep Kaur, B.Sc., M.Sc. A recent study reports the development of an advanced AI algorithm which predicts up to five years in advance the starting of type 2 diabetes by utilizing regularly collected medical data. PHARMACEUTICAL INNOVATION Advinus Therapeutics, a research-based pharmaceutical company founded by globally experienced industry executives and promoted by the TATA Group, announced that it has successfully completed a 14-day POC study in 60 Type II diabetic patients on its lead molecule, GKM-001, a glucokinase activator. GLYCOSYLATION AND ITS ROLE IN SARS-COV-2 VIRAL Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis Author: Meg Baker, PhD N-Glycosylation and COVID19 Glycobiology N-linked glycosylation (NLG) is a complex biosynthetic process that regulates proper folding of proteins through and intracellular transport of proteins to the secretory pathway. This co- and post-translational modification occurs by a series of enzymatic reactions, which MECHANISM OF THROMBOSIS WITH ASTRAZENECA AND J & J Mechanism of thrombosis with AstraZeneca and J & J vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD UPDATED on 4/15/2021 Atul Gawande@Atul_Gawande·15h Why wait for more info? A new case of cerebral sinus venus thrombosis was reported in a 25 year old man who became critically ill from a cerebral MICROBIOME | LEADERS IN PHARMACEUTICAL BUSINESS Collectively, these microbes, known as the microbiome, outnumber the body’s human cells by about 10 to 1 and include more than 1,000 species of microorganisms and several million genes residing in the skin, respiratory system, urogenital, and gastrointestinal tracts. GR CLADE | LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE Posts about GR clade written by Amandeep KaurCANCER METASTASIS
Leaders in Pharmaceutical Business Intelligence (LPBI) Group Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences BRADYKININ HYPOTHESIS: POTENTIAL EXPLANATION FOR COVID-19 Bradykinin Hypothesis: Potential Explanation for COVID-19 Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 9/14/2020 First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients BRACE CORONA trial presented in a Hot Line Session at ESC Congress 2020 September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensinINTRACELLULAR FLUX
Figure 2. Schematic of sampling and scoring analysis to determine intracellular flux changes. (A) Reaction fluxes are sampled for two conditions. (B & C) Sample of flux differences is calculated by selecting random flux values from each condition CONFERENCE COVERAGE WITH SOCIAL MEDIA Posts about Conference Coverage with Social Media written by2012pharmaceutical
APRIL | 2021 | LEADERS IN PHARMACEUTICAL BUSINESS Results. A total of 927,884 eligible echocardiograms were identified during the study period among 519,967 patients. Application of the final NLP algorithm classified 104,090 (11.2%) echocardiograms with any AS (mean age 75.2 years, 52% women), with only 67,297 (64.6%) having a diagnosis code for AS between 14 days before and up to 6months
FDA | LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE The Food and Drug Administration (FDA or Agency) plays a critical role in protecting the United States (U.S.) from threats including emerging infectious diseases, such as the Coronavirus Disease 2019 (COVID-19) pandemic. FDA is committed to providing timely guidance to support response efforts to this pandemic. PHARMACEUTICAL INNOVATION Advinus Therapeutics, a research-based pharmaceutical company founded by globally experienced industry executives and promoted by the TATA Group, announced that it has successfully completed a 14-day POC study in 60 Type II diabetic patients on its lead molecule, GKM-001, a glucokinase activator.PLANT EXTRACT
Item Level of Evidence Available and Included in This Paper Recommendations for Patients Dietary pattern with added fats, fried food, eggs, organ and processed meats, and sugar-sweetened beverages (Southern diet pattern) Prospective studies Avoid Dietary cholesterol RCTs and prospective studies along with meta-analyses Limit Canola oil RCT meta-analyses show improvement in lipids but no MICROBIOME | LEADERS IN PHARMACEUTICAL BUSINESS Collectively, these microbes, known as the microbiome, outnumber the body’s human cells by about 10 to 1 and include more than 1,000 species of microorganisms and several million genes residing in the skin, respiratory system, urogenital, and gastrointestinal tracts. MANUFACTURING AND CONTROLS (CMC) Second-quarter net income surged 34 percent to $386.8 million, or $1.61 a share, from $288 million, or $1.18, a year earlier, the Weston, Massachusetts-based company said today in a statement. Earnings excluding some items of $1.82 topped by 26 cents the average of 21 analysts’ estimates ( PHASE 1 CLINICAL TRIAL FAILURE What was the drug in Clinical Trial Tragedy In France Jan 2016. BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. The drug was developed to relieve pain, to ease mood and anxiety problems, and to improve movement coordination linked to HALSTEDIAN MODEL OF CANCER PROGRESSION Halstedian model of cancer progression Writer and Curator: Larry H. Bernstein, MD, FCAP The Halstedian model of cancer progression is attributed to the meticulous care that William Halsted, Chairman of Surgery at the founding of the Johns Hopkins Medical School who in 1894 introduced “radical mastectomy” (1-3). This would be thestandard of care
STEROIDS, INFLAMMATION, AND CAR-T THERAPY Steroids, Inflammation, and CAR-T Therapy (UPDATED) Reporter: Stephen J. Williams, Ph.D. UPDATED: 08/31/2020 (CRISPR edited CAR-T clinical trials) Corticosteroids have been used as anticancer agents since the 1940s, with activity reported in a wide variety of solid tumors, including breast and prostate cancer, and the lymphoid hematologic malignancies. PACEMAKERS, IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD The ‘Can‘ (metal box that contains all the circuitry and battery), is buried under the skin on the outside of the ribs. Put your arms down by your sides, the device would go where your ribs meet the middle of your bicep. A lead is then run under the skin to the centre of your chest where its is anchored and then north, under the skin again until the tip of the lead is roughly at the top of APRIL | 2021 | LEADERS IN PHARMACEUTICAL BUSINESS Results. A total of 927,884 eligible echocardiograms were identified during the study period among 519,967 patients. Application of the final NLP algorithm classified 104,090 (11.2%) echocardiograms with any AS (mean age 75.2 years, 52% women), with only 67,297 (64.6%) having a diagnosis code for AS between 14 days before and up to 6months
FDA | LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE The Food and Drug Administration (FDA or Agency) plays a critical role in protecting the United States (U.S.) from threats including emerging infectious diseases, such as the Coronavirus Disease 2019 (COVID-19) pandemic. FDA is committed to providing timely guidance to support response efforts to this pandemic. PHARMACEUTICAL INNOVATION Advinus Therapeutics, a research-based pharmaceutical company founded by globally experienced industry executives and promoted by the TATA Group, announced that it has successfully completed a 14-day POC study in 60 Type II diabetic patients on its lead molecule, GKM-001, a glucokinase activator.PLANT EXTRACT
Item Level of Evidence Available and Included in This Paper Recommendations for Patients Dietary pattern with added fats, fried food, eggs, organ and processed meats, and sugar-sweetened beverages (Southern diet pattern) Prospective studies Avoid Dietary cholesterol RCTs and prospective studies along with meta-analyses Limit Canola oil RCT meta-analyses show improvement in lipids but no MICROBIOME | LEADERS IN PHARMACEUTICAL BUSINESS Collectively, these microbes, known as the microbiome, outnumber the body’s human cells by about 10 to 1 and include more than 1,000 species of microorganisms and several million genes residing in the skin, respiratory system, urogenital, and gastrointestinal tracts. MANUFACTURING AND CONTROLS (CMC) Second-quarter net income surged 34 percent to $386.8 million, or $1.61 a share, from $288 million, or $1.18, a year earlier, the Weston, Massachusetts-based company said today in a statement. Earnings excluding some items of $1.82 topped by 26 cents the average of 21 analysts’ estimates ( PHASE 1 CLINICAL TRIAL FAILURE What was the drug in Clinical Trial Tragedy In France Jan 2016. BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. The drug was developed to relieve pain, to ease mood and anxiety problems, and to improve movement coordination linked to HALSTEDIAN MODEL OF CANCER PROGRESSION Halstedian model of cancer progression Writer and Curator: Larry H. Bernstein, MD, FCAP The Halstedian model of cancer progression is attributed to the meticulous care that William Halsted, Chairman of Surgery at the founding of the Johns Hopkins Medical School who in 1894 introduced “radical mastectomy” (1-3). This would be thestandard of care
STEROIDS, INFLAMMATION, AND CAR-T THERAPY Steroids, Inflammation, and CAR-T Therapy (UPDATED) Reporter: Stephen J. Williams, Ph.D. UPDATED: 08/31/2020 (CRISPR edited CAR-T clinical trials) Corticosteroids have been used as anticancer agents since the 1940s, with activity reported in a wide variety of solid tumors, including breast and prostate cancer, and the lymphoid hematologic malignancies. PACEMAKERS, IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD The ‘Can‘ (metal box that contains all the circuitry and battery), is buried under the skin on the outside of the ribs. Put your arms down by your sides, the device would go where your ribs meet the middle of your bicep. A lead is then run under the skin to the centre of your chest where its is anchored and then north, under the skin again until the tip of the lead is roughly at the top of LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE (LPBI Developing Machine Learning Models for Prediction of Onset of Type-2 Diabetes. Reporter: Amandeep Kaur, B.Sc., M.Sc. A recent study reports the development of an advanced AI algorithm which predicts up to five years in advance the starting of type 2 diabetes by utilizing regularly collected medical data. PHARMACEUTICAL INNOVATION Advinus Therapeutics, a research-based pharmaceutical company founded by globally experienced industry executives and promoted by the TATA Group, announced that it has successfully completed a 14-day POC study in 60 Type II diabetic patients on its lead molecule, GKM-001, a glucokinase activator. GLYCOSYLATION AND ITS ROLE IN SARS-COV-2 VIRAL Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis Author: Meg Baker, PhD N-Glycosylation and COVID19 Glycobiology N-linked glycosylation (NLG) is a complex biosynthetic process that regulates proper folding of proteins through and intracellular transport of proteins to the secretory pathway. This co- and post-translational modification occurs by a series of enzymatic reactions, which MECHANISM OF THROMBOSIS WITH ASTRAZENECA AND J & J Mechanism of thrombosis with AstraZeneca and J & J vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD UPDATED on 4/15/2021 Atul Gawande@Atul_Gawande·15h Why wait for more info? A new case of cerebral sinus venus thrombosis was reported in a 25 year old man who became critically ill from a cerebral MICROBIOME | LEADERS IN PHARMACEUTICAL BUSINESS Collectively, these microbes, known as the microbiome, outnumber the body’s human cells by about 10 to 1 and include more than 1,000 species of microorganisms and several million genes residing in the skin, respiratory system, urogenital, and gastrointestinal tracts. GR CLADE | LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE Posts about GR clade written by Amandeep KaurCANCER METASTASIS
Leaders in Pharmaceutical Business Intelligence (LPBI) Group Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences BRADYKININ HYPOTHESIS: POTENTIAL EXPLANATION FOR COVID-19 Bradykinin Hypothesis: Potential Explanation for COVID-19 Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 9/14/2020 First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients BRACE CORONA trial presented in a Hot Line Session at ESC Congress 2020 September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensinINTRACELLULAR FLUX
Figure 2. Schematic of sampling and scoring analysis to determine intracellular flux changes. (A) Reaction fluxes are sampled for two conditions. (B & C) Sample of flux differences is calculated by selecting random flux values from each condition CONFERENCE COVERAGE WITH SOCIAL MEDIA Posts about Conference Coverage with Social Media written by2012pharmaceutical
APRIL | 2021 | LEADERS IN PHARMACEUTICAL BUSINESS Results. A total of 927,884 eligible echocardiograms were identified during the study period among 519,967 patients. Application of the final NLP algorithm classified 104,090 (11.2%) echocardiograms with any AS (mean age 75.2 years, 52% women), with only 67,297 (64.6%) having a diagnosis code for AS between 14 days before and up to 6months
FDA | LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE The Food and Drug Administration (FDA or Agency) plays a critical role in protecting the United States (U.S.) from threats including emerging infectious diseases, such as the Coronavirus Disease 2019 (COVID-19) pandemic. FDA is committed to providing timely guidance to support response efforts to this pandemic. PHARMACEUTICAL INNOVATION Advinus Therapeutics, a research-based pharmaceutical company founded by globally experienced industry executives and promoted by the TATA Group, announced that it has successfully completed a 14-day POC study in 60 Type II diabetic patients on its lead molecule, GKM-001, a glucokinase activator.PLANT EXTRACT
Item Level of Evidence Available and Included in This Paper Recommendations for Patients Dietary pattern with added fats, fried food, eggs, organ and processed meats, and sugar-sweetened beverages (Southern diet pattern) Prospective studies Avoid Dietary cholesterol RCTs and prospective studies along with meta-analyses Limit Canola oil RCT meta-analyses show improvement in lipids but no MICROBIOME | LEADERS IN PHARMACEUTICAL BUSINESS Collectively, these microbes, known as the microbiome, outnumber the body’s human cells by about 10 to 1 and include more than 1,000 species of microorganisms and several million genes residing in the skin, respiratory system, urogenital, and gastrointestinal tracts. MANUFACTURING AND CONTROLS (CMC) Second-quarter net income surged 34 percent to $386.8 million, or $1.61 a share, from $288 million, or $1.18, a year earlier, the Weston, Massachusetts-based company said today in a statement. Earnings excluding some items of $1.82 topped by 26 cents the average of 21 analysts’ estimates ( PHASE 1 CLINICAL TRIAL FAILURE What was the drug in Clinical Trial Tragedy In France Jan 2016. BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. The drug was developed to relieve pain, to ease mood and anxiety problems, and to improve movement coordination linked to HALSTEDIAN MODEL OF CANCER PROGRESSION Halstedian model of cancer progression Writer and Curator: Larry H. Bernstein, MD, FCAP The Halstedian model of cancer progression is attributed to the meticulous care that William Halsted, Chairman of Surgery at the founding of the Johns Hopkins Medical School who in 1894 introduced “radical mastectomy” (1-3). This would be thestandard of care
STEROIDS, INFLAMMATION, AND CAR-T THERAPY Steroids, Inflammation, and CAR-T Therapy (UPDATED) Reporter: Stephen J. Williams, Ph.D. UPDATED: 08/31/2020 (CRISPR edited CAR-T clinical trials) Corticosteroids have been used as anticancer agents since the 1940s, with activity reported in a wide variety of solid tumors, including breast and prostate cancer, and the lymphoid hematologic malignancies. PACEMAKERS, IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD The ‘Can‘ (metal box that contains all the circuitry and battery), is buried under the skin on the outside of the ribs. Put your arms down by your sides, the device would go where your ribs meet the middle of your bicep. A lead is then run under the skin to the centre of your chest where its is anchored and then north, under the skin again until the tip of the lead is roughly at the top of APRIL | 2021 | LEADERS IN PHARMACEUTICAL BUSINESS Results. A total of 927,884 eligible echocardiograms were identified during the study period among 519,967 patients. Application of the final NLP algorithm classified 104,090 (11.2%) echocardiograms with any AS (mean age 75.2 years, 52% women), with only 67,297 (64.6%) having a diagnosis code for AS between 14 days before and up to 6months
FDA | LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE The Food and Drug Administration (FDA or Agency) plays a critical role in protecting the United States (U.S.) from threats including emerging infectious diseases, such as the Coronavirus Disease 2019 (COVID-19) pandemic. FDA is committed to providing timely guidance to support response efforts to this pandemic. PHARMACEUTICAL INNOVATION Advinus Therapeutics, a research-based pharmaceutical company founded by globally experienced industry executives and promoted by the TATA Group, announced that it has successfully completed a 14-day POC study in 60 Type II diabetic patients on its lead molecule, GKM-001, a glucokinase activator.PLANT EXTRACT
Item Level of Evidence Available and Included in This Paper Recommendations for Patients Dietary pattern with added fats, fried food, eggs, organ and processed meats, and sugar-sweetened beverages (Southern diet pattern) Prospective studies Avoid Dietary cholesterol RCTs and prospective studies along with meta-analyses Limit Canola oil RCT meta-analyses show improvement in lipids but no MICROBIOME | LEADERS IN PHARMACEUTICAL BUSINESS Collectively, these microbes, known as the microbiome, outnumber the body’s human cells by about 10 to 1 and include more than 1,000 species of microorganisms and several million genes residing in the skin, respiratory system, urogenital, and gastrointestinal tracts. MANUFACTURING AND CONTROLS (CMC) Second-quarter net income surged 34 percent to $386.8 million, or $1.61 a share, from $288 million, or $1.18, a year earlier, the Weston, Massachusetts-based company said today in a statement. Earnings excluding some items of $1.82 topped by 26 cents the average of 21 analysts’ estimates ( PHASE 1 CLINICAL TRIAL FAILURE What was the drug in Clinical Trial Tragedy In France Jan 2016. BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. The drug was developed to relieve pain, to ease mood and anxiety problems, and to improve movement coordination linked to HALSTEDIAN MODEL OF CANCER PROGRESSION Halstedian model of cancer progression Writer and Curator: Larry H. Bernstein, MD, FCAP The Halstedian model of cancer progression is attributed to the meticulous care that William Halsted, Chairman of Surgery at the founding of the Johns Hopkins Medical School who in 1894 introduced “radical mastectomy” (1-3). This would be thestandard of care
STEROIDS, INFLAMMATION, AND CAR-T THERAPY Steroids, Inflammation, and CAR-T Therapy (UPDATED) Reporter: Stephen J. Williams, Ph.D. UPDATED: 08/31/2020 (CRISPR edited CAR-T clinical trials) Corticosteroids have been used as anticancer agents since the 1940s, with activity reported in a wide variety of solid tumors, including breast and prostate cancer, and the lymphoid hematologic malignancies. PACEMAKERS, IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD The ‘Can‘ (metal box that contains all the circuitry and battery), is buried under the skin on the outside of the ribs. Put your arms down by your sides, the device would go where your ribs meet the middle of your bicep. A lead is then run under the skin to the centre of your chest where its is anchored and then north, under the skin again until the tip of the lead is roughly at the top of LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE (LPBI Developing Machine Learning Models for Prediction of Onset of Type-2 Diabetes. Reporter: Amandeep Kaur, B.Sc., M.Sc. A recent study reports the development of an advanced AI algorithm which predicts up to five years in advance the starting of type 2 diabetes by utilizing regularly collected medical data. PHARMACEUTICAL INNOVATION Advinus Therapeutics, a research-based pharmaceutical company founded by globally experienced industry executives and promoted by the TATA Group, announced that it has successfully completed a 14-day POC study in 60 Type II diabetic patients on its lead molecule, GKM-001, a glucokinase activator. GLYCOSYLATION AND ITS ROLE IN SARS-COV-2 VIRAL Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis Author: Meg Baker, PhD N-Glycosylation and COVID19 Glycobiology N-linked glycosylation (NLG) is a complex biosynthetic process that regulates proper folding of proteins through and intracellular transport of proteins to the secretory pathway. This co- and post-translational modification occurs by a series of enzymatic reactions, which MECHANISM OF THROMBOSIS WITH ASTRAZENECA AND J & J Mechanism of thrombosis with AstraZeneca and J & J vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD UPDATED on 4/15/2021 Atul Gawande@Atul_Gawande·15h Why wait for more info? A new case of cerebral sinus venus thrombosis was reported in a 25 year old man who became critically ill from a cerebral MICROBIOME | LEADERS IN PHARMACEUTICAL BUSINESS Collectively, these microbes, known as the microbiome, outnumber the body’s human cells by about 10 to 1 and include more than 1,000 species of microorganisms and several million genes residing in the skin, respiratory system, urogenital, and gastrointestinal tracts. GR CLADE | LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE Posts about GR clade written by Amandeep KaurCANCER METASTASIS
Leaders in Pharmaceutical Business Intelligence (LPBI) Group Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences BRADYKININ HYPOTHESIS: POTENTIAL EXPLANATION FOR COVID-19 Bradykinin Hypothesis: Potential Explanation for COVID-19 Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 9/14/2020 First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients BRACE CORONA trial presented in a Hot Line Session at ESC Congress 2020 September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensinINTRACELLULAR FLUX
Figure 2. Schematic of sampling and scoring analysis to determine intracellular flux changes. (A) Reaction fluxes are sampled for two conditions. (B & C) Sample of flux differences is calculated by selecting random flux values from each condition CONFERENCE COVERAGE WITH SOCIAL MEDIA Posts about Conference Coverage with Social Media written by2012pharmaceutical
APRIL | 2021 | LEADERS IN PHARMACEUTICAL BUSINESS Linking Thrombotic Thrombocytopenia to ChAdOx1 nCov-19 Vaccination, AstraZeneca. Reporter: Aviva Lev-Ari, PhD, RN. UPDATED on 4/13/2021 “Right now, these adverse events appear to be extremely rare,” Anne Schuchat, MD, principal deputy director of the CDC, and Peter Marks, MD, PhD, director of the FDA’s Center for Biologics Evaluation and Research, said in a joint statement from the PHARMACEUTICAL INNOVATION Recent Posts. Developing Machine Learning Models for Prediction of Onset of Type-2 Diabetes May 29, 2021; Renal tumor macrophages linked to recurrence are identified using single-cell protein activity analysis May 27, 2021; The collaboration between National Center for Advancing Translational Sciences (NCATS) at NIH and BurstIQ May 26, 2021; C.D.C. Reviewing Cases of Heart FDA | LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE Multiple Barriers Identified Which May Hamper Use of Artificial Intelligence in the Clinical Setting. Reporter: Stephen J. Williams, PhD. From the Journal Science: Science 21 Jun 2019: Vol. 364, Issue 6446, pp. 1119-1120. By Jennifer Couzin-Frankel. 3.3.21 Multiple Barriers Identified Which May Hamper Use of Artificial Intelligence in the Clinical Setting, Volume 2 (Volume Two: Latest in MANUFACTURING AND CONTROLS (CMC) Source: IMS Health (Midas). Biosimilars Drugs by US Sales – not included in the Top 100 Drug List Recombinate $2.9 1998 — Antihemophilic Factor VIII (Recombinant) by Baxter 5.7 Billion in 2012. Cerezyme $1.5 1994 — Gaucher disease and Fabrazyme for Fabry disease by Genzyme 200 millions in sales. TYSABRI(R) (natalizumab) revenues were $280 million, in-line with the second quarter of 2011PLANT EXTRACT
Item Level of Evidence Available and Included in This Paper Recommendations for Patients Dietary pattern with added fats, fried food, eggs, organ and processed meats, and sugar-sweetened beverages (Southern diet pattern) Prospective studies Avoid Dietary cholesterol RCTs and prospective studies along with meta-analyses Limit Canola oil RCT meta-analyses show improvement in lipids but no MICROBIOME | LEADERS IN PHARMACEUTICAL BUSINESS In the systematic review, observational data showed a 15% to 30% decline in cardiovascular-related death, all-cause mortality, and incidence of stroke, coronary heart disease, type 2 diabetes, and colorectal cancer among people who consumed the most dietary fiber compared to those consuming the lowest amounts. Whole grain intake yielded similar findings. HNPCC | LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE New Generation of Platinated Compounds to Circumvent Resistance. Curator/Writer: Stephen J. Williams, Ph.D. Resistance to chemotherapeutic drugs continues to be a major hurdle in the treatment of neoplastic disorders, irregardless if the drug is a member of the cytotoxic “older” drugs or the cytostatic “newer” personalized therapies like the tyrosine kinase inhibitors. PHASE 1 CLINICAL TRIAL FAILUREBIA 10-2474.
3-(1-(cyclohexyl(methyl)carbamoyl)-1H-imidazol-4-yl)pyridine 1-oxide. BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA.The drug was developed to relieve pain, to ease mood and anxiety problems, and to improve movement coordination linked to neurodegenerative illnesses. HALSTEDIAN MODEL OF CANCER PROGRESSION Halstedian model of cancer progression Writer and Curator: Larry H. Bernstein, MD, FCAP The Halstedian model of cancer progression is attributed to the meticulous care that William Halsted, Chairman of Surgery at the founding of the Johns Hopkins Medical School who in 1894 introduced “radical mastectomy” (1-3). This would be thestandard of care
PACEMAKERS, IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD The ‘Can‘ (metal box that contains all the circuitry and battery), is buried under the skin on the outside of the ribs. Put your arms down by your sides, the device would go where your ribs meet the middle of your bicep. A lead is then run under the skin to the centre of your chest where its is anchored and then north, under the skin again until the tip of the lead is roughly at the top of APRIL | 2021 | LEADERS IN PHARMACEUTICAL BUSINESS Results. A total of 927,884 eligible echocardiograms were identified during the study period among 519,967 patients. Application of the final NLP algorithm classified 104,090 (11.2%) echocardiograms with any AS (mean age 75.2 years, 52% women), with only 67,297 (64.6%) having a diagnosis code for AS between 14 days before and up to 6months
FDA | LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE The Food and Drug Administration (FDA or Agency) plays a critical role in protecting the United States (U.S.) from threats including emerging infectious diseases, such as the Coronavirus Disease 2019 (COVID-19) pandemic. FDA is committed to providing timely guidance to support response efforts to this pandemic. PHARMACEUTICAL INNOVATION Advinus Therapeutics, a research-based pharmaceutical company founded by globally experienced industry executives and promoted by the TATA Group, announced that it has successfully completed a 14-day POC study in 60 Type II diabetic patients on its lead molecule, GKM-001, a glucokinase activator. MICROBIOME | LEADERS IN PHARMACEUTICAL BUSINESS Collectively, these microbes, known as the microbiome, outnumber the body’s human cells by about 10 to 1 and include more than 1,000 species of microorganisms and several million genes residing in the skin, respiratory system, urogenital, and gastrointestinal tracts.PLANT EXTRACT
Item Level of Evidence Available and Included in This Paper Recommendations for Patients Dietary pattern with added fats, fried food, eggs, organ and processed meats, and sugar-sweetened beverages (Southern diet pattern) Prospective studies Avoid Dietary cholesterol RCTs and prospective studies along with meta-analyses Limit Canola oil RCT meta-analyses show improvement in lipids but no HNPCC | LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE New Generation of Platinated Compounds to Circumvent Resistance. Curator/Writer: Stephen J. Williams, Ph.D. Resistance to chemotherapeutic drugs continues to be a major hurdle in the treatment of neoplastic disorders, irregardless if the drug is a member of the cytotoxic “older” drugs or the cytostatic “newer” personalized therapies like the tyrosine kinase inhibitors. MANUFACTURING AND CONTROLS (CMC) Second-quarter net income surged 34 percent to $386.8 million, or $1.61 a share, from $288 million, or $1.18, a year earlier, the Weston, Massachusetts-based company said today in a statement. Earnings excluding some items of $1.82 topped by 26 cents the average of 21 analysts’ estimates ( PHASE 1 CLINICAL TRIAL FAILURE What was the drug in Clinical Trial Tragedy In France Jan 2016. BIA 10-2474 is an experimental fatty acid amide hydrolase inhibitor developed by the Portuguese pharmaceutical company Bial-Portela & Ca. SA. The drug was developed to relieve pain, to ease mood and anxiety problems, and to improve movement coordination linked to HALSTEDIAN MODEL OF CANCER PROGRESSION Halstedian model of cancer progression Writer and Curator: Larry H. Bernstein, MD, FCAP The Halstedian model of cancer progression is attributed to the meticulous care that William Halsted, Chairman of Surgery at the founding of the Johns Hopkins Medical School who in 1894 introduced “radical mastectomy” (1-3). This would be thestandard of care
PACEMAKERS, IMPLANTABLE CARDIOVERTER DEFIBRILLATORS (ICD The ‘Can‘ (metal box that contains all the circuitry and battery), is buried under the skin on the outside of the ribs. Put your arms down by your sides, the device would go where your ribs meet the middle of your bicep. A lead is then run under the skin to the centre of your chest where its is anchored and then north, under the skin again until the tip of the lead is roughly at the top of LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE (LPBI Developing Machine Learning Models for Prediction of Onset of Type-2 Diabetes. Reporter: Amandeep Kaur, B.Sc., M.Sc. A recent study reports the development of an advanced AI algorithm which predicts up to five years in advance the starting of type 2 diabetes by utilizing regularly collected medical data. PHARMACEUTICAL INNOVATION Recent Posts. Developing Machine Learning Models for Prediction of Onset of Type-2 Diabetes May 29, 2021; Renal tumor macrophages linked to recurrence are identified using single-cell protein activity analysis May 27, 2021; The collaboration between National Center for Advancing Translational Sciences (NCATS) at NIH and BurstIQ May 26, 2021; C.D.C. Reviewing Cases of Heart DATA IS EATING THE WORLD, ONE BYTE AT A TIME Home; 2.0 LPBI Executive Summary; 1.0 LPBI Executive Summary; 2.0 LPBI Brochure; Coronavirus, SARS-CoV-2 Portal GLYCOSYLATION AND ITS ROLE IN SARS-COV-2 VIRAL Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis Author: Meg Baker, PhD N-Glycosylation and COVID19 Glycobiology N-linked glycosylation (NLG) is a complex biosynthetic process that regulates proper folding of proteins through and intracellular transport of proteins to the secretory pathway. This co- and post-translational modification occurs by a series of enzymatic reactions, which MECHANISM OF THROMBOSIS WITH ASTRAZENECA AND J & J Mechanism of thrombosis with AstraZeneca and J & J vaccines: Expert Opinion by Kate Chander Chiang & Ajay Gupta, MD UPDATED on 4/15/2021 Atul Gawande@Atul_Gawande·15h Why wait for more info? A new case of cerebral sinus venus thrombosis was reported in a 25 year old man who became critically ill from a cerebral GR CLADE | LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE Posts about GR clade written by Amandeep Kaur BRADYKININ HYPOTHESIS: POTENTIAL EXPLANATION FOR COVID-19 Bradykinin Hypothesis: Potential Explanation for COVID-19 Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 9/14/2020 First Randomized Trial Backs Safety of ACE and ARB Heart Drugs in COVID-19 Patients BRACE CORONA trial presented in a Hot Line Session at ESC Congress 2020 September 8, 2020 - Heart patients hospitalized with COVID-19 (SARS-CoV-2) can safely continue taking angiotensin HNPCC | LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE New Generation of Platinated Compounds to Circumvent Resistance. Curator/Writer: Stephen J. Williams, Ph.D. Resistance to chemotherapeutic drugs continues to be a major hurdle in the treatment of neoplastic disorders, irregardless if the drug is a member of the cytotoxic “older” drugs or the cytostatic “newer” personalized therapies like the tyrosine kinase inhibitors.INTRACELLULAR FLUX
Figure 2. Schematic of sampling and scoring analysis to determine intracellular flux changes. (A) Reaction fluxes are sampled for two conditions. (B & C) Sample of flux differences is calculated by selecting random flux values from each condition CONFERENCE COVERAGE WITH SOCIAL MEDIA Posts about Conference Coverage with Social Media written by2012pharmaceutical
* Home
* 2.0 LPBI Executive Summary * 1.0 LPBI Executive Summary* 2.0 LPBI Brochure
* Coronavirus, SARS-CoV-2 Portal * Knowledge PORTALS System (KPS) * Journal PharmaceuticalIntelligence.com * 2020-21 VISTA 1.0 LPBI * LPBI Group’s History * 2020-21 VISION – 2.0 LPBI* BioMed e-Series
* Press Coverage
* Investor Relations* Our TEAM
* Founder
* Funding, Deals & Partnerships* LPBI Group News
* CALENDAR
* Testimonials about LPBI * DrugDiscovery @LPBI Group * Medical 3D Printing * e-VOICES Podcasting* LPBI Newsletters
* Customer Surveys
* Health Care INVESTOR’s Corner ($) * 2020 Summer Internship Portal * 2021 Medical Text Analysis (NLP) * Artificial Intelligence: Genomics & Cancer * Blockchain Transactions Network Ecosystem* Contact Us
* 1.0 LPBI Brochure
*
LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE (LPBI) GROUP FUNDING, DEALS & PARTNERSHIPS: BIOLOGICS & MEDICAL DEVICES; BIOMED E-SERIES; MEDICINE AND LIFE SCIENCES SCIENTIFIC JOURNAL – HTTP://PHARMACEUTICALINTELLIGENCE.COM* FEEDS: Posts
Comments
DEVELOPING MACHINE LEARNING MODELS FOR PREDICTION OF ONSET OFTYPE-2 DIABETES
May 29, 2021 by Amandeep Kauri
10 Votes
DEVELOPING MACHINE LEARNING MODELS FOR PREDICTION OF ONSET OF TYPE-2DIABETES
REPORTER: AMANDEEP KAUR, B.SC., M.SC. A recent study reports the development of an advanced AI algorithm which predicts up to five years in advance the starting of type 2 diabetes by utilizing regularly collected medical data. Researchers described their AI model as notable and distinctive based on the specific design which perform assessments at the population level.*
MACHINE LEARNING, BIG DATA AND ARTIFICIAL INTELLIGENCE IN HEALTHCARESYSTEM
Image source:
https://healthinformatics.uic.edu/blog/machine-learning-in-healthcare/ > The first author Mathieu Ravaut, M.Sc. of the University of Toronto > and other team members stated that “The main purpose of our model > was to inform population health planning and management for the > prevention of diabetes that incorporates health equity. It was not > our goal for this model to be applied in the context of individual > patient care.” Research group collected data from 2006 to 2016 of approximately 2.1 million patients treated at the same healthcare system in Ontario, Canada. Even though the patients were belonged to the same area, the authors highlighted that Ontario encompasses a diverse and largepopulation.
The newly developed algorithm was instructed with data of approximately 1.6 million patients, validated with data of about 243,000 patients and evaluated with more than 236,000 patient’s data. The data used to improve the algorithm included the medical history of each patient from previous two years- prescriptions, medications, lab tests and demographic information. When predicting the onset of type 2 diabetes within five years, the algorithm model reached a test area under the ROC curve of 80.26. > The authors reported that “Our model showed consistent calibration > across sex, immigration status, racial/ethnic and material > deprivation, and a low to moderate number of events in the health > care history of the patient. The cohort was representative of the > whole population of Ontario, which is itself among the most diverse > in the world. The model was well calibrated, and its discrimination, > although with a slightly different end goal, was competitive with > results reported in the literature for other machine > learning–based studies that used more granular clinical data from > electronic medical records without any modifications to the original > test set distribution.” This model could potentially improve the healthcare system of countries equipped with thorough administrative databases and aim towards specific cohorts that may encounter the faulty outcomes. > Research group stated that “Because our machine learning model > included social determinants of health that are known to contribute > to diabetes risk, our population-wide approach to risk assessment > may represent a tool for addressing health disparities.”SOURCES:
https://www.cardiovascularbusiness.com/topics/prevention-risk-reduction/new-ai-model-healthcare-data-predict-type-2-diabetes?utm_source=newsletterREFERENCE:
Ravaut M, Harish V, Sadeghi H, et al. Development and Validation of a Machine Learning Model Using Administrative Health Data to Predict Onset of Type 2 Diabetes. _JAMA Netw Open._ 2021;4(5):e2111315. doi:10.1001/jamanetworkopen.2021.11315 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2780137 OTHER RELATED ARTICLES WERE PUBLISHED IN THIS OPEN ACCESS ONLINE SCIENTIFIC JOURNAL, INCLUDING THE FOLLOWING: AI IN DRUG DISCOVERY: DATA SCIENCE AND CORE BIOLOGY @MERCK &CO, INC., @GNS HEALTHCARE, @QUARTZBIO, @BENEVOLENT AI AND NURITAS Reporters: Aviva Lev-Ari, PhD, RN and Irina Robu, PhD https://pharmaceuticalintelligence.com/2020/08/27/ai-in-drug-discovery-data-science-and-core-biology-merck-co-inc-gns-healthcare-quartzbio-benevolent-ai-and-nuritas/ CAN BLOCKCHAIN TECHNOLOGY AND ARTIFICIAL INTELLIGENCE CURE WHAT AILS BIOMEDICAL RESEARCH AND HEALTHCARE Curator: Stephen J. Williams, Ph.D. https://pharmaceuticalintelligence.com/2018/12/10/can-blockchain-technology-and-artificial-intelligence-cure-what-ails-biomedical-research-and-healthcare/ HEALTHCARE FOCUSED AI STARTUPS FROM THE 100 COMPANIES LEADING THE WAYIN A.I. GLOBALLY
Reporter: Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2018/01/18/healthcare-focused-ai-startups-from-the-100-companies-leading-the-way-in-a-i-globally/ AI IN PSYCHIATRIC TREATMENT – USING MACHINE LEARNING TO INCREASE TREATMENT EFFICACY IN MENTAL HEALTH Reporter: Aviva Lev- Ari, PhD, RN https://pharmaceuticalintelligence.com/2019/06/04/ai-in-psychiatric-treatment-using-machine-learning-to-increase-treatment-efficacy-in-mental-health/ VYASA ANALYTICS DEMOS DEEP LEARNING SOFTWARE FOR LIFE SCIENCES AT BIO-IT WORLD 2018 – VYASA’S BOOTH (#632) Reporter: Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2018/05/10/vyasa-analytics-demos-deep-learning-software-for-life-sciences-at-bio-it-world-2018-vyasas-booth-632/ NEW DIABETES TREATMENT USING SMART ARTIFICIAL BETA CELLS Reporter: Irina Robu, PhD https://pharmaceuticalintelligence.com/2017/11/08/new-diabetes-treatment-using-smart-artificial-beta-cells/ Posted in Academic Publishing,
Advanced Computing Platform,
AI Models in Healthcare,
Artificial Intelligence - Breakthroughs in Theories and Technologies,
Artificial Intelligence Applications in Health Care,
Artificial Intelligence in Health Care - Tools & Innovations,
Artificial Intelligence in Medicine - Application for Diagnosis,
Artificial Intelligence in Medicine - Applications in Therapeutics,
Big Data
, Big
Data & Analytics
,
BioIT: BioInformatics,
BioTechnology - Venture Creation,
BioTechnology - Venture Creation, Venture Capital,
Blockchain Transactions System,
Centers for Medicare & Medicaid Services,
Computational Biology/Systems and Bioinformatics,
Curation
,
Data Science
,
Health Care System by Country,
HealthCare IT
,
Innovations
,
Intelligent Information Systems,
Machine Learning
,
Machine learning in predicting type 2 diabetes,
Scientific Publishing,
Technology Advance Assessment of | Tagged AI in Healthcare,
Artificial intelligence,
Big data ,
databases ,
deep learning
, Machine
Learning
,
Machine Learning models,
Medical history
,
Population-wide approach,
type 2 diabetes
| Leave
a Comment »
RENAL TUMOR MACROPHAGES LINKED TO RECURRENCE ARE IDENTIFIED USING SINGLE-CELL PROTEIN ACTIVITY ANALYSIS May 27, 2021 by Dr. Patii
6 Votes
RENAL TUMOR MACROPHAGES LINKED TO RECURRENCE ARE IDENTIFIED USING SINGLE-CELL PROTEIN ACTIVITY ANALYSIS CURATOR AND REPORTER: DR. PREMALATA PATI, PH.D., POSTDOC When malignancy returns after a period of remission, it is called a CANCER RECURRENCE. After the initial or primary cancer has been treated, this can happen weeks, months, or even years later. The possibility of recurrence is determined by the type of primary cancer. Because small patches of cancer cells might stay in the body after treatment, cancer might reoccur. These cells may multiply and develop large enough to cause symptoms or cause cancer over time. The type of cancer determines when and where cancer recurs. Some malignancies have a predictable recurrence pattern. Even if primary cancer recurs in a different place of the body, recurrent cancer is designated for the area where it first appeared. If breast cancer recurs distantly in the liver, for example, it is still referred to as breast cancer rather than liver cancer. It’s referred to as metastatic breast cancer by doctors. Despite treatment, many people with kidney cancer eventually develop cancer recurrence and incurable metastatic illness. The most frequent type of kidney cancer is RENAL CELL CARCINOMA (RCC). RCC is responsible for over 90% of all kidney malignancies. The appearance of cancer cells when viewed under a microscope helps to recognize the various forms of RCC. Knowing the RCC subtype can help the doctor assess if the cancer is caused by an inherited genetic condition and help to choose the best treatment option. The three most prevalent RCC subtypes are as follows:* Clear cell RCC
* Papillary RCC
* Chromophobe RCC
CLEAR CELL RCC (CCRCC) is the most prevalent subtype of RCC. The cells are clear or pale in appearance and are referred to as the clear cell or conventional RCC. Around 70% of people with renal cell cancer have ccRCC. The rate of growth of these cells might be sluggish or rapid. According to the AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO),
clear cell RCC responds favorably to treatments like immunotherapy and treatments that target specific proteins or genes.Fig.
1. Clear cell RCC (ccRCC) Image Source: Moffitt Cancer Center https://moffitt.org/for-healthcare-professionals/clinical-perspectives/clinical-perspectives-story-archive/moffitt-study-seeks-to-inform-improved-treatment-strategies-for-clear-cell-renal-cell-carcinoma/ Researchers at COLUMBIA UNIVERSITY’S VAGELOS COLLEGE OF PHYSICIANS AND SURGEONS have developed a novel method for identifying which patients are most likely to have cancer relapse following surgery.THE STUDY
Their findings are detailed in a study published in the journal CELLentitled,
“Single-Cell Protein Activity Analysis Identifies Recurrence-Associated Renal Tumor Macrophages.”
The researchers show that the presence of a previously unknown type of immune cell in kidney tumors can predict who will have cancerrecurrence.
Fig.
2. Graphical abstract (Obradovic et al., 2021)Image Source:
https://marlin-prod.literatumonline.com/cms/attachment/a1208337-6b5b-4ef3-996d-227eb2536553/fx1_lrg.jpg According to co-senior author CHARLES DRAKE, MD, PhD, adjunct professor of medicine at COLUMBIA UNIVERSITY VAGELOS COLLEGE OF PHYSICIANS AND SURGEONS and the HERBERT IRVING COMPREHENSIVE CANCER CENTER,
> the findings imply that the existence of these cells could be used > to identify individuals at high risk of disease recurrence following > surgery who may be candidates for more aggressive therapy. As ALEKSANDAR OBRADOVIC, an MD/PhD student at COLUMBIA UNIVERSITY VAGELOS COLLEGE OF PHYSICIANS AND SURGEONS and the study’s co-first author,put it,
> it’s like looking down over Manhattan and seeing that enormous > numbers of people from all over travel into the city every morning. > We need deeper details to understand how these different commuters > engage with Manhattan residents: who are they, what do they enjoy, > where do they go, and what are they doing? To learn more about the immune cells that invade kidney cancers, the researchers employed single-cell RNA sequencing. Obradovic remarked, > In many investigations, single-cell RNA sequencing misses up to 90% > of gene activity, a phenomenon known as gene dropout. The researchers next tackled gene dropout by designing a prediction algorithm that can identify which genes are active based on the expression of other genes in the same family. “Even when a lot of data is absent owing to dropout, we have enough evidence to estimate the activity of the upstream regulator gene,” Obradovic explained. “It’s like when playing ‘Wheel of Fortune,’ because I can generally figure out what’s on the board even if most of the lettersare missing.”
The META-VIPER algorithm is based on the VIPER algorithm, which was developed in ANDREA CALIFANO’S GROUP. Califano is the head of HERBERT IRVING COMPREHENSIVE CANCER CENTER’S JP SULZBERGER COLUMBIAGENOME CENTER and
the Clyde and Helen Wu professor of chemistry and systems biology. The researchers believe that by including meta-VIPER, they will be able to reliably detect the activity of 70% to 80% of all regulatory genes in each cell, eliminating cell-to-cell dropout. Using these two methods, the researchers were able to examine 200,000 tumor cells and normal cells in surrounding tissues from eleven patients with ccRCC who underwent surgery at Columbia’s urologydepartment.
The researchers discovered a unique subpopulation of immune cells that can only be found in tumors and is linked to disease relapse after initial treatment. The top genes that control the activity of these immune cells were discovered through the VIPER analysis. This “signature” was validated in the second set of patient data obtained through a collaboration with Vanderbilt University researchers; in this second set of over 150 patients, the signature strongly predicted recurrence. > These findings raise the intriguing possibility that these > macrophages are not only markers of more risky disease, but may also > be responsible for the disease’s recurrence and progression,” > Obradovic said, adding that targeting these cells could improve > clinical outcomesDrake said,
> Our research shows that when the two techniques are combined, they > are extremely effective at characterizing cells within a tumor and > in surrounding tissues, and they should have a wide range of > applications, even beyond cancer research.MAIN SOURCE
Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages https://www.cell.com/cell/fulltext/S0092-8674(21)00573-0 OTHER RELATED ARTICLES PUBLISHED IN THIS OPEN ACCESS ONLINE SCIENTIFIC JOURNAL INCLUDE THE FOLLOWING: MACHINE LEARNING (ML) IN CANCER PROGNOSIS PREDICTION HELPS THE RESEARCHER TO IDENTIFY MULTIPLE KNOWN AS WELL AS CANDIDATE CANCERDIVER GENES
Curator and Reporter: Dr. Premalata Pati, Ph.D., Postdoc https://pharmaceuticalintelligence.com/2021/05/04/machine-learning-ml-in-cancer-prognosis-prediction-helps-the-researcher-to-identify-multiple-known-as-well-as-candidate-cancer-diver-genes/ RENAL (KIDNEY) CANCER: CONNECTIONS IN METABOLISM AT KREBS CYCLE ANDHISTONE MODULATION
Curator: Demet Sag, PhD, CRA, GCP https://pharmaceuticalintelligence.com/2015/10/14/renal-kidney-cancer-connections-in-metabolism-at-krebs-cycle-through-histone-modulation/ ARTIFICIAL INTELLIGENCE: GENOMICS & CANCER https://pharmaceuticalintelligence.com/ai-in-genomics-cancer/ BIOINFORMATIC TOOLS FOR CANCER MUTATIONAL ANALYSIS: COSMIC AND BEYOND Curator: Stephen J. Williams, Ph.D. https://pharmaceuticalintelligence.com/2015/12/02/bioinformatic-tools-for-cancer-mutational-analysis-cosmic-and-beyond-2/ DEEP-LEARNING AI ALGORITHM SHINES NEW LIGHT ON MUTATIONS IN ONCE OBSCURE AREAS OF THE GENOME Reporter: Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2014/12/24/deep-learning-ai-algorithm-shines-new-light-on-mutations-in-once-obscure-areas-of-the-genome/ PREMALATA PATI, PHD, POSTDOC IN BIOLOGICAL SCIENCES, MEDICAL TEXT ANALYSIS WITH MACHINE LEARNING https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/premalata-pati-phd-postdoc-in-pharmaceutical-sciences-medical-text-analysis-with-machine-learning/ Posted in Artificial Intelligence in CANCER,
Cancer - General
, CANCER
BIOLOGY & Innovations in Cancer Therapy,
Cancer Genomics
,
Immuno-Oncology & Genomics,
Metastasis Process
,
RNA Biology, Cancer and Therapeutics,
Single-cell sequencing,
tumor microenvironment | Tagged cancer metastasis,
cancer recurrence
,
immune cells
, learning
algorithms
,
renal cell carcinoma,
single-cell RNA sequencing,
tumor associated macrophage| 2 Comments »
THE COLLABORATION BETWEEN NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS) AT NIH AND BURSTIQ May 26, 2021 by 2012pharmaceuticali
Rate This
BURSTIQ AND THE NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES (NCATS) AT THE NATIONAL INSTITUTES OF HEALTH (NIH) COLLABORATE TO APPLY BLOCKCHAIN TO INTELLECTUAL PROPERTY MANAGEMENT REPORTER: AVIVA LEV-ARI, PHD, RN>
The collaboration between National Center for Advancing Translational Sciences (NCATS) at NIH and BurstIQ will transform how IP-sensitive data is managed and shared across theNCATS’ network
>
DENVER, May 25, 2021 /PRNewswire/ —BurstIQ,
the leading provider of blockchain-based data exchange solutions, announced today that the company has entered into a research collaboration agreement with The National Center for Advancing Translational Sciences(NCATS)
at the National Institutes of Health(NIH)
to address the protection of intellectual property associated with NCATS’ work on translational science.>
BurstIQ
The collaboration focuses on development of artificial intelligence/machine learning models for modulating investigators’ data access within collaborative research environments. The segmentation, encryption, and secure storage of chemical information happens seamlessly and data access is enforced with minimal manual intervention and management. The technology enables evidence-based synthesis route design with the help of electronic laboratory notebooks (eLNs) while protecting IP-sensitive chemical information of active research projects. The collaboration leverages BurstIQ’s groundbreaking blockchain-based secure data exchange platform, which allows governments and organizations to manage the ownership and sharing of sensitive data using dynamic consent and multi-level governance. The platform combines blockchain, best-in-class data security, and orchestration, allowing organizations to build and manage secure data networks in which highly sensitive data can be seamlessly contributed, verified and shared with ownership, governance, and automation builtin.
The initial project will integrate BurstIQ’s blockchain platform with NCATS/NIH’s computational infrastructure that is designed to streamline the translational research process so that new treatments and cures for disease can be delivered to patients faster. “For research communities, the ability to maintain intellectual property ownership is critical,” says Frank Ricotta, CEO of BurstIQ. “In the past, this has been a barrier to collaborative research. This collaboration with NCATS is designed break down this barrier and make it possible for researchers to share ideas and information with each other confidently, which will truly accelerate the pace of discovery.” To learn more about BurstIQ’s collaboration with NCATS and how the companies are working together to drive collaborative research, please contact us at info@burstiq.com.ABOUT BURSTIQ™
BurstIQ is the leading provider of blockchain-enabled data solutions for the identity, healthcare, and life sciences industries. The company’s secure data exchange network allows organizations to build secure networks to manage the ownership and sharing of sensitive data, with ownership, consent, governance, and workflow orchestration built in. The platform combines blockchain, Big Data, and best-in-class security to build multi-dimensional profiles of people, places, and things and empower the interactions between them. The result is a global, secure data network that allows health systems, payers, digital health companies, pharma & life science companies, and governments to collaborate, share, discover, and build the impossible. For more information visit: WebsiteContacts:
BurstIQ: Amber HartleyP: 888-355-7345
E: 310625@email4pr.comW: www.burstIQ.com
SOURCE BurstIQ
https://www.prnewswire.com/news-releases/burstiq-and-the-national-center-for-advancing-translational-sciences-ncats-at-the-national-institutes-of-health-nih-collaborate-to-apply-blockchain-to-intellectual-property-management-301298469.html BURSTIQ TECHNOLOGY OF BLOCKCHAIN TRANSACTIONS NETWORK IS THE SELECTED IT DESIGN FOR LPBI CONSIDERING ITS OWN IP ASSET CLASSES:* +6,000 articles
* 18 e-Books in Medicine * 100 e-Proceedings and Tweet Collections * +5,100 Gallery of Biological Images*
Detained descriptions provided here > Blockchain Transactions Network Ecosystem>
https://pharmaceuticalintelligence.com/blockchain-transactions-network/ > Blockchain Transactions Network Ecosystem>
Posted in Uncategorized|
Leave a Comment »
C.D.C. REVIEWING CASES OF HEART PROBLEM IN YOUNGSTERS AFTER GETTING VACCINATED AND AHA REASSURES THAT BENEFITS OVERWHELM THE RISKSOF VACCINATION
May 25, 2021 by Amandeep Kauri
2 Votes
C.D.C. REVIEWING CASES OF HEART PROBLEM IN YOUNGSTERS AFTER GETTING VACCINATED AND AHA REASSURES THAT BENEFITS OVERWHELM THE RISKS OFVACCINATION
REPORTER: AMANDEEP KAUR, B.SC. , M.SC. The latest article in New York times reported by Apoorva Mandavilli outlines the statement of officials that C.D.C. agency is investigating few cases of young adults and teenagers who might have developed myocarditis after getting vaccinated. It is not confirmed by the agency that whether this condition is caused by vaccine or not.*
Teenager getting vaccinatedImage source:
https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/is-the-covid19-vaccine-safe According to the vaccine safety group of the Centers for Disease Control and Prevention, the reports of heart problems experienced by youngsters is relatively very small in number. The group stated that these cases could be unlinked to vaccination. The condition of inflammation of heart muscle which can occur due to certain infections is known as myocarditis. Moreover, the agency still has to determine any evidence related to vaccines causing the heart issues. The C.D.C. has posted on its website the updated guidance for doctors and clinicians, urging them to be alert to uncommon symptoms related to heart cases among teenagers who are vaccine recipients. > In New York, Dr. Celine Gounder, an infectious disease specialist at > Bellevue Hospital Center stated that “It may simply be a > coincidence that some people are developing myocarditis after > vaccination. It’s more likely for something like that to happen by > chance, because so many people are getting vaccinated right now.” The article reported that the cases appeared mainly in young adults after about four days of their second shot of mRNA vaccines, made by Moderna and Pfizer-BioNTech. Such cases are more prevalent in males as compared to females. The vaccine safety group stated “Most cases appear to be mild, and follow-up of cases is ongoing.” It is strongly recommended by C.D.C. that American young adults from the age of 12 and above should get vaccinated against COVID-19. > Dr. Yvonne Maldonado, chair of the American Academy of > Pediatrics’s Committee on Infectious Diseases stated “We look > forward to seeing more data about these cases, so we can better > understand if they are related to the vaccine or if they are > coincidental. Meanwhile, it’s important for pediatricians and > other clinicians to report any health concerns that arise after> vaccination.”
Experts affirmed that the potentially uncommon side effects of myocarditis get insignificant compared to the potential risks of SARS-CoV-2 infection, including the continuous syndrome known as “long Covid.” It is reported in the article that acute Covid can lead to myocarditis. According to the data collected by A.A.P,
about 16 thousand children were hospitalized and more than 3.9 million children were infected by coronavirus till the second week of May. In the United States, about 300 children died of SARS-CoV-2 infection, which makes it among the top 10 death causes in children since thestart of pandemic.
> Dr. Jeremy Faust, an emergency medicine physician at Brigham and > Women’s Hospital in Boston stated that “And that’s in the > context of all the mitigation measures taken.” According to researchers, about 10 to 20 of every 1 lakh people each year develop myocarditis in the general population, facing symptoms from fatigue and chest pain to arrhythmias and cardiac arrest, whereas some have mild symptoms which remain undiagnosed. Currently, the number of reports of myocarditis after vaccination is less than that reported normally in young adults, confirmed by C.D.C. The article reported that the members of vaccine safety group felt to communicate the information about upcoming cases of myocarditis to theproviders.
The C.D.C. has not yet specified the ages of the patients involved in reporting. Since December 2020, the Pfizer-BioNTech vaccine was authorized for young people of age 16 and above. The Food and Drug Administration extended the authorization to children of age 12 to 15 years, by the starting of this month. On 14th May, the clinicians have been alerted by C.D.C. regarding the probable link between myocarditis and vaccination. Within three days, the team started reviewing data on myocarditis, reports filed with the Vaccine Adverse Event Reporting System and others from the Departmentof Defense.
A report on seven cases has been submitted to the journal Pediatrics for review and State health departments in Washington, Oregon and California have notified emergency providers and cardiologists about the potential problem. In an interview, Dr. Liam Yore, past president of the Washington State chapter of the American College of Emergency Physicians detailed a case of teenager with myocarditis after vaccination. The patient was provided treatment for mild inflammation of the inner lining of the heart and was discharged afterwards. Later, the young adult returned for care due to decrease in the heart’s output. Dr. Yore reported that still he had come across worse cases in youngsters with Covid, including in a 9-year-old child who arrived at the hospital after a cardiac arrest last winter. > He stated that “The relative risk is a lot in favor of getting the > vaccine, especially considering how coronavirus vaccine have been> administered.”
In the United States, more than 161 million people have received their first shot of vaccine in which about 4.5 million people were between the age 12 to 18 years. BENEFITS OVERWHELM RISKS OF COVID VACCINATION, AHA REASSURES The latest statement of American Heart Association (AHA)/ American Stroke Association (ASA) on May 23rd states that the benefits of COVID-19 vaccination enormously outweigh the rare risk for myocarditis cases, which followed the C.D.C. report that the agency is tracking the Vaccine Adverse Events Reporting System (VAERS) and the Vaccine Safety Datalink (VSD) for myocarditis cases linked with mRNA vaccines against coronavirus. The myocarditis cases in young adults are more often observed after the second dose of vaccine rather than the first one, and have more cases of males than females. The CDC’s COVID-19 Vaccine Safety Technical Work Group (VaST) observed such heart complications after 4 days of vaccination. CDC reported that “Within CDC safety monitoring systems, rates of myocarditis reports in the window following COVID-19 vaccination have not differed from expected baseline rates.” The CDC team stated that “The evidence continues to indicate that the COVID-19 vaccines are nearly 100% effective at preventing death and hospitalization due to COVID-19 infection, and Strongly urged all young adults and children 12 years and above to get vaccinated as soonas possible.”
Even though the analysis of myocarditis reports related to coronavirus vaccine is in progress, the AHA/ASA stated that “myocarditis is typically the result of an actual viral infection, and it is yet to be determined if these cases have any correlation to receiving a COVID-19vaccine.”
Richard Besser, MD, president and CEO of the Robert Wood Johnson Foundation (RWJF) and former acting director of the CDC stated on ABC’s _Good Morning America_ “We’ve lost hundreds of children and there have been thousands who have been hospitalized, thousands who developed an inflammatory syndrome, and one of the pieces of that can be myocarditis.” He added “still, from my perspective, the risk of COVID is so much greater than any theoretical risk from thevaccine.”
After COVID-19 vaccination the symptoms that occur include tiredness, muscle pain, headaches, chills, nausea and fever. The AHA/ASA stated that “typically appear within 24 to 48 hours and usually pass within 36-48 hours after receiving the vaccine.” All healthcare providers are suggested to be aware of the rare adverse symptoms such as myocarditis, low platelets, blood clots, and severe inflammation. The agency stated that “Healthcare professionals should strongly consider inquiring about the timing of any recent COVID vaccination among patients presenting with these conditions, as needed, in order to provide appropriate treatment quickly.” President Mitchell S.V. Elkind, M.D., M.S., FAHA, FAAN, Immediate Past President Robert A. Harrington, M.D., FAHA, President-Elect Donald M. Lloyd-Jones, M.D., Sc.M., FAHA, Chief Science and Medical Officer Mariell Jessup, M.D., FAHA, and Chief Medical Officer for Prevention Eduardo Sanchez, M.D, M.P.H., FAAFP are science leaders of AHA/ASA and reflected their views in the following statements: > _We strongly urge all adults and children ages 12 and older in the > U.S. to receive a COVID vaccine as soon as they can receive it, as > recently approved by the U.S. Food and Drug Administration and the > CDC. The evidence continues to indicate that the COVID-19 vaccines > are nearly 100% effective at preventing death and hospitalization > due to COVID-19 infection. According to the CDC as of May 22, 2021, > over 283 million doses of COVID-19 vaccines have been administered > in the U.S. since December 14, 2020, and more than 129 million > Americans are fully vaccinated (i.e., they have received either two > doses of the Pfizer-BioNTech or Moderna COVID-19 vaccine, or the > single-dose Johnson & Johnson/Janssen COVID-19 vaccine)._ > _We remain confident that the benefits of vaccination far exceed the > very small, rare risks. The risks of vaccination are also far > smaller than the risks of COVID-19 infection itself, including its > potentially fatal consequences and the potential long-term health > effects that are still revealing themselves, including > myocarditis. The recommendation for vaccination specifically > includes people with cardiovascular risk factors such as high blood > pressure, obesity and type 2 diabetes, those with heart disease, and > heart attack and stroke survivors, because they are at much greater > risk of an adverse outcome from the COVID-19 virus than they are > from the vaccine._ > _We commend the CDC’s continual monitoring for adverse events > related to the COVID-19 vaccines through VAERS and VSD, and the > consistent meetings of ACIP’s VaST Work Group, > demonstrating transparent and robust attention to any and all > health events possibly related to a COVID-19 vaccine. The few cases > of myocarditis that have been reported after COVID-19 vaccination > are being investigated. However, myocarditis is usually the result > of a viral infection, and it is yet to be determined if these cases > have any correlation to receiving a COVID-19 vaccine, especially > since the COVID-19 vaccines authorized in the U.S. do not contain > any live virus._ > _We also encourage everyone to keep in touch with their primary > care professionals and seek care immediately if they have any of > these symptoms in the weeks after receiving the COVID-19 vaccine:_ > _chest pain including sudden, sharp, stabbing pains;_ _difficulty > breathing/shortness of breath;_ _abnormal heartbeat;_ _severe > headache;_ _blurry vision;_ _fainting or loss of consciousness;_ > _weakness or sensory changes;_ _confusion or trouble speaking;_ > _seizures;_ _unexplained abdominal pain; or_ _new leg pain or> swelling._
> _We will stay up to date with the CDC’s recommendations regarding > all potential complications related to COVID-19 vaccines, including > myocarditis, pericarditis, central venous sinus thrombosis (CVST) > and other blood clotting events, thrombosis thrombocytopenia > syndrome (TTS), and vaccine-induced immune thrombosis > thrombocytopenia (VITT)._ > _The American Heart Associationrecommends all health care > professionals be aware of these very rare adverse events that may be > related to a COVID-19 vaccine, including myocarditis, blood clots, > low platelets, or symptoms of severe inflammation. Health care > professionals should strongly consider inquiring about the timing of > any recent COVID vaccination among patients presenting with these > conditions, as needed, in order to provide appropriate treatment > quickly. As detailed in last month’s AHA/ASA __statement_> _,
> all suspected CVST or blood clots associated with the COVID-19 > vaccine should be treated initially using non-heparin > anticoagulants. Heparin products should not be administered in any > dose if TTS/VITT is suspected, until appropriate testing can be done > to exclude heparin-induced antibodies. In addition, health care > professionals are required to report suspected vaccine-related > adverse events to the __Vaccine Adverse Event Reporting System_ > _, in accordance with federal> regulations._
> _Individuals should refer to their local and state health > departments for specific information about when and where they can > get vaccinated. We implore everyone ages 12 and older to get > vaccinated so we can return to being together, in person – > enjoying life with little to no risk of severe COVID-19 infection, > hospitalization or death._ > _We also support the CDC recommendations last week that loosen > restrictions on mask wearing and social distancing for people who > are fully vaccinated. For those who are unable to be vaccinated, we > reiterate the importance of handwashing, social distancing and > wearing masks, particularly for people at high risk of infection > and/or severe COVID-19. These simple precautions remain crucial to > protecting people who are not vaccinated from the virus that causes> COVID-19._
SOURCE:
*
https://www.nytimes.com/2021/05/22/health/cdc-heart-teens-vaccination.html?referringSource=articleShare*
https://www.medscape.com/viewarticle/951730?src=mkm_covid_update_210524_MSCPEDIT*
https://newsroom.heart.org/news/covid-19-vaccine-benefits-still-outweigh-risks-despite-possible-rare-heart-complications OTHER RELATED ARTICLES WERE PUBLISHED IN THIS OPEN ACCESS ONLINE SCIENTIFIC JOURNAL, INCLUDING THE FOLLOWING: THRIVING VACCINES AND RESEARCH: WEIZMANN INSTITUTE CORONAVIRUS RESEARCH DEVELOPMENT Reporter: Amandeep Kaur, B.Sc., M.Sc. https://pharmaceuticalintelligence.com/2021/05/04/thriving-vaccines-and-research-weizmann-coronavirus-research-development/ IDENTIFICATION OF NOVEL GENES IN HUMAN THAT FIGHT COVID-19 INFECTION Reporter: Amandeep Kaur, B.Sc., M.Sc. https://pharmaceuticalintelligence.com/2021/04/19/identification-of-novel-genes-in-human-that-fight-covid-19-infection/ FIGHTING CHAOS WITH CARE, COMMUNITY TRUST, ENGAGEMENT MUST BE CORNERSTONES OF PANDEMIC RESPONSE Reporter: Amandeep Kaur, B.Sc., M.Sc. https://pharmaceuticalintelligence.com/2021/04/13/fighting-chaos-with-care/ T CELLS RECOGNIZE RECENT SARS-COV-2 VARIANTS Reporter: Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2021/03/30/t-cells-recognize-recent-sars-cov-2-variants/ NEED FOR GLOBAL RESPONSE TO SARS-COV-2 VIRAL VARIANTS Reporter: Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2021/02/12/need-for-global-response-to-sars-cov-2-viral-variants/ Posted in coronavirus,
COVID-19 ,
COVID-19
,
COVID-19 effects on Human Heart,
Myocarditis
,
SARS-CoV-2
,
Treatment Protocols for COVID-19,
United States
,
Vaccinology
,
Virology
| Tagged Cardiac Arrest, Centers
for Disease Control and Prevention,
Chest pain ,
COVID Vaccine
, COVID-19
Treatment
, Food
and Drug Administration,
Moderna ,
Myocarditis ,
Pfizer Vaccine
,
Vaccination ,
Youngsters Vaccines
|
Leave a Comment »
E-PROCEEDINGS FOR 2021 WORLD MEDICAL INNOVATION FORUM, MASS GENERAL BRIGHAM, GENE AND CELL THERAPY, VIRTUAL MAY 19–21, 2021 May 22, 2021 by 2012pharmaceuticali
5 Votes
2021 VIRTUAL WORLD MEDICAL INNOVATION FORUM, MASS GENERAL BRIGHAM, GENE AND CELL THERAPY, VIRTUAL MAY 19–21, 2021 The 2021 Virtual World Medical Innovation Forum will focus on the growing impact of gene and cell therapy. Senior healthcare leaders from all over look to shape and debate the area of gene and cell therapy. Our shared belief: no matter the magnitude of change, responsible healthcare is centered on a shared commitment to collaborative innovation–industry, academia, and practitioners working together to improve patients’ lives. ABOUT THE WORLD MEDICAL INNOVATION FORUM Mass General Brigham is pleased to present the World Medical Innovation Forum (WMIF) virtual event Wednesday, May 19 – Friday, May 21. This interactive web event features expert discussions of gene and cell therapy (GCT) and its potential to change the future of medicine through its disease-treating and potentially curative properties. The agenda features 150+ executive speakers from the healthcare industry, venture, startups, life sciences manufacturing, consumer health and the front lines of care, including many Harvard Medical School-affiliated researchers and clinicians. The annual in-person Forum will resume live in Boston in 2022. The World Medical Innovation Forum is presented by Mass General Brigham Innovation, the global business development unit supporting the research requirements of 7,200 Harvard Medical School faculty and research hospitals including Massachusetts General, Brigham and Women’s, Massachusetts Eye and Ear, Spaulding Rehab and McLean Hospital. Follow us on Twitter: twitter.com/@MGBInnovation ACCELERATING THE FUTURE OF MEDICINE WITH GENE AND CELL THERAPY WHATCOMES NEXT
Click to access 2021-WMIF-White-Paper-1.0.pdf HTTPS://WORLDMEDICALINNOVATION.ORG/AGENDA/ VIRTUAL | MAY 19–21, 2021#WMIF2021
@MGBINNOVATION
LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE (LPBI) GROUP WILL COVER THE EVENT IN REAL TIME AVIVA LEV-ARI, PHD, RNFOUNDER LPBI 1.0
&
LPBI 2.0
WILL BE IN VIRTUAL ATTENDANCE PRODUCING THE E-PROCEEDINGS AND THE TWEET COLLECTION OF THIS GLOBAL EVENT EXPECTING +15,000ATTENDEES
@PHARMA_BI
@AVIVA1950
LPBI’S EIGHTEEN BOOKS IN MEDICINE HTTPS://LNKD.IN/EKWGNQA AMONG THEM, BOOKS ON GENE AND CELL THERAPY INCLUDE THE FOLLOWING: TOPICS FOR MAY 19 – 21 INCLUDE: Impact on Patient Care – Therapeutic and Potentially Curative GCTDevelopments
GCT Delivery, Manufacturing – What’s Next GCT Platform Development Oncolytic Viruses – Cancer applications, start-ups Regenerative Medicine/Stem CellsFuture of CAR-T
M&A Shaping GCT’s FutureMarket Priorities
Venture Investing in GCT China’s GCT Juggernaut Disease and Patient Focus: Benign blood disorders, diabetes, neurodegenerative diseases Click here for the current WMIF agendaPlus:
Fireside Chats: 1:1 interviews with industry CEOs/C-Suite leaders including Novartis Gene Therapies, ThermoFisher, Bayer AG, FDA First Look: 18 briefings on emerging GCT research from Mass GeneralBrigham scientists
Virtual Poster Session: 40 research posters and presenters on potential GCT discoveries from Mass General Brigham Announcement of the Disruptive Dozen, 12 GCT technologies likely to break through in the next few yearsAGENDA
WEDNESDAY, MAY 19, 20218:00 AM – 8:10 AM
OPENING REMARKS
Welcome and the vision for Gene and Cell Therapy and why it is a top Mass General Brigham priority. Introducer: Scott Sperling * Co-President, Thomas H. Lee Partners * Chairman of the Board of Directors, PHS Presenter: Anne Klibanski, MD * CEO, Mass General Brigham 3,000 people joined 5/19 morning 30 sessions: Lab to Clinic, academia, industry, investment community May 22,23,24, 2022 – in Boston, in-person 2022 WMIF on CGT 8:10 AM– 8:30 AM
THE GRAND CHALLENGE OF WIDESPREAD GCT PATIENT BENEFITS Co-Chairs identify the key themes of the Forum – set the stage for top GCT opportunities, challenges, and where the field might take medicine in the future. Moderator: Susan Hockfield, PhD * President Emerita and Professor of Neuroscience, MIT GCT – poised to deliver therapies Inflection point as Panel will present Doctors and Patients – Promise for some patients Barriers for Cell & Gene Access for patients to therapies like CGT Speakers: Nino Chiocca, MD,PhD
* Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH * Harvey W. Cushing Professor of Neurosurgery, HMS Oncolytic virus triple threat: Toxic, immunological, combine with anticancer therapies
Polygenic therapy – multiple genes involved, plug-play, SusanSlaugenhaupt, PhD
* Scientific Director and Elizabeth G. Riley and Daniel E. Smith Jr., Endowed Chair, Mass General Research Institute * Professor, Neurology, HMSRavi Thadhani, MD
* CAO, Mass General Brigham * Professor, Medicine and Faculty Dean, HMS Role of academia special to spear head the Polygenic therapy – multiple genes involved, plug-play, Access critical, relations with IndustryLuk Vandenberghe, PhD * Grousbeck Family Chair, Gene Therapy, MEE * Associate Professor, Ophthalmology, HMS Pharmacology Gene-Drug, Interface academic centers and industry many CGT drugs emerged in Academic center 8:35 AM – 8:50 AM FIRESIDE GENE AND CELL THERAPY 2.0 – WHAT’S NEXT AS WE REALIZE THEIR POTENTIAL FOR PATIENTSDave Lennon, PhD
* President, Novartis Gene Therapies Hope that CGT emerging, how the therapies work, neuro, muscular, ocular, genetic diseases of liver and of heart revolution for the industry 900 IND application 25 approvals Economic driver Skilled works, VC disease. Modality one time intervention, long duration of impart, reimbursement, ecosystem to be built around CGT FDA works by indications and risks involved, Standards and expectations for streamlining manufacturing, understanding of processand products
payments over time payers and Innovators relations Moderator: JulianHarris, MD
* Partner, Deerfield Promise of CGT realized, what part? FDA role and interaction in CGT Manufacturing aspects which is critical Speaker: Dave Lennon, PhD * President, Novartis Gene Therapies Hope that CGT emerging, how the therapies work, neuro, muscular, ocular, genetic diseases of liver and of heart revolution for the industry 900 IND application 25 approvals Economic driver Skilled works, VC disease. Modality one time intervention, long duration of impart, reimbursement, ecosystem to be built around CGT FDA works by indications and risks involved, Standards and expectations for streamlining manufacturing, understanding of processand products
payments over time payers and Innovators relations* Q&A
8:55 AM – 9:10 AM8:55 AM – 9:20 AM
THE PATIENT AND GCT
GCT development for rare diseases is driven by patient and patient-advocate communities. Understanding their needs and perspectives enables biomarker research, the development of value-driving clinical trial endpoints and successful clinical trials. Industry works with patient communities that help identify unmet needs and collaborate with researchers to conduct disease natural history studies that inform the development of biomarkers and trial endpoints. This panel includes patients who have received cutting-edge GCT therapy as well as caregivers and patient advocates. Moderator: Patricia Musolino, MD, PhD * Co-Director Pediatric Stroke and Cerebrovascular Program, MGH * Assistant Professor of Neurology, HMS What is the Power of One – the impact that a patient can have on their own destiny by participating in Clinical Trials Contacting other participants in same trial can be beneficial Speakers: Jack Hogan* Patient, MEE
Jeanette Hogan
* Parent of Patient, MEEJim Holland
* CEO, Backcountry.com Parkinson patient Constraints by regulatory on participation in clinical trial advance stage is approved participation Patients to determine the level of risk they wish to take Information dissemination is critical Barbara Lavery * Chief Program Officer, ACGT Foundation Advocacy agency beginning of work Global Genes educational content and out reach to access the information Patient has the knowledge of the symptoms and recording all input needed for diagnosis by multiple clinicians Early application forCGTDan Tesler
* Clinical Trial Patient, BWH/DFCC Experimental Drug clinical trial patient participation in clinical trial is very important to advance the state of scienceSarah BethThomas, RN
* Professional Development Manager, BWH Outcome is unknown, hope for good, support with resources all advocacygroups,
* Q&A
9:25 AM – 9:40 AM 9:25 AM – 9:45 AM FIRESIDE GCT REGULATORY FRAMEWORK | WHY DIFFERENT? Moderator: Vicki Sato, PhD * Chairman of the Board, Vir Biotechnology Diversity of approaches Process at FDA generalize from 1st entry to rules more generalizable Speaker: Peter Marks, MD, PhD * Director, Center for Biologics Evaluation and Research, FDA Last Spring it became clear that something will work a vaccine by June 2020 belief that enough candidates the challenge manufacture enough and scaling up FDA did not predicted the efficacy of mRNA vaccine vs other approaches expected to work Recover Work load for the pandemic will wean & clear, Gene Therapies IND application remained flat in the face of the pandemic Rare diseases urgency remains Consensus with industry advisory to get input gene therapy Guidance T-Cell therapy vs Regulation best thinking CGT evolve speedily flexible gained by Guidance Immune modulators, Immunotherapy Genome editing can make use of viral vectors future technologies nanoparticles and liposome encapsulation* Q&A
9:50 AM – 10:05 AM 9:50 AM – 10:15 AM BUILDING A GCT PLATFORM FOR MAINSTREAM SUCCESS This panel of GCT executives, innovators and investors explore how to best shape a successful GCT strategy. Among the questions to beaddressed:
* How are GCT approaches set around defining and building a platform? * Is AAV the leading modality and what are the remaining challenges? * What are the alternatives? * Is it just a matter of matching modalities to the rightindications?
Moderator: Jean-François Formela, MD * Partner, Atlas Venture Established core components of the Platform Speakers: Katherine High,MD
* President, Therapeutics, AskBio Three drugs approved in Europe in the Gene therapy space Regulatory Infrastructure exists for CGT drug approval – as new class of therapeutics Participants investigators, regulators, patients i. e., MDM Hemophilia in male most challenging Human are natural hosts for AV safety signals Dave Lennon, PhD * President, Novartis Gene Therapies big pharma has portfolios of therapeutics not one drug across Tx areas: cell, gene iodine therapy collective learning infrastructure features manufacturing at scale early in development Acquisitions strategy for growth # applications for scaling Rick Modi * CEO, Affinia Therapeutics Copy, paste EDIT from product A to B novel vectors leverage knowledge varient of vector, coder optimization choice of indication is critical exploration on larger populations Speed to R&D and Speed to better gene construct get to clinic with better design vs ASAP Data sharing clinical experience with vectors strategies patients selection, vector selection, mitigation, patient type specific LouiseRodino-Klapac, PhD
* EVP, Chief Scientific Officer, Sarepta Therapeutics AAV based platform 15 years in development same disease indication vs more than one indication stereotype, analytics as hurdle 1st was 10 years 2nd was 3 years Safety to clinic vs speed to clinic, difference of vectors to trust* Q&A
10:20 AM – 10:35 AM 10:20 AM – 10:45 AM AAV SUCCESS STUDIES | RETINAL DYSTROPHY | SPINAL MUSCULAR ATROPHY Recent AAV gene therapy product approvals have catalyzed the field. This new class of therapies has shown the potential to bring transformative benefit to patients. With dozens of AAV treatments in clinical studies, all eyes are on the field to gauge its disruptiveimpact.
The panel assesses the largest challenges of the first two products, the lessons learned for the broader CGT field, and the extent to which they serve as a precedent to broaden the AAV modality. * Is AAV gene therapy restricted to genetically defined disorders, or will it be able to address common diseases in the near term? * Lessons learned from these first-in-class approvals. * Challenges to broaden this modality to similar indications. * Reflections on safety signals in the clinical studies? Moderator: Joan Miller, MD * Chief, Ophthalmology, MEE * Cogan Professor & Chair of Ophthalmology, HMS Retina specialist, Luxturna success FMA condition cell therapy assolution
Lessons learned
Safety Speakers: Ken Mills* CEO, RegenXBio
Tissue types additional administrations, tech and science, address additional diseases, more science for photoreceptors a different tissue type underlying pathology novelties in last 10 years Cell therapy vs transplant therapy no immunosuppressionEric Pierce,MD, PhD
* Director, Ocular Genomics Institute, MEE * Professor of Ophthalmology, HMS Laxterna success to be replicated platform, paradigms measurementvisual improved
More science is needed to continue develop vectors reduce toxicity, AAV can deliver different cargos reduce adverse events improvevectorsRon Philip
* Chief Operating Officer, Spark Therapeutics The first retinal gene therapy, voretigene
neparvovec-rzyl (Luxturna, Spark Therapeutics), was approved by the FDA in 2017.Meredith Schultz, MD * Executive Medical Director, Lead TME, Novartis Gene Therapies Impact of cell therapy beyond muscular dystrophy, translational medicine, each indication, each disease, each group of patients build platform unlock the promise Monitoring for Safety signals real world evidence remote markers, home visits, clinical trial made safer, better communication of information* Q&A
10:50 AM – 11:05 AM 10:45 AM – 10:55 AMBREAK
10:55 AM – 11:05 AM FIRST LOOK CONTROL OF AAV PHARMACOLOGY BY RATIONAL CAPSID DESIGN Luk Vandenberghe, PhD * Grousbeck Family Chair, Gene Therapy, MEE * Associate Professor, Ophthalmology, HMS AAV a complex driver in Pharmacology durable, vector of choice, administer in vitro, gene editing tissue specificity, pharmacokinetics side effects and adverse events manufacturability site variation diversify portfolios, Pathway for rational AAV rational design, curated smart variant libraries, AAV sequence screen multiparametric , data enable liver (de-) targeting unlock therapeutics areas: cochlea* Q&A
11:05 AM – 11:25 AM 11:05 AM – 11:15 AM FIRST LOOK ENHANCED GENE DELIVERY AND IMMUNOEVASION OF AAV VECTORS WITHOUT CAPSIDMODIFICATION
Casey Maguire, PhD
* Associate Professor of Neurology, MGH & HMS Virus Biology: Enveloped (e) or not enveloped for gene therapy eAAV platform technology: tissue targets and Indications commercialization of eAAV* Q&A
11:15 AM – 11:35 AM 11:20 AM – 11:45 AM HOT TOPICSAAV DELIVERY
This panel will address the advances in the area of AAV gene therapy delivery looking out the next five years. Questions that loom large are: How can biodistribution of AAV be improved? What solutions are in the wings to address immunogenicity of AAV? Will patients be able to receive systemic redosing of AAV-based gene therapies in the future? What technical advances are there for payload size? Will the cost of manufacturing ever become affordable for ultra-rare conditions? Will non-viral delivery completely supplant viral delivery within the next five years?What are the safety concerns and how will they be addressed? Moderators: Xandra Breakefield, PhD * Geneticist, MGH, MGH * Professor, Neurology, HMSFlorian Eichler, MD
* Director, Center for Rare Neurological Diseases, MGH * Associate Professor, Neurology, HMS Speakers: Jennifer Farmer * CEO, Friedreich’s Ataxia Research Alliance Ataxia requires therapy targeting multiple organ with one therapy, brain, spinal cord, heart several IND, clinical trials in 2022MathewPletcher, PhD
* SVP, Head of Gene Therapy Research and Technical Operations,Astellas
Work with diseases poorly understood, collaborations needs example of existing: DMD is a great example explain dystrophin share placedodata
Continue to explore large animal _guinea pig_ not the mice, not primates (ethical issues) for understanding immunogenicity and immune response Manny Simons, PhD* CEO, Akouos
AAV Therapy for the fluid of the inner ear, CGT for the ear vector accessible to surgeons translational work on the inner ear for gene therapy right animal model Biology across species nerve ending in the cochlea engineer out of the caspid, lowest dose possible, get desired effect by vector use, 2022 new milestones* Q&A
11:50 AM – 12:05 PM 11:50 AM – 12:15 PM M&A | SHAPING GCT INNOVATION The GCT M&A market is booming – many large pharmas have made at least one significant acquisition. How should we view the current GCT M&A market? What is its impact of the current M&A market on technology development? Are these M&A trends new are just another cycle? Has pharma strategy shifted and, if so, what does it mean for GCT companies? What does it mean for patients? What are the long-term prospects – can valuations hold up? Moderator: Adam Koppel, MD, PhD * Managing Director, Bain Capital Life Sciences What acquirers are looking for?? What is the next generation vs what is real where is the industrygoing? Speakers:
Debby Baron,
* Worldwide Business Development, Pfizer CGT is an important area Pfizer is active looking for innovators, advancing forward programs of innovation with the experience Pfizerhas internally
Scalability and manufacturing regulatory conversations, clinical programs safety in parallel to planning getting drug to patientsKenneth Custer, PhD
* Vice President, Business Development and Lilly New Ventures, EliLilly and Company
Marianne De Backer, PhD Head of Strategy, Business Development & Licensing, and Member of the Executive Committee, Bayer Absolute Leadership in Gene editing, gene therapy, via acquisition andstrategic alliance
Operating model of the acquired company discussed , company continueindependence
Sean Nolan
* Board Chairman, Encoded Therapeutics & Affinia Executive Chairman, Jaguar Gene Therapy & Istari Oncology As acquiree multiple M&A: How the acquirer looks at integration and cultures of the two companies Traditional integration vs jump start by external acquisition AAV – epilepsy, next generation of vectors* Q&A
12:20 PM – 12:35 PM 12:15 PM – 12:25 PM FIRST LOOK GENE THERAPIES FOR NEUROLOGICAL DISORDERS: INSIGHTS FROM MOTOR NEURONDISORDERS
Merit Cudkowicz, MD
* Chief of Neurology, MGH ALS – Man 1in 300, Women 1 in 400, next decade increase 7% 10% ALS is heredity 160 pharma in ALS space, diagnosis is late 1/3 of people are not diagnosed, active community for clinical trials Challenges: disease heterogeneity cases of 10 years late in diagnosis. Clinical Trials for ALS in Gene Therapy targeting ASO1 protein therapies FUS gene struck youngstersQ&A
* 12:25 PM – 12:45 PM 12:25 PM – 12:35 PM FIRST LOOK GENE THERAPY FOR NEUROLOGIC DISEASES Patricia Musolino, MD, PhD * Co-Director Pediatric Stroke and Cerebrovascular Program, MGH * Assistant Professor of Neurology, HMS Cerebral Vascular disease – ACTA2 179H gene smooth muscle cell proliferation disorder no surgery or drug exist – Cell therapy for ACTA2 Vasculopathy in the brain and control the BP and stroke – smooth muscle intima proliferation. Viral vector deliver aiming to change platform to non-viral delivery rare disease , gene editing, other mutations of ACTA2 gene target other pathway foratherosclerosis
* Q&A
12:35 PM – 12:55 PM 12:35 PM – 1:15 PMLUNCH
1:15 PM – 1:40 PM ONCOLYTIC VIRUSES IN CANCER | CURING MELANOMA AND BEYOND Oncolytic viruses represent a powerful new technology, but so far an FDA-approved oncolytic (Imlygic) has only occurred in one area – melanoma and that what is in 2015. This panel involves some of the protagonists of this early success story. They will explore why and how Imlygic became approved and its path to commercialization. Yet, no other cancer indications exist for Imlygic, unlike the expansion of FDA-approved indication for immune checkpoint inhibitors to multiple cancers. Why? Is there a limitation to what and which cancers can target? Is the mode of administration a problem? No other oncolytic virus therapy has been approved since 2015. Where will the next success story come from and why? Will these therapies only be beneficial for skin cancers or other easily accessible cancers based on intratumoral delivery? The panel will examine whether the preclinical models that have been developed for other cancer treatment modalities will be useful for oncolytic viruses. It will also assess the extent pre-clinical development challenges have slowed the development of OVs. Moderator: Nino Chiocca, MD, PhD * Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH * Harvey W. Cushing Professor of Neurosurgery, HMS Challenges of manufacturing at Amgen what are they? Speakers: RobertCoffin, PhD
* Chief Research & Development Officer, Replimune 2002 in UK promise in oncolytic therapy GNCSF Phase III melanoma 2015 M&A with Amgen oncolytic therapy remains non effecting on immune response data is key for commercialization do not belief in systemic therapy achieve maximum immune response possible from a tumor by localized injection Roger Perlmutter, MD,PhD
* Chairman, Merck & Co. response rates systemic therapy like PD1, Keytruda, OPTIVA well tolerated combination of Oncolytic with systemic GMP critical for manufacturing David Reese, MD * Executive Vice President, Research and Development, Amgen Inter lesion injection of agent vs systemic therapeutics cold tumors immune resistant render them immune susceptible Oncolytic virus is a Mono therapy addressing the unknown Ann Silk, MD * Physician, Dana Farber-Brigham and Women’s Cancer Center * Assistant Professor of Medicine, HMS Which person gets oncolytics virus if patient has immune suppression due to other indications Safety of oncolytic virus greater than Systemic treatment series biopsies for injected and non injected tissue and compare Suspect of hot tumor and cold tumors likely to have sme response to agent unknown all potential* Q&A
1:45 PM – 2:00 PM1:45 PM – 2:10 PM
MARKET INTEREST IN ONCOLYTIC VIRUSES | CALIBRATING There are currently two oncolytic virus products on the market, one in the USA and one in China. As of late 2020, there were 86 clinical trials 60 of which were in phase I with just 2 in Phase III the rest in Phase I/II or Phase II. Although global sales of OVs are still in the ramp-up phase, some projections forecast OVs will be a $700 million market by 2026. This panel will address some of the major questions in this area: What regulatory challenges will keep OVs from realizing their potential? Despite the promise of OVs for treating cancer only one has been approved in the US. Why has this been the case? Reasons such have viral tropism, viral species selection and delivery challenges have all been cited. However, these are also true of other modalities. Why then have oncolytic virus approaches not advanced faster and what are the primary challenges to be overcome? * Will these need to be combined with other agents to realize their full efficacy and how will that impact the market? * Why are these companies pursuing OVs while several others aretaking a pass?
Moderators: Martine Lamfers, PhD * Visiting Scientist, BWH Challenged in development of strategies Demonstrate efficacyRobert Martuza, MD * Consultant in Neurosurgery, MGH * William and Elizabeth Sweet Distinguished Professor ofNeurosurgery, HMS
Modulation mechanism Speakers: Anlong Li, MD, PhD * Clinical Director, Oncology Clinical Development, Merck ResearchLaboratories
IV delivery preferred – delivery alternative are less aggereableJeffrey Infante, MD
* Early development Oncolytic viruses, Oncology, Janssen Research &Development
oncologic virus if it will generate systemic effects the adoption willaccelerate
What areas are the best efficacious Direct effect with intra-tumor single injection with right payload Platform approach Prime with 1 and Boost with 2 – not yetexperimented with
Do not have the data at trial design for stratification of patients Turn off strategy not existing yetLoic Vincent, PhD * Head of Oncology Drug Discovery Unit, Takeda R&D in collaboration with Academic Vaccine platform to explore different payload IV administration may not bring sufficient concentration to the tumor is administer in the blood stream Classification of Patients by prospective response type id UNKNOWN yet, population of patients require stratification* Q&A
2:15 PM – 2:30 PM 2:10 PM – 2:20 PM FIRST LOOK ONCOLYTIC VIRUSES: TURNING PATHOGENS INTO ANTICANCER AGENTS Nino Chiocca, MD, PhD * Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH * Harvey W. Cushing Professor of Neurosurgery, HMS Oncolytic therapy DID NOT WORK Pancreatic Cancer and Glioblastoma Intra- tumoral heterogeniety hinders success Solution: Oncolytic VIRUSES – Immunological “coldness” GADD-34 20,000 GBM 40,000 pancreatic cancer* Q&A
2:25 PM – 2:40 PM2:20 PM – 2:45 PM
ENTREPRENEURIAL GROWTH | ONCOLYTIC VIRUS In 2020 there were a total of 60 phase I trials for Oncolytic Viruses. There are now dozens of companies pursuing some aspect of OV technology. This panel will address: * How are small companies equipped to address the challenges of developing OV therapies better than large pharma or biotech? * Will the success of COVID vaccines based on Adenovirus help the regulatory environment for small companies developing OV products inEurope and the USA?
* Is there a place for non-viral delivery and other immunotherapy companies to engage in the OV space? Would they bring any realadvantages?
Moderator: Reid Huber, PhD * Partner, Third Rock Ventures Critical milestones to observe Speakers: Caroline Breitbach, PhD * VP, R&D Programs and Strategy, Turnstone Biologics Trying Intra-tumor delivery and IV infusion delivery oncolytic vaccinepushing dose
translation biomarkers program transformation tumor microenvironment Brett Ewald, PhD * SVP, Development & Corporate Strategy, DNAtrix Studies gets larger, kicking off Phase III multiple tumors PaulHallenbeck, PhD
* President and Chief Scientific Officer, Seneca Therapeutics Translation: Stephen Russell, MD, PhD* CEO, Vyriad
Systemic delivery Oncolytic Virus IV delivery woman in remission Collaboration with Regeneron Data collection: Imageable reporter secretable reporter, geneexpression
Field is intense systemic oncolytic delivery is exciting in mice and in human, response rates are encouraging combination immune stimulant,check inhibitors
* Q&A
2:50 PM – 3:05 PM2:45 PM – 3:00 PM
BREAK
3:00 PM – 3:25 PM CAR-T | LESSONS LEARNED | WHAT’S NEXT Few areas of potential cancer therapy have had the attention and excitement of CAR-T. This panel of leading executives, developers, and clinician-scientists will explore the current state of CAR-T and its future prospects. Among the questions to be addressed are: * Is CAR-T still an industry priority – i.e. are new investments being made by large companies? Are new companies being financed? Whatare the trends?
* What have we learned from first-generation products, what can we expect from CAR-T going forward in novel targets, combinations, armored CAR’s and allogeneic treatment adoption? * Early trials showed remarkable overall survival and progression-free survival. What has been observed regarding how enduring these responses are? * Most of the approvals to date have targeted CD19, and most recently BCMA. What are the most common forms of relapses that have beenobserved?
* Is there a consensus about what comes after these CD19 and BCMA trials as to additional targets in liquid tumors? How have dual-targeted approaches fared?* Moderator:
* Marcela Maus, MD, PhD * Director, Cellular Immunotherapy Program, Cancer Center, MGH * Associate Professor, Medicine, HMSIs CAR-T Industry priority* Speakers:
* Jakob Dupont, MD
* Head of R&D, Atara BioTherapeutics * Phyno-type of the cells for hematologic cancers* solid tumor
* inventory of Therapeutics for treating patients in the future * Progressive MS program * EBBT platform B-Cells and T-Cells*
* Stefan Hendriks
* Gobal Head, Cell & Gene, Novartis * yes, CGT is a strategy in the present and future * Journey started years ago * Confirmation the effectiveness of CAR-T therapies, 1 year response prolonged to 5 years 26 months * Patient not responding – a lot to learn * Patient after 8 months of chemo can be helped by CAR-T* Christi Shaw
* CEO, Kite
* CAR-T is priority 120 companies in the space * Manufacturing consistency * Patients respond with better quality of life * Blood cancer – more work to be doneQ&A
* 3:30 PM – 3:45 PM 3:30 PM – 3:55 PM HOT TOPICS CAR-T | SOLID TUMORS SUCCESS | WHEN? The potential application of CAR-T in solid tumors will be a game-changer if it occurs. The panel explores the prospects of solid tumor success and what the barriers have been. Questions include: * How would industry and investor strategy for CAR-T and solid tumors be characterized? Has it changed in the last couple of years? * Does the lack of tumor antigen specificity in solid tumors mean that lessons from liquid tumor CAR-T constructs will not translate well and we have to start over? * Whether due to antigen heterogeneity, a hostile tumor micro-environment, or other factors are some specific solid tumors more attractive opportunities than others for CAR-T therapydevelopment?
* Given the many challenges that CAR-T faces in solid tumors, does the use of combination therapies from the start, for example, to mitigate TME effects, offer a more compelling opportunity. Moderator: Oladapo Yeku, MD, PhD * Clinical Assistant in Medicine, MGH window of opportunities studies Speakers: Jennifer Brogdon * Executive Director, Head of Cell Therapy Research, Exploratory Immuno-Oncology, NIBR 2017 CAR-T first approval M&A and research collaborations TCR tumor specific antigens avoid tissue toxicity Knut Niss, PhD* CTO, Mustang Bio
tumor hot start in 12 month clinical trial solid tumors , theraties not ready yet. Combination therapy will be an experimental treatment long journey checkpoint inhibitors to be used in combination maintenance Lipid tumor Barbra Sasu, PhD* CSO, Allogene
T cell response at prostate cancertumor specific
cytokine tumor specific signals move from solid to metastatic cell type for easier infiltration Where we might go: safety autologous and allogeneic Jay Short, PhD * Chairman, CEO, Cofounder, BioAlta, Inc. Tumor type is not enough for development of therapeutics other organs are involved in the periphery difficult to penetrate solid tumors biologics activated in the tumor only, positive changes surrounding all charges, water molecules inside the tissue acidic environment target the cells inside the tumor andnot outside
Combination staggered key is try combination* Q&A
4:00 PM – 4:15 PM4:00 PM – 4:25 PM
GCT MANUFACTURING | VECTOR PRODUCTION | AUTOLOGOUS AND ALLOGENEIC | STEM CELLS | SUPPLY CHAIN | SCALABILITY & MANAGEMENT The modes of GCT manufacturing have the potential of fundamentally reordering long-established roles and pathways. While complexity goes up the distance from discovery to deployment shrinks. With the likelihood of a total market for cell therapies to be over $48 billion by 2027, groups of products are emerging. Stem cell therapies are projected to be $28 billion by 2027 and non-stem cell therapies such as CAR-T are projected be $20 billion by 2027. The manufacturing challenges for these two large buckets are very different. Within the CAR-T realm there are diverging trends of autologous and allogeneic therapies and the demands on manufacturing infrastructure are very different. Questions for the panelists are: * Help us all understand the different manufacturing challenges for cell therapies. What are the trade-offs among storage cost, batch size, line changes in terms of production cost and what is the current state of scaling naïve and stem cell therapy treatment vs engineeredcell therapies?
* For cell and gene therapy what is the cost of Quality Assurance/Quality Control vs. production and how do you think this will trend over time based on your perspective on learning curvestoday?
* Will point of care production become a reality? How will that change product development strategy for pharma and venture investors? What would be the regulatory implications for such products? * How close are allogeneic CAR-T cell therapies? If successful what are the market implications of allogenic CAR-T? What are the cost implications and rewards for developing allogeneic cell therapytreatments?
Moderator: Michael Paglia* VP, ElevateBio
Speakers:
* Dannielle Appelhans * SVP TechOps and Chief Technical Officer, Novartis Gene Therapies* Thomas Page, PhD
* VP, Engineering and Asset Development, FUJIFILM DiosynthBiotechnologies
* Rahul Singhvi, ScD * CEO and Co-Founder, National Resilience, Inc. * Thomas VanCott, PhD * Global Head of Product Development, Gene & Cell Therapy, Catalent * 2/3 autologous 1/3 allogeneic CAR-T high doses and high populations scale up is not done today quality maintain required the timing logistics issues centralized vs decentralized allogeneic are health donors innovations in cell types in use improvements inmanufacturing
Ropa Pike, Director, Enterprise Science & Partnerships, ThermoFisher Scientific
Centralized biopharma industry is moving to decentralized models site specific license* Q&A
4:30 PM – 4:45 PM 4:30 PM – 4:40 PM FIRST LOOKCAR-T
Marcela Maus, MD, PhD * Director, Cellular Immunotherapy Program, Cancer Center, MGH * Assistant Professor, Medicine, HMS Fit-to-purpose CAR-T cells: 3 lead programsTr-fill
CAR-T induce response myeloma and multiple myeloma GBM27 patents on CAR-T
+400 patients treaded 40 Clinical Trials* Q&A
4:40 PM – 5:00 PM 4:40 PM – 4:50 PM FIRST LOOK REPURPOSED TUMOR CELLS AS KILLERS AND IMMUNOMODULATORS FOR CANCERTHERAPY
Khalid Shah, PhD
* Vice Chair, Neurosurgery Research, BWH * Director, Center for Stem Cell Therapeutics and Imaging, HMS Solid tumors are the hardest to treat because: immunosuppressive, hypoxic, Acidic Use of autologous tumor cells self homing ThTC self targeting therapeutic cells Therapeutic tumor cells efficacy pre-clinical models GBM 95% metastesis ThTC translation to patientsettings
* Q&A
4:50 PM – 5:10 PM 4:50 PM – 5:00 PM FIRST LOOK OTHER CELL THERAPIES FOR CANCERDavid Scadden, MD
* Director, Center for Regenerative Medicine; Co-Director, Harvard Stem Cell Institute, Director, Hematologic Malignancies & ExperimentalHematology, MGH
* Jordan Professor of Medicine, HMS T-cell are made in bone marrow create cryogel can be an off-the-shelf product repertoire on T Receptor CCL19+ mesenchymal cells mimic Tymus cells – inter-tymic injection. Non human primate validationQ&A
5:00 PM – 5:20 PM 5:00 PM – 5:20 PM FIRESIDE FIRESIDE WITH MIKAEL DOLSTEN, MD, PHD Introducer: Jonathan Kraft Moderator: Daniel Haber, MD, PhD * Chair, Cancer Center, MGH * Isselbacher Professor of Oncology, HMS Vaccine Status Mikael Dolsten, MD, PhD * Chief Scientific Officer and President, Worldwide Research, Development and Medical, Pfizer Deliver vaccine around the Globe, Israel, US, Europe. 3BIL vaccine in 2022 for all Global vaccination Bio Ntech in Germany Experience with Biologics immuneoncology & allogeneic antibody cells – new field for drug discovery mRNA curative effort and cancer vaccine Access to drugs developed by Pfizer to underdeveloped countries* Q&A
5:25 PM – 5:40 AM5:20 PM – 5:30 PM
CLOSING REMARKS
THURSDAY, MAY 20, 20218:00 AM – 8:25 AM
GCT | THE CHINA JUGGERNAUT China embraced gene and cell therapies early. The first China gene therapy clinical trial was in 1991. China approved the world’s first gene therapy product in 2003—Gendicine—an oncolytic adenovirus for the treatment of advanced head and neck cancer. Driven by broad national strategy, China has become a hotbed of GCT development, ranking second in the world with more than 1,000 clinical trials either conducted or underway and thousands of related patents. It has a booming GCT biotech sector, led by more than 45 local companies with growing IND pipelines. In late 1990, a T cell-based immunotherapy, cytokine-induced killer (CIK) therapy became a popular modality in the clinic in China for tumor treatment. In early 2010, Chinese researchers started to carry out domestic CAR T trials inspired by several important reports suggested the great antitumor function of CAR T cells. Now, China became the country with the most registered CAR T trials, CAR T therapy is flourishing in China. The Chinese GCT ecosystem has increasingly rich local innovation and growing complement of development and investment partnerships – and also many subtleties. This panel, consisting of leaders from the China GCT corporate, investor, research and entrepreneurial communities, will consider strategic questions on the growth of the gene and cell therapy industry in China, areas of greatest strength, evolving regulatory framework, early successes and products expected to reach the US and world market. Moderator: Min Wu, PhD * Managing Director, Fosun Health Fund What are the area of CGT in China, regulatory similar to the US Speakers: Alvin Luk, PhD * CEO, Neuropath Therapeutics Monogenic rare disease with clear genomic target Increase of 30% in patient enrollment Regulatory reform approval is 60 days no delayPin Wang, PhD * CSO, Jiangsu Simcere Pharmaceutical Co., Ltd. Similar starting point in CGT as the rest of the World unlike a later starting point in other biologicalRichard Wang, PhD * CEO, Fosun Kite Biotechnology Co., Ltd Possibilities to be creative and capitalize the new technologies forinnovating drug
Support of the ecosystem by funding new companie allowing the industry to be developed in China Autologous in patients differences cost challengeTian Xu, PhD * Vice President, Westlake University ICH committee and Chinese FDA -r regulation similar to the US Difference is the population recruitment, in China patients are active participants in skin disease Active in development of transposome Development of non-viral methods, CRISPR still in D and transposome In China price of drugs regulatory are sensitive Shunfei Yan, PhD * Investment Manager, InnoStar Capital Indication driven: Hymophilia, Allogogenic efficiency therapies Licensing opportunities* Q&A
8:30 AM – 8:45 AM8:30 AM – 8:55 AM
IMPACT OF MRNA VACCINES | GLOBAL SUCCESS LESSONS The COVID vaccine race has propelled mRNA to the forefront of biomedicine. Long considered as a compelling modality for therapeutic gene transfer, the technology may have found its most impactful application as a vaccine platform. Given the transformative industrialization, the massive human experience, and the fast development that has taken place in this industry, where is the horizon? Does the success of the vaccine application, benefit or limit its use as a therapeutic for CGT? * How will the COVID success impact the rest of the industry both in therapeutic and prophylactic vaccines and broader mRNA lessons? * How will the COVID success impact the rest of the industry both on therapeutic and prophylactic vaccines and broader mRNA lessons? * Beyond from speed of development, what aspects make mRNA so well suited as a vaccine platform? * Will cost-of-goods be reduced as the industry matures? * How does mRNA technology seek to compete with AAV and other genetherapy approaches?
Moderator: Lindsey Baden, MD * Director, Clinical Research, Division of Infectious Diseases, BWH * Associate Professor, HMS In vivo delivery process regulatory cooperation new opportunities for same platform for new indication Speakers:* Melissa Moore
* Chief Scientific Officer, Moderna Many years of mRNA pivoting for new diseases, DARPA, nucleic Acids global deployment of a manufacturing unit on site where the need arise Elan Musk funds new directions at Moderna How many mRNA can be put in one vaccine: Dose and tolerance to achieveefficacy
45 days for Personalized cancer vaccine one per patient* Ron Renaud
* CEO, Translate Bio 1.6 Billion doses produced rare disease monogenic correct mRNA like CF multiple mutation infection disease and oncology applications Platform allowing to swap cargo reusing same nanoparticles address disease beyond Big Pharma options for biotech WHat strain of Flu vaccine will come back in the future when people donot use masks
* Kate Bingham, UK Vaccine Taskforce July 2020, AAV vs mRNA delivery across UK local centers administered both types supply and delivery uplift* Q&A
9:00 AM – 9:15 AM 9:00 AM – 9:25 AM HOT TOPICS BENIGN BLOOD DISORDERS Hemophilia has been and remains a hallmark indication for the CGT. Given its well-defined biology, larger market, and limited need for gene transfer to provide therapeutic benefit, it has been at the forefront of clinical development for years, however, product approval remains elusive. What are the main hurdles to this success? Contrary to many indications that CGT pursues no therapeutic options are available to patients, hemophiliacs have an increasing number of highly efficacious treatment options. How does the competitive landscape impact this field differently than other CGT fields? With many different players pursuing a gene therapy option for hemophilia, what are the main differentiators? Gene therapy for hemophilia seems compelling for low and middle-income countries, given the cost of currently available treatments; does your company see opportunities in this market? Moderator: Nancy Berliner, MD * Chief, Division of Hematology, BWH * H. Franklin Bunn Professor of Medicine, HMS Speakers: Theresa Heggie * CEO, Freeline Therapeutics Safety concerns, high burden of treatment CGT has record of safety and risk/benefit adoption of Tx functional cure CGT is potent Tx relative small quantity of protein needs be delivered Potency and QUALITY less quantity drug and greater POTENCY risk of delivery unwanted DNA, capsules are critical analytics is critical regulator involvement in potency definition Close of collaboration is excitingGallia Levy, MD, PhD * Chief Medical Officer, Spark Therapeutics Hemophilia CGT is the highest potential for Global access logistics in underdeveloped countries working with NGOs practicality of the Tx Roche reached 120 Counties great to be part of the Roche GroupAmirNashat, PhD
* Managing Partner, Polaris VenturesSuneet Varma
* Global President of Rare Disease, Pfizer Gene therapy at Pfizer small molecule, large molecule and CGT – spectrum of choice allowing Hemophilia patients to marry 1/3 internal 1/3 partnership 1/3 acquisitions Learning from COVID-19 is applied for other vaccine development review of protocols and CGT for Hemophelia You can’t buy Time With MIT Pfizer is developing a model for Hemopilia CGT treatment* Q&A
9:30 AM – 9:45 AM 9:25 AM – 9:35 AM FIRST LOOK TREATING RETT SYNDROME THROUGH X-REACTIVATION Jeannie Lee, MD, PhD * Molecular Biologist, MGH * Professor of Genetics, HMS 200 disease X chromosome unlock for neurological genetic diseases: Rett Syndromeand other autism spectrum disorders female model vs malemice model
deliver protein to the brain restore own missing or dysfunctional protein Epigenetic not CGT – no exogent intervention Xist ASO drugFemale model
* Q&A
9:35 AM – 9:55 AM 9:35 AM – 9:45 AM FIRST LOOK RARE BUT MIGHTY: SCALING UP SUCCESS IN SINGLE GENE DISORDERSFlorian Eichler, MD
* Director, Center for Rare Neurological Diseases, MGH * Associate Professor, Neurology, HMS Single gene disorder NGS enable diagnosis, DIagnosis to Treatment How to know whar cell to target, make it available and scale up Address gap: missing components Biomarkers to cell types lipid chemistry cellanimal biology
crosswalk from bone marrow matter New gene discovered that causes neurodevelopment of stagnant genes Examining new Biology cell type specific biomarkers* Q&A
9:45 AM – 10:05 AM 9:50 AM – 10:15 AM HOT TOPICS DIABETES | GRAND CHALLENGE The American Diabetes Association estimates 30 million Americans have diabetes and 1.5 million are diagnosed annually. GCT offers the prospect of long-sought treatment for this enormous cohort and their chronic requirements. The complexity of the disease and its management constitute a grand challenge and highlight both the potential of GCT and its current limitations. * Islet transplantation for type 1 diabetes has been attempted for decades. Problems like loss of transplanted islet cells due to autoimmunity and graft site factors have been difficult to address. Is there anything different on the horizon for gene and cell therapies to help this be successful? * How is the durability of response for gene or cell therapies for diabetes being addressed? For example, what would the profile of an acceptable (vs. optimal) cell therapy look like? Moderator: Marie McDonnell, MD * Chief, Diabetes Section and Director, Diabetes Program, BWH * Lecturer on Medicine, HMS Type 1 Diabetes cost of insulin for continuous delivery of drug alternative treatments: The Future: neuropotent stem cells What keeps you up at night Speakers: Tom Bollenbach, PhD * Chief Technology Officer, Advanced Regenerative ManufacturingInstitute
Data managment sterility sensors, cell survival after implantation, stem cells manufacturing, process development in manufacturing ofcomplex cells
Data and instrumentation the Process is the Product Manufacturing tight schedules Manasi Jaiman, MD * Vice President, Clinical Development, ViaCyte * Pediatric Endocrinologist continous glucose monitoring Bastiano Sanna, PhD * EVP, Chief of Cell & Gene Therapies and VCGT Site Head, VertexPharmaceuticals
100 years from discovering Insulin, Insulin is not a cure in 2021 – asking patients to partner more Produce large quantities of the Islet cells encapsulation technologybeen developed
Scaling up is a challengeRogerio Vivaldi, MD * CEO, Sigilon Therapeutics Advanced made, Patient of Type 1 Outer and Inner compartments of spheres (not capsule) no immune suppression continuous secretion of enzyme Insulin independence without immune suppression Volume to have of-the-shelf inventory oxegenation in location lymphatic and vascularization conrol the whole process modular platform learning from others* Q&A
10:20 AM – 10:35 AM 10:20 AM – 10:40 AM FIRESIDE BUILDING A UNIFIED GCT STRATEGY Introducer: John Fish* CEO, Suffolk
* Chairman of Board Trustees, Brigham Health Moderator: Meg Tirrell * Senior Health and Science Reporter, CNBC Last year, what was it at Novartis Speaker: Jay Bradner, MD* President, NIBR
Keep eyes open, waiting the Pandemic to end and enable working back onall the indications
Portfolio of MET, Mimi Emerging Therapies Learning from the Pandemic – operationalize the practice science, R&D leaders, new collaboratives at NIH, FDA, Novartis Pursue programs that will yield growth, tropic diseases with Gates Foundation, Rising Tide pods for access CGT within Novartis Partnership with UPenn in Cell Therapy Cost to access to IP from Academia to a Biotech CRISPR accessing few translations to Clinic Protein degradation organization constraint valuation by parties in apartnership
Novartis: nuclear protein lipid nuclear particles, tamplate for Biotech to collaborate Game changing: 10% of the Portfolio, New frontiers human genetics in Ophthalmology, CAR-T, CRISPR, Gene Therapy Neurological and payloadsof different matter
* Q&A
10:45 AM – 11:00 AM 10:40 AM – 10:50 AMBREAK
10:50 AM – 11:00 AM FIRST LOOK GETTING TO THE HEART OF THE MATTER: CURING GENETIC CARDIOMYOPATHY Christine Seidman, MD * Director, Cardiovascular Genetics Center, BWH * Smith Professor of Medicine & Genetics, HMS THE VOICE OF DR. SEIDMAN – HER ABSTRACT IS CITED BELOW The ultimate opportunity presented by discovering the genetic basis of human disease is accurate prediction and disease prevention. To enable this achievement, genetic insights must enable the identification ofat-risk
individuals prior to end-stage disease manifestations and strategies that delay or prevent clinical expression. Genetic cardiomyopathies provide a paradigm for fulfilling these opportunities. Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy, diastolic dysfunction with normal or enhanced systolic performance and a unique histopathology: myocyte hypertrophy, disarray and fibrosis. Dilated cardiomyopathy (DCM) exhibits enlarged ventricular volumes with depressed systolic performance and nonspecific histopathology. Both HCM and DCM are prevalent clinical conditions that increase risk for arrhythmias, sudden death, and heart failure. Today treatments for HCM and DCM focus on symptoms, but none prevent disease progression. Human molecular genetic studies demonstrated that these pathologies often result from dominant mutations in genes that encode protein components of the sarcomere, the contractile unit in striated muscles. These data combined with the emergence of molecular strategies to specifically modulate gene expression provide unparalleled opportunities to silence or correct mutant genes and to boost healthy gene expression in patients with genetic HCM and DCM. Many challenges remain, but the active and vital efforts of physicians, researchers, and patients are poised to ensure success. Hypertrophic and Dilated Cardiomyopaies ‘ 10% receive heart transplant 12 years survival Mutation puterb function TTN: contribute 20% of dilated cardiomyopatySilence gene
pleuripotential cells deliver therapies* Q&A
11:00 AM – 11:20 AM 11:00 AM – 11:10 AM FIRST LOOK UNLOCKING THE SECRET LIVES OF PROTEINS IN HEALTH AND DISEASEAnna Greka, MD, PhD
* Medicine, BWH
* Associate Professor, Medicine, HMS Cyprus Island, kidney disease by mutation causing MUC1 accumulation and death BRD4780 molecule that will clear the misfolding proteins from the kidney organoids: pleuripotent stem cells small molecule developed for applications in the other cell types in brain, eye, gene mutation build mechnism for therapy clinical models transition fromAcademia to biotech
Q&A
* 11:10 AM – 11:30 AM 11:10 AM – 11:35 AM RARE AND ULTRA RARE DISEASES | GCT BREAKS THROUGH One of the most innovative segments in all of healthcare is the development of GCT driven therapies for rare and ultra-rare diseases. Driven by a series of insights and tools and funded in part by disease focused foundations, philanthropists and abundant venture funding disease after disease is yielding to new GCT technology. These often become platforms to address more prevalent diseases. The goal of making these breakthroughs routine and affordable is challenged by a range of issues including clinical trial design and pricing. * What is driving the interest in rare diseases? * What are the biggest barriers to making breakthroughs ‘routineand affordable?’
* What is the role of retrospective and prospective natural history studies in rare disease? When does the expected value of retrospective disease history studies justify the cost? * Related to the first question, what is the FDA expecting as far as controls in clinical trials for rare diseases? How does this impact the collection of natural history data? Moderator: Susan Slaugenhaupt, PhD * Scientific Director and Elizabeth G. Riley and Daniel E. Smith Jr., Endowed Chair, Mass General Research Institute * Professor, Neurology, HMS Speakers: Leah Bloom, PhD * SVP, External Innovation and Strategic Alliances, Novartis GeneTherapies
Ultra rare (less than 100) vs rare difficulty to recruit patients and to follow up after treatment Bobby Gaspar, MD, PhD * CEO, Orchard Therapeutics Study of rare condition have transfer to other larger diseases – delivery of therapeutics genes, like immune disorders Patient testimonials just to hear what a treatment can make EmilKakkis, MD, PhD
* CEO, Ultragenyx
Do 100 patient study then have information on natural history to develop a clinical trial Stuart Peltz, PhD * CEO, PTC Therapeutics Rare disease, challenge for FDA approval and after market commercialization follow ups Justification of cost for Rare disease – demonstration of Change is IP in value patients advocacy is helpful* Q&A
11:40 AM – 11:55 AM 11:40 AM – 12:00 PM FIRESIDE PARTNERING ACROSS THE GCT SPECTRUM Moderator: Erin Harris * Chief Editor, Cell & Gene Perspective & professional tenure Partnership in manufacturing what are the recommendations? Hospital systems: Partnership Challenges Speaker: Marc Casper* CEO, ThermoFisher
25 years in Diagnostics last 20 years at ThermoFisher products used in the Lab for CAR-T research and manufacture CGT Innovations: FDA will have a high level of approval each year How move from research to clinical trials to manufacturing Quickerprocess
Best practices in Partnerships: the root cause if acceleration to market service providers to deliver highest standards Building capacity by acquisition to avoid the waiting time Accelerate new products been manufactured Collaborations with Academic Medical center i.e., UCSF in CGT joint funding to accelerate CGT to clinics’ Customers are extremely knowledgable, scale the capital investmentmade investment
150MIL a year to improve the Workflow* Q&A
12:05 PM – 12:20 PM 12:05 PM – 12:30 PM * 12:05 PM – 12:20 PM 12:05 PM – 12:30 PM CEO PANEL | ANTICIPATING DISRUPTION | PLANNING FOR WIDESPREAD GCT The power of GCT to cure disease has the prospect of profoundly improving the lives of patients who respond. Planning for a disruption of this magnitude is complex and challenging as it will change care across the spectrum. Leading chief executives shares perspectives on how the industry will change and how this change should be anticipated. Moderator: Meg Tirrell * Senior Health and Science Reporter, CNBC CGT becoming staple therapy what are the disruptors emerging Speakers:Lisa Dechamps
* SVP & Chief Business Officer, Novartis Gene Therapies Reimagine medicine with collaboration at MGH, MDM condition inchildren
The Science is there, sustainable processes and systems impact istransformational
Value based pricing, risk sharing Payers and Pharma for one time therapy with life span effect Collaboration with FDAKieran Murphy * CEO, GE Healthcare Diagnosis of disease to be used in CGT 2021 investment in CAR-T platform Investment in several CGT frontier Investment in AI, ML in system design new technologies GE: Scale and Global distributions, sponsor companies in software Waste in Industry – Healthcare % of GDP, work with MGH to smooth the workflow faster entry into hospital and out of Hospital Telemedicine during is Pandemic: Radiologist needs to read remotely Supply chain disruptions slow down all ecosystem Production of ventilators by collaboration with GM – ingenuity Scan patients outside of hospital a scanner in a Box ChristianRommel, PhD
* Head, Pharmaceuticals Research & Development, Bayer AG CGT – 2016 and in 2020 new leadership and capability Disease Biology and therapeutics Regenerative Medicine: CGT vs repair building pipeline in ophthalmology and cardiovascular During Pandemic: Deliver Medicines like Moderna, Pfizer – collaborations between competitors with Government Bayer entered into Vaccines in 5 days, all processes had to change access innovations developed over decades for medical solutions* Q&A
12:35 PM – 12:50 PM 12:35 PM – 12:55 PM FIRESIDE BUILDING A GCT PORTFOLIO GCT represents a large and growing market for novel therapeutics that has several segments. These include Cardiovascular Disease, Cancer, Neurological Diseases, Infectious Disease, Ophthalmology, Benign Blood Disorders, and many others; Manufacturing and Supply Chain including CDMO’s and CMO’s; Stem Cells and Regenerative Medicine; Tools and Platforms (viral vectors, nano delivery, gene editing, etc.). Bayer’s pharma business participates in virtually all of these segments. How does a Company like Bayer approach the development of a portfolio in a space as large and as diverse as this one? How does Bayer approach the support of the production infrastructure with unique demands and significant differences from its historical requirements? Moderator: Shinichiro Fuse, PhD * Managing Partner, MPM Capital Speaker: Wolfram Carius, PhD * EVP, Pharmaceuticals, Head of Cell & Gene Therapy, Bayer AG CGT will bring treatment to cure, delivery of therapies Be a Leader repair, regenerate, cure Technology and Science for CGT – building a portfolio vs single asset decision criteria development of IP market access patients access acceleration of new products Bayer strategy: build platform for use by four domainsGener augmentation
Autologeneic therapy, analyticsGene editing
Oncology Cell therapy tumor treatment: What kind of cells – the juryis out
Of 23 product launch at Bayer no prediction is possible some high somelows
* Q&A
1:00 PM – 1:15 PM 12:55 PM – 1:35 PMLUNCH
1:40 PM – 2:05 PM GCT DELIVERY | PERFECTING THE TECHNOLOGY Gene delivery uses physical, chemical, or viral means to introduce genetic material into cells. As more genetically modified therapies move closer to the market, challenges involving safety, efficacy, and manufacturing have emerged. Optimizing lipidic and polymer nanoparticles and exosomal delivery is a short-term priority. This panel will examine how the short-term and long-term challenges are being tackled particularly for non-viral delivery modalities. Moderator: Natalie Artzi, PhD * Assistant Professor, BWH Speakers: Geoff McDonough, MD * CEO, Generation BioSonya Montgomery
* CMO, Evox Therapeutics Laura Sepp-Lorenzino, PhD * Chief Scientific Officer, Executive Vice President, IntelliaTherapeutics
Doug Williams, PhD
* CEO, Codiak BioSciences* Q&A
2:10 PM – 2:25 PM2:05 PM – 2:10 PM
INVENTION DISCOVERY GRANT ANNOUNCEMENT 2:10 PM – 2:20 PM FIRST LOOK ENHANCING VESICLES FOR THERAPEUTIC DELIVERY OF BIOPRODUCTS Xandra Breakefield, PhD * Geneticist, MGH, MGH * Professor, Neurology, HMS* Q&A
2:20 PM – 2:35 PM 2:20 PM – 2:30 PM FIRST LOOK VERSATILE POLYMER-BASED NANOCARRIERS FOR TARGETED THERAPY ANDIMMUNOMODULATION
Natalie Artzi, PhD
* Assistant Professor, BWH* Q&A
2:30 PM – 2:45 PM 2:55 PM – 3:20 PM HOT TOPICS GENE EDITING | ACHIEVING THERAPEUTIC MAINSTREAM Gene editing was recognized by the Nobel Committee as “one of gene technology’s sharpest tools, having a revolutionary impact on life sciences.” Introduced in 2011, gene editing is used to modify DNA. It has applications across almost all categories of disease and is also being used in agriculture and public health. Today’s panel is made up of pioneers who represent foundational aspects of gene editing. They will discuss the movement of the technology into the therapeutic mainstream. * Successes in gene editing – lessons learned from late-stage assets (sickle cell, ophthalmology) * When to use what editing tool – pros and cons of traditional gene-editing v. base editing. Is prime editing the future? Specific use cases for epigenetic editing. * When we reach widespread clinical use – role of off-target editing – is the risk real? How will we mitigate? How practical is patient-specific off-target evaluation? Moderator: J. Keith Joung, MD, PhD * Robert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist,MGH
* Professor of Pathology, HMS Speakers: John Evans * CEO, Beam TherapeuticsLisa Michaels
* EVP & CMO, Editas Medicine* Q&A
3:25 PM – 3:50 PM 3:25 PM – 3:50 PM HOT TOPICS COMMON BLOOD DISORDERS | GENE THERAPY There are several dozen companies working to develop gene or cell therapies for Sickle Cell Disease, Beta Thalassemia, and Fanconi Anemia. In some cases, there are enzyme replacement therapies that are deemed effective and safe. In other cases, the disease is only managed at best. This panel will address a number of questions that are particular to this class of genetic diseases: * What are the pros and cons of various strategies for treatment? There are AAV-based editing, non-viral delivery even oligonucleotide recruitment of endogenous editing/repair mechanisms. Which approaches are most appropriate for which disease? * How can companies increase the speed of recruitment for clinical trials when other treatments are available? What is the best approach to educate patients on a novel therapeutic? * How do we best address ethnic and socio-economic diversity to be more representative of the target patient population? * How long do we have to follow up with the patients from the scientific, patient’s community, and payer points of view? What are the current FDA and EMA guidelines for long-term follow-up? * Where are we with regards to surrogate endpoints and their application to clinically meaningful endpoints? * What are the emerging ethical dilemmas in pediatric gene therapy research? Are there challenges with informed consent and pediatric assent for trial participation? * Are there differences in reimbursement policies for these different blood disorders? Clearly durability of response is a big factor. Are there other considerations? Moderator: David Scadden, MD * Director, Center for Regenerative Medicine; Co-Director, Harvard Stem Cell Institute, Director, Hematologic Malignancies & ExperimentalHematology, MGH
* Jordan Professor of Medicine, HMS Speakers: Samarth Kukarni, PhDNick
Leschly
* Chief Bluebird, Bluebird Bio Mike McCune, MD, PhD * Head, HIV Frontiers, Global Health Innovative Technology Solutions, Bill & Melinda Gates Foundation* Q&A
3:55 PM – 4:15 PM 3:50 PM – 4:00 PM FIRST LOOKGENE EDITING
J. Keith Joung, MD, PhD * Robert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist,MGH
* Professor of Pathology, HMS* Q&A
4:00 PM – 4:20 PM 4:20 PM – 4:45 PM HOT TOPICS GENE EXPRESSION | MODULATING WITH OLIGONUCLEOTIDE-BASED THERAPIES Oligonucleotide drugs have recently come into their own with approvals from companies such as Biogen, Alnylam, Novartis and others. This panel will address several questions: How important is the delivery challenge for oligonucleotides? Are technological advancements emerging that will improve the delivery of oligonucleotides to the CNS or skeletal muscle after systemicadministration?
* Will oligonucleotides improve as a class that will make them even more effective? Are further advancements in backbone chemistry anticipated, for example. * Will oligonucleotide based therapies blaze trails for follow-on gene therapy products? * Are small molecules a threat to oligonucleotide-based therapies? * Beyond exon skipping and knock-down mechanisms, what other roles will oligonucleotide-based therapies take mechanistically — can genes be activating oligonucleotides? Is there a place for multiple mechanism oligonucleotide medicines? * Are there any advantages of RNAi-based oligonucleotides over ASOs, and if so for what use? Moderator: Jeannie Lee, MD, PhD * Molecular Biologist, MGH * Professor of Genetics, HMS Speakers: Bob Brown, PhD * CSO, EVP of R&D, DicernaBrett Monia, PhD
* CEO, Ionis
Alfred Sandrock, MD, PhD * EVP, R&D and CMO, Biogen* Q&A
4:50 PM – 5:05 PM 4:45 PM – 4:55 PM FIRST LOOK RNA THERAPY FOR BRAIN CANCER Pierpaolo Peruzzi, MD, PhD* Nuerosurgery, BWH
* Assistant Professor of Neurosurgery, HMS* Q&A
4:55 PM – 5:15 PM FRIDAY, MAY 21, 20218:30 AM – 8:55 AM
VENTURE INVESTING | SHAPING GCT TRANSLATION What is occurring in the GCT venture capital segment? Which elements are seeing the most activity? Which areas have cooled? How is the investment market segmented between gene therapy, cell therapy and gene editing? What makes a hot GCT company? How long will the market stay frothy? Some review of demographics — # of investments, sizes, etc. Why is the market hot and how long do we expect it to stay that way? Rank the top 5 geographic markets for GCT company creation and investing? Are there academic centers that have been especially adept at accelerating GCT outcomes? Do the business models for the rapid development of coronavirus vaccine have any lessons for how GCT technology can be brought to market more quickly? Moderator: MeredithFisher, PhD
* Partner, Mass General Brigham Innovation Fund Speakers: David Berry, MD, PhD* CEO, Valo Health
* General Partner, Flagship PioneeringRobert Nelsen
* Managing Director, Co-founder, ARCH Venture Partners Kush Parmar, MD, PhD * Managing Partner, 5AM Ventures* Q&A
9:00 AM – 9:15 AM9:00 AM – 9:25 AM
REGENERATIVE MEDICINE | STEM CELLS The promise of stem cells has been a highlight in the realm of regenerative medicine. Unfortunately, that promise remains largely in the future. Recent breakthroughs have accelerated these potential interventions in particular for treating neurological disease. Among the topics the panel will consider are: * Stem cell sourcing * Therapeutic indication growth * Genetic and other modification in cell production * Cell production to final product optimization and challenges * How to optimize the final product Moderator: Ole Isacson, MD, PhD * Director, Neuroregeneration Research Institute, McLean * Professor, Neurology and Neuroscience, HMS Speakers: Kapil Bharti, PhD * Senior Investigator, Ocular and Stem Cell Translational ResearchSection, NIH
Joe Burns, PhD
* VP, Head of Biology, Decibel TherapeuticsErin Kimbrel, PhD
* Executive Director, Regenerative Medicine, Astellas Nabiha Saklayen, PhD * CEO and Co-Founder, Cellino* Q&A
9:30 AM – 9:45 AM 9:25 AM – 9:35 AM FIRST LOOKSTEM CELLS
Bob Carter, MD, PhD
* Chairman, Department of Neurosurgery, MGH * William and Elizabeth Sweet, Professor of Neurosurgery, HMS* Q&A
9:35 AM – 9:55 AM 9:35 AM – 10:00 AM CAPITAL FORMATION ’21-30 | INVESTING MODES DRIVING GCT TECHNOLOGYAND TIMING
The dynamics of venture/PE investing and IPOs are fast evolving. What are the drivers – will the number of investors grow will the size of early rounds continue to grow? How is this reflected in GCT target areas, company design, and biotech overall? Do patients benefit from these trends? Is crossover investing a distinct class or a little of both? Why did it emerge and what are the characteristics of the players? Will SPACs play a role in the growth of the gene and cell therapy industry. What is the role of corporate investment arms eg NVS, Bayer, GV, etc. – has a category killer emerged? Are we nearing the limit of what the GCT market can absorb or will investment capital continue to grow unabated? Moderator: Roger Kitterman * VP, Venture, Mass General Brigham Speakers: Ellen Hukkelhoven, PhD * Managing Director, Perceptive Advisors Peter Kolchinsky, PhD * Founder and Managing Partner, RA Capital ManagementDeep Nishar
* Senior Managing Partner, SoftBank Investment AdvisorsOleg Nodelman
* Founder & Managing Partner, EcoR1 Capital* Q&A
10:05 AM – 10:20 AM 10:00 AM – 10:10 AM FIRST LOOK NEW SCIENTIFIC AND CLINICAL DEVELOPMENTS FOR AUTOLOGOUS STEM CELL THERAPY FOR PARKINSON’S DISEASE PATIENTS Penelope Hallett, PhD* NRL, McLean
* Assistant Professor Psychiatry, HMS* Q&A
10:10 AM – 10:30 AM 10:10 AM – 10:35 AM HOT TOPICS NEURODEGENERATIVE CLINICAL OUTCOMES | ACHIEVING GCT SUCCESS Can stem cell-based platforms become successful treatments for neurodegenerative diseases? * What are the commonalities driving GCT success in neurodegenerative disease and non-neurologic disease, what are the keydifferences?
* Overcoming treatment administration challenges * GCT impact on degenerative stage of disease * How difficult will it be to titrate the size of the cell therapy effect in different neurological disorders and for different patients? * Demonstrating clinical value to patients and payers * Revised clinical trial models to address issues and concernsspecific to GCT
Moderator: Bob Carter, MD, PhD * Chairman, Department of Neurosurgery, MGH * William and Elizabeth Sweet, Professor of Neurosurgery, HMS Speakers: Erwan Bezard, PhD * INSERM Research Director, Institute of Neurodegenerative DiseasesNikola Kojic, PhD
* CEO and Co-Founder, Oryon Cell TherapiesGeoff MacKay
* President & CEO, AVROBIOViviane Tabar, MD
* Founding Investigator, BlueRock Therapeutics * Chair of Neurosurgery, Memorial Sloan Kettering* Q&A
10:40 AM – 10:55 AM 10:35 AM – 11:35 AM DISRUPTIVE DOZEN: 12 TECHNOLOGIES THAT WILL REINVENT GCT Nearly one hundred senior Mass General Brigham Harvard faculty contributed to the creation of this group of twelve GCT technologies that they believe will breakthrough in the next two years. The Disruptive Dozen identifies and ranks the GCT technologies that will be available on at least an experimental basis to have the chance of significantly improving health care. 11:35 AM – 11:45 AMCONCLUDING REMARKS
FRIDAY, MAY 21, 2021 COMPUTER CONNECTION TO THE ICLOUD OF WORDPRESS.COM FROZE COMPLETELY AT 10:30AM EST AND NO FILE UPDATE WAS POSSIBLE. COVERAGE OF MAY 21, 2021 IS RECORDED BELOW FOLLOWING THE AGENDA BY COPY AN DPASTE OF ALL THE TWEETS I PRODUCED ON MAY 21, 2021 8:30 AM – 8:55 AM VENTURE INVESTING | SHAPING GCT TRANSLATION What is occurring in the GCT venture capital segment? Which elements are seeing the most activity? Which areas have cooled? How is the investment market segmented between gene therapy, cell therapy and gene editing? What makes a hot GCT company? How long will the market stay frothy? Some review of demographics — # of investments, sizes, etc. Why is the market hot and how long do we expect it to stay that way? Rank the top 5 geographic markets for GCT company creation and investing? Are there academic centers that have been especially adept at accelerating GCT outcomes? Do the business models for the rapid development of coronavirus vaccine have any lessons for how GCT technology can be brought to market more quickly? Moderator: MeredithFisher, PhD
* Partner, Mass General Brigham Innovation Fund Speakers: David Berry, MD, PhD* CEO, Valo Health
* General Partner, Flagship PioneeringRobert Nelsen
* Managing Director, Co-founder, ARCH Venture Partners Kush Parmar, MD, PhD * Managing Partner, 5AM Ventures* Q&A
9:00 AM – 9:15 AM9:00 AM – 9:25 AM
REGENERATIVE MEDICINE | STEM CELLS The promise of stem cells has been a highlight in the realm of regenerative medicine. Unfortunately, that promise remains largely in the future. Recent breakthroughs have accelerated these potential interventions in particular for treating neurological disease. Among the topics the panel will consider are: * Stem cell sourcing * Therapeutic indication growth * Genetic and other modification in cell production * Cell production to final product optimization and challenges * How to optimize the final product Moderator: Ole Isacson, MD, PhD * Director, Neuroregeneration Research Institute, McLean * Professor, Neurology and Neuroscience, HMS Speakers: Kapil Bharti, PhD * Senior Investigator, Ocular and Stem Cell Translational ResearchSection, NIH
Joe Burns, PhD
* VP, Head of Biology, Decibel TherapeuticsErin Kimbrel, PhD
* Executive Director, Regenerative Medicine, Astellas Nabiha Saklayen, PhD * CEO and Co-Founder, Cellino* Q&A
9:30 AM – 9:45 AM 9:25 AM – 9:35 AM FIRST LOOKSTEM CELLS
Bob Carter, MD, PhD
* Chairman, Department of Neurosurgery, MGH * William and Elizabeth Sweet, Professor of Neurosurgery, HMS* Q&A
9:35 AM – 9:55 AM 9:35 AM – 10:00 AM CAPITAL FORMATION ’21-30 | INVESTING MODES DRIVING GCT TECHNOLOGYAND TIMING
The dynamics of venture/PE investing and IPOs are fast evolving. What are the drivers – will the number of investors grow will the size of early rounds continue to grow? How is this reflected in GCT target areas, company design, and biotech overall? Do patients benefit from these trends? Is crossover investing a distinct class or a little of both? Why did it emerge and what are the characteristics of the players? Will SPACs play a role in the growth of the gene and cell therapy industry. What is the role of corporate investment arms eg NVS, Bayer, GV, etc. – has a category killer emerged? Are we nearing the limit of what the GCT market can absorb or will investment capital continue to grow unabated? Moderator: Roger Kitterman * VP, Venture, Mass General Brigham Speakers: Ellen Hukkelhoven, PhD * Managing Director, Perceptive Advisors Peter Kolchinsky, PhD * Founder and Managing Partner, RA Capital ManagementDeep Nishar
* Senior Managing Partner, SoftBank Investment AdvisorsOleg Nodelman
* Founder & Managing Partner, EcoR1 Capital* Q&A
10:05 AM – 10:20 AM 10:00 AM – 10:10 AM FIRST LOOK NEW SCIENTIFIC AND CLINICAL DEVELOPMENTS FOR AUTOLOGOUS STEM CELL THERAPY FOR PARKINSON’S DISEASE PATIENTS Penelope Hallett, PhD* NRL, McLean
* Assistant Professor Psychiatry, HMS* Q&A
10:10 AM – 10:30 AM 10:10 AM – 10:35 AM HOT TOPICS NEURODEGENERATIVE CLINICAL OUTCOMES | ACHIEVING GCT SUCCESS Can stem cell-based platforms become successful treatments for neurodegenerative diseases? * What are the commonalities driving GCT success in neurodegenerative disease and non-neurologic disease, what are the keydifferences?
* Overcoming treatment administration challenges * GCT impact on degenerative stage of disease * How difficult will it be to titrate the size of the cell therapy effect in different neurological disorders and for different patients? * Demonstrating clinical value to patients and payers * Revised clinical trial models to address issues and concernsspecific to GCT
Moderator: Bob Carter, MD, PhD * Chairman, Department of Neurosurgery, MGH * William and Elizabeth Sweet, Professor of Neurosurgery, HMS Speakers: Erwan Bezard, PhD * INSERM Research Director, Institute of Neurodegenerative DiseasesNikola Kojic, PhD
* CEO and Co-Founder, Oryon Cell TherapiesGeoff MacKay
* President & CEO, AVROBIOViviane Tabar, MD
* Founding Investigator, BlueRock Therapeutics * Chair of Neurosurgery, Memorial Sloan Kettering* Q&A
10:40 AM – 10:55 AM 10:35 AM – 11:35 AM DISRUPTIVE DOZEN: 12 TECHNOLOGIES THAT WILL REINVENT GCT Nearly one hundred senior Mass General Brigham Harvard faculty contributed to the creation of this group of twelve GCT technologies that they believe will breakthrough in the next two years. The Disruptive Dozen identifies and ranks the GCT technologies that will be available on at least an experimental basis to have the chance of significantly improving health care. 11:35 AM – 11:45 AMCONCLUDING REMARKS
The co-chairs convene to reflect on the insights shared over the three days. They will discuss what to expect at the in-person GCT focused May 2-4, 2022 World Medical Innovation Forum. The co-chairs convene to reflect on the insights shared over the three days. They will discuss what to expect at the in-person GCT focused May 2-4, 2022 World Medical Innovation Forum.Christine Seidman, MD Hypertrophic and Dilated Cardiomyopaies ‘ 10% receive heart transplant 12 years survival Mutation puterb function TTN: contribute 20% of dilated cardiomyopatySilence gene
pleuripotential cells deliver therapies* Q&A
11:00 AM – 11:20 AM 11:00 AM – 11:10 AM FIRST LOOK UNLOCKING THE SECRET LIVES OF PROTEINS IN HEALTH AND DISEASEAnna Greka, MD, PhD
* Medicine, BWH
* Associate Professor, Medicine, HMS Cyprus Island, kidney disease by mutation causing MUC1 accumulation and death BRD4780 molecule that will clear the misfolding proteins from the kidney organoids: pleuripotent stem cells small molecule developed for applications in the other cell types in brain, eye, gene mutation build mechnism for therapy clinical models transition fromAcademia to biotech
Q&A
* 11:10 AM – 11:30 AM 11:10 AM – 11:35 AM RARE AND ULTRA RARE DISEASES | GCT BREAKS THROUGH One of the most innovative segments in all of healthcare is the development of GCT driven therapies for rare and ultra-rare diseases. Driven by a series of insights and tools and funded in part by disease focused foundations, philanthropists and abundant venture funding disease after disease is yielding to new GCT technology. These often become platforms to address more prevalent diseases. The goal of making these breakthroughs routine and affordable is challenged by a range of issues including clinical trial design and pricing. * What is driving the interest in rare diseases? * What are the biggest barriers to making breakthroughs ‘routineand affordable?’
* What is the role of retrospective and prospective natural history studies in rare disease? When does the expected value of retrospective disease history studies justify the cost? * Related to the first question, what is the FDA expecting as far as controls in clinical trials for rare diseases? How does this impact the collection of natural history data? Moderator: Susan Slaugenhaupt, PhD * Scientific Director and Elizabeth G. Riley and Daniel E. Smith Jr., Endowed Chair, Mass General Research Institute * Professor, Neurology, HMS Speakers: Leah Bloom, PhD * SVP, External Innovation and Strategic Alliances, Novartis GeneTherapies
Ultra rare (less than 100) vs rare difficulty to recruit patients and to follow up after treatment Bobby Gaspar, MD, PhD * CEO, Orchard Therapeutics Study of rare condition have transfer to other larger diseases – delivery of therapeutics genes, like immune disorders Patient testimonials just to hear what a treatment can make EmilKakkis, MD, PhD
* CEO, Ultragenyx
Do 100 patient study then have information on natural history to develop a clinical trial Stuart Peltz, PhD * CEO, PTC Therapeutics Rare disease, challenge for FDA approval and after market commercialization follow ups Justification of cost for Rare disease – demonstration of Change is IP in value patients advocacy is helpful* Q&A
11:40 AM – 11:55 AM 11:40 AM – 12:00 PM FIRESIDE PARTNERING ACROSS THE GCT SPECTRUM Moderator: Erin Harris * Chief Editor, Cell & Gene Perspective & professional tenure Partnership in manufacturing what are the recommendations? Hospital systems: Partnership Challenges Speaker: Marc Casper* CEO, ThermoFisher
25 years in Diagnostics last 20 years at ThermoFisher products used in the Lab for CAR-T research and manufacture CGT Innovations: FDA will have a high level of approval each year How move from research to clinical trials to manufacturing Quickerprocess
Best practices in Partnerships: the root cause if acceleration to market service providers to deliver highest standards Building capacity by acquisition to avoid the waiting time Accelerate new products been manufactured Collaborations with Academic Medical center i.e., UCSF in CGT joint funding to accelerate CGT to clinics’ Customers are extremely knowledgable, scale the capital investmentmade investment
150MIL a year to improve the Workflow* Q&A
12:05 PM – 12:20 PM 12:05 PM – 12:30 PM CEO PANEL | ANTICIPATING DISRUPTION | PLANNING FOR WIDESPREAD GCT The power of GCT to cure disease has the prospect of profoundly improving the lives of patients who respond. Planning for a disruption of this magnitude is complex and challenging as it will change care across the spectrum. Leading chief executives shares perspectives on how the industry will change and how this change should be anticipated. Moderator: Meg Tirrell * Senior Health and Science Reporter, CNBC CGT becoming staple therapy what are the disruptors emerging Speakers:Lisa Dechamps
* SVP & Chief Business Officer, Novartis Gene Therapies Reimagine medicine with collaboration at MGH, MDM condition inchildren
The Science is there, sustainable processes and systems impact istransformational
Value based pricing, risk sharing Payers and Pharma for one time therapy with life span effect Collaboration with FDAKieran Murphy * CEO, GE Healthcare Diagnosis of disease to be used in CGT 2021 investment in CAR-T platform Investment in several CGT frontier Investment in AI, ML in system design new technologies GE: Scale and Global distributions, sponsor companies in software Waste in Industry – Healthcare % of GDP, work with MGH to smooth the workflow faster entry into hospital and out of Hospital Telemedicine during is Pandemic: Radiologist needs to read remotely Supply chain disruptions slow down all ecosystem Production of ventilators by collaboration with GM – ingenuity Scan patients outside of hospital a scanner in a Box ChristianRommel, PhD
* Head, Pharmaceuticals Research & Development, Bayer AG CGT – 2016 and in 2020 new leadership and capability Disease Biology and therapeutics Regenerative Medicine: CGT vs repair building pipeline in ophthalmology and cardiovascular During Pandemic: Deliver Medicines like Moderna, Pfizer – collaborations between competitors with Government Bayer entered into Vaccines in 5 days, all processes had to change access innovations developed over decades for medical solutions* Q&A
12:35 PM – 12:50 PM 12:35 PM – 12:55 PM FIRESIDE BUILDING A GCT PORTFOLIO GCT represents a large and growing market for novel therapeutics that has several segments. These include Cardiovascular Disease, Cancer, Neurological Diseases, Infectious Disease, Ophthalmology, Benign Blood Disorders, and many others; Manufacturing and Supply Chain including CDMO’s and CMO’s; Stem Cells and Regenerative Medicine; Tools and Platforms (viral vectors, nano delivery, gene editing, etc.). Bayer’s pharma business participates in virtually all of these segments. How does a Company like Bayer approach the development of a portfolio in a space as large and as diverse as this one? How does Bayer approach the support of the production infrastructure with unique demands and significant differences from its historical requirements? Moderator: Shinichiro Fuse, PhD * Managing Partner, MPM Capital Speaker: Wolfram Carius, PhD * EVP, Pharmaceuticals, Head of Cell & Gene Therapy, Bayer AG CGT will bring treatment to cure, delivery of therapies Be a Leader repair, regenerate, cure Technology and Science for CGT – building a portfolio vs single asset decision criteria development of IP market access patients access acceleration of new products Bayer strategy: build platform for use by four domainsGener augmentation
Autologeneic therapy, analyticsGene editing
Oncology Cell therapy tumor treatment: What kind of cells – the juryis out
Of 23 product launch at Bayer no prediction is possible some high somelows
* Q&A
1:00 PM – 1:15 PM 12:55 PM – 1:35 PMLUNCH
1:40 PM – 2:05 PM GCT DELIVERY | PERFECTING THE TECHNOLOGY Gene delivery uses physical, chemical, or viral means to introduce genetic material into cells. As more genetically modified therapies move closer to the market, challenges involving safety, efficacy, and manufacturing have emerged. Optimizing lipidic and polymer nanoparticles and exosomal delivery is a short-term priority. This panel will examine how the short-term and long-term challenges are being tackled particularly for non-viral delivery modalities. Moderator: Natalie Artzi, PhD * Assistant Professor, BWH Speakers: Geoff McDonough, MD * CEO, Generation BioSonya Montgomery
* CMO, Evox Therapeutics Laura Sepp-Lorenzino, PhD * Chief Scientific Officer, Executive Vice President, IntelliaTherapeutics
Doug Williams, PhD
* CEO, Codiak BioSciences* Q&A
2:10 PM – 2:25 PM2:05 PM – 2:10 PM
INVENTION DISCOVERY GRANT ANNOUNCEMENT 2:10 PM – 2:20 PM FIRST LOOK ENHANCING VESICLES FOR THERAPEUTIC DELIVERY OF BIOPRODUCTS Xandra Breakefield, PhD * Geneticist, MGH, MGH * Professor, Neurology, HMS* Q&A
2:20 PM – 2:35 PM 2:20 PM – 2:30 PM FIRST LOOK VERSATILE POLYMER-BASED NANOCARRIERS FOR TARGETED THERAPY ANDIMMUNOMODULATION
Natalie Artzi, PhD
* Assistant Professor, BWH* Q&A
2:30 PM – 2:45 PM 2:55 PM – 3:20 PM HOT TOPICS GENE EDITING | ACHIEVING THERAPEUTIC MAINSTREAM Gene editing was recognized by the Nobel Committee as “one of gene technology’s sharpest tools, having a revolutionary impact on life sciences.” Introduced in 2011, gene editing is used to modify DNA. It has applications across almost all categories of disease and is also being used in agriculture and public health. Today’s panel is made up of pioneers who represent foundational aspects of gene editing. They will discuss the movement of the technology into the therapeutic mainstream. * Successes in gene editing – lessons learned from late-stage assets (sickle cell, ophthalmology) * When to use what editing tool – pros and cons of traditional gene-editing v. base editing. Is prime editing the future? Specific use cases for epigenetic editing. * When we reach widespread clinical use – role of off-target editing – is the risk real? How will we mitigate? How practical is patient-specific off-target evaluation? Moderator: J. Keith Joung, MD, PhD * Robert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist,MGH
* Professor of Pathology, HMS Speakers: John Evans * CEO, Beam TherapeuticsLisa Michaels
* EVP & CMO, Editas Medicine* Q&A
3:25 PM – 3:50 PM 3:25 PM – 3:50 PM HOT TOPICS COMMON BLOOD DISORDERS | GENE THERAPY There are several dozen companies working to develop gene or cell therapies for Sickle Cell Disease, Beta Thalassemia, and Fanconi Anemia. In some cases, there are enzyme replacement therapies that are deemed effective and safe. In other cases, the disease is only managed at best. This panel will address a number of questions that are particular to this class of genetic diseases: * What are the pros and cons of various strategies for treatment? There are AAV-based editing, non-viral delivery even oligonucleotide recruitment of endogenous editing/repair mechanisms. Which approaches are most appropriate for which disease? * How can companies increase the speed of recruitment for clinical trials when other treatments are available? What is the best approach to educate patients on a novel therapeutic? * How do we best address ethnic and socio-economic diversity to be more representative of the target patient population? * How long do we have to follow up with the patients from the scientific, patient’s community, and payer points of view? What are the current FDA and EMA guidelines for long-term follow-up? * Where are we with regards to surrogate endpoints and their application to clinically meaningful endpoints? * What are the emerging ethical dilemmas in pediatric gene therapy research? Are there challenges with informed consent and pediatric assent for trial participation? * Are there differences in reimbursement policies for these different blood disorders? Clearly durability of response is a big factor. Are there other considerations? Moderator: David Scadden, MD * Director, Center for Regenerative Medicine; Co-Director, Harvard Stem Cell Institute, Director, Hematologic Malignancies & ExperimentalHematology, MGH
* Jordan Professor of Medicine, HMS Speakers: Samarth Kukarni, PhDNick
Leschly
* Chief Bluebird, Bluebird Bio Mike McCune, MD, PhD * Head, HIV Frontiers, Global Health Innovative Technology Solutions, Bill & Melinda Gates Foundation* Q&A
3:55 PM – 4:15 PM 3:50 PM – 4:00 PM FIRST LOOKGENE EDITING
J. Keith Joung, MD, PhD * Robert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist,MGH
* Professor of Pathology, HMS* Q&A
4:00 PM – 4:20 PM 4:20 PM – 4:45 PM HOT TOPICS GENE EXPRESSION | MODULATING WITH OLIGONUCLEOTIDE-BASED THERAPIES Oligonucleotide drugs have recently come into their own with approvals from companies such as Biogen, Alnylam, Novartis and others. This panel will address several questions: How important is the delivery challenge for oligonucleotides? Are technological advancements emerging that will improve the delivery of oligonucleotides to the CNS or skeletal muscle after systemicadministration?
* Will oligonucleotides improve as a class that will make them even more effective? Are further advancements in backbone chemistry anticipated, for example. * Will oligonucleotide based therapies blaze trails for follow-on gene therapy products? * Are small molecules a threat to oligonucleotide-based therapies? * Beyond exon skipping and knock-down mechanisms, what other roles will oligonucleotide-based therapies take mechanistically — can genes be activating oligonucleotides? Is there a place for multiple mechanism oligonucleotide medicines? * Are there any advantages of RNAi-based oligonucleotides over ASOs, and if so for what use? Moderator: Jeannie Lee, MD, PhD * Molecular Biologist, MGH * Professor of Genetics, HMS Speakers: Bob Brown, PhD * CSO, EVP of R&D, DicernaBrett Monia, PhD
* CEO, Ionis
Alfred Sandrock, MD, PhD * EVP, R&D and CMO, Biogen* Q&A
4:50 PM – 5:05 PM 4:45 PM – 4:55 PM FIRST LOOK RNA THERAPY FOR BRAIN CANCER Pierpaolo Peruzzi, MD, PhD* Nuerosurgery, BWH
* Assistant Professor of Neurosurgery, HMS* Q&A
4:55 PM – 5:15 PM FRIDAY, MAY 21, 2021 COMPUTER CONNECTION TO THE ICLOUD OF WORDPRESS.COM FROZE COMPLETELY AT 10:30AM EST AND NO FILE UPDATE WAS POSSIBLE. COVERAGE OF MAY 21, 2021 IS RECORDED BELOW FOLLOWING THE AGENDA BY COPY AN DPASTE OF ALL THE TWEETS I PRODUCED ON MAY 21, 20218:30 AM – 8:55 AM
VENTURE INVESTING | SHAPING GCT TRANSLATION What is occurring in the GCT venture capital segment? Which elements are seeing the most activity? Which areas have cooled? How is the investment market segmented between gene therapy, cell therapy and gene editing? What makes a hot GCT company? How long will the market stay frothy? Some review of demographics — # of investments, sizes, etc. Why is the market hot and how long do we expect it to stay that way? Rank the top 5 geographic markets for GCT company creation and investing? Are there academic centers that have been especially adept at accelerating GCT outcomes? Do the business models for the rapid development of coronavirus vaccine have any lessons for how GCT technology can be brought to market more quickly? Moderator: Meredith Fisher, PhD * Partner, Mass General Brigham Innovation Fund Strategies, success what changes are needed in the drug discovery process Speakers: * David Berry, MD, PhD* CEO, Valo Health
* General Partner, Flagship Pioneering Bring disruptive frontier as a platform with reliable delivery CGT double knock out disease cure all change efficiency and scope human centric vs mice centered right scale of data converted into therapeutics acceleratetion Innovation in drugs 60% fails in trial because of Toxicology system of the future deal with big diseases Moderna is an example in unlocking what is inside us Microbiome and beyond discover new drugs epigenetics* Robert Nelsen
* Managing Director, Co-founder, ARCH Venture Partners Manufacturing change is not a new clinical trial FDA need to be presented with new rethinking for big innovations Drug pricing cheaper requires systematization How to systematically scaling up systematize the discovery and the production regulatory innovations * Kush Parmar, MD, PhD * Managing Partner, 5AM Ventures Responsibility mismatch should be and what is “are” Long term diseases Stack holders and modalities risk benefir forpopulations
* Q&A
9:00 AM – 9:15 AM9:00 AM – 9:25 AM
REGENERATIVE MEDICINE | STEM CELLS The promise of stem cells has been a highlight in the realm of regenerative medicine. Unfortunately, that promise remains largely in the future. Recent breakthroughs have accelerated these potential interventions in particular for treating neurological disease. Among the topics the panel will consider are: * Stem cell sourcing * Therapeutic indication growth * Genetic and other modification in cell production * Cell production to final product optimization and challenges * How to optimize the final product* Moderator:
* Ole Isacson, MD, PhD * Director, Neuroregeneration Research Institute, McLean * Professor, Neurology and Neuroscience, MGH, HMS Opportunities in the next generation of the tactical level Welcome the oprimism and energy level of all Translational medicine funding stem cells enormous opportunities* Speakers:
* Kapil Bharti, PhD
* Senior Investigator, Ocular and Stem Cell Translational ResearchSection, NIH
* first drug required to establish the process for that innovations design of animal studies not done before * Off-th-shelf one time treatment becoming cure * Intact tissue in a dish is fragile to maintain metabolismJoe Burns, PhD
* VP, Head of Biology, Decibel Therapeutics * Ear inside the scall compartments and receptors responsible for hearing highly differentiated tall ask to identify cell for anticipated differentiation * multiple cell types and tissue to followErin Kimbrel, PhD
* Executive Director, Regenerative Medicine, Astellas * In the ocular space immunogenecity * regulatory communication * use gene editing for immunogenecity Cas1 and Cas2 autologous cells * gene editing and programming big opportunities Nabiha Saklayen, PhD * CEO and Co-Founder, Cellino * scale production of autologous cells foundry using semiconductor process in building cassettes * solution for autologous cells* Q&A
9:30 AM – 9:45 AM 9:25 AM – 9:35 AM FIRST LOOKSTEM CELLS
Bob Carter, MD, PhD
* Chairman, Department of Neurosurgery, MGH * William and Elizabeth Sweet, Professor of Neurosurgery, HMS * Cell therapy for Parkinson to replace dopamine producing cells lost ability to produce dopamin * skin cell to become autologous cells reprograms to become cellsproducing dopamine
* transplantation fibroblast cells metabolic driven process lowermutation burden
* Quercetin inhibition elimination undifferentiated cells graft survival oxygenation increased* Q&A
9:35 AM – 9:55 AM 9:35 AM – 10:00 AM CAPITAL FORMATION ’21-30 | INVESTING MODES DRIVING GCT TECHNOLOGYAND TIMING
The dynamics of venture/PE investing and IPOs are fast evolving. What are the drivers – will the number of investors grow will the size of early rounds continue to grow? How is this reflected in GCT target areas, company design, and biotech overall? Do patients benefit from these trends? Is crossover investing a distinct class or a little of both? Why did it emerge and what are the characteristics of the players? Will SPACs play a role in the growth of the gene and cell therapy industry. What is the role of corporate investment arms eg NVS, Bayer, GV, etc. – has a category killer emerged? Are we nearing the limit of what the GCT market can absorb or will investment capital continue to grow unabated? Moderator: Roger Kitterman * VP, Venture, Mass General Brigham * Saturation reached or more investment is coming in CGT Speakers: Ellen Hukkelhoven, PhD * Managing Director, Perceptive Advisors * Cardiac area transduct cells* matching tools
* 10% success of phase 1 in drug development next phase mattersmore
Peter Kolchinsky, PhD * Founder and Managing Partner, RA Capital Management * Future proof for new comers disruptors * Ex Vivo gene therapy to improve funding products what tool kitbelongs to
* company insulation from next instability vs comapny stabilizing themselves along few years * Company interested in SPAC * cross over investment vs SPAC * Multi Omics in cancer early screening metastatic diseas will bewiped out
Deep Nishar
* Senior Managing Partner, SoftBank Investment Advisors * Young field vs CGT started in the 80s * high payloads is a challenge * cost effective fast delivery to large populations * Mission oriented by the team and management * Multi Omics disease modalityOleg Nodelman
* Founder & Managing Partner, EcoR1 Capital * Invest in company next round of investment will be IPO * Help company raise money cross over investment vs SPAC * Innovating ideas from academia in need for funding* Q&A
10:05 AM – 10:20 AM 10:00 AM – 10:10 AM FIRST LOOK NEW SCIENTIFIC AND CLINICAL DEVELOPMENTS FOR AUTOLOGOUS STEM CELL THERAPY FOR PARKINSON’S DISEASE PATIENTS Penelope Hallett, PhD* NRL, McLean
* Assistant Professor Psychiatry, HMS * Pharmacologic agent in existing cause another disorders locomo-movement related * efficacy Autologous cell therapy transplantation approach program T cells into dopamine generating neurons greater than Allogeneic celltransplantation
* Q&A
10:10 AM – 10:30 AM 10:10 AM – 10:35 AM HOT TOPICS NEURODEGENERATIVE CLINICAL OUTCOMES | ACHIEVING GCT SUCCESS Can stem cell-based platforms become successful treatments for neurodegenerative diseases? * What are the commonalities driving GCT success in neurodegenerative disease and non-neurologic disease, what are the keydifferences?
* Overcoming treatment administration challenges * GCT impact on degenerative stage of disease * How difficult will it be to titrate the size of the cell therapy effect in different neurological disorders and for different patients? * Demonstrating clinical value to patients and payers * Revised clinical trial models to address issues and concernsspecific to GCT
Moderator: Bob Carter, MD, PhD * Chairman, Department of Neurosurgery, MGH * William and Elizabeth Sweet, Professor of Neurosurgery, HMS * Neurogeneration REVERSAL or slowing down Speakers: Erwan Bezard, PhD * INSERM Research Director, Institute of Neurodegenerative Diseases * Cautious on reversal * Early intervantion versus lateNikola Kojic, PhD
* CEO and Co-Founder, Oryon Cell Therapies * Autologus cell therapy placed focal replacing missing synapses reestablishment of neural circuitaryGeoff MacKay
* President & CEO, AVROBIO * Prevent condition to be manifested in the first place * clinical effect durable single infusion preventions of symptoms tomanifest
* Cerebral edema – stabilization * Gene therapy know which is the abnormal gene grafting the correctedone
* More than biomarker as end point functional benefit not yetestablished
Viviane Tabar, MD
* Founding Investigator, BlueRock Therapeutics * Chair of Neurosurgery, Memorial Sloan Kettering * Current market does not have delivery mechanism that a drug-delivery is the solution Trials would fail on DELIVERY * Immune suppressed patients during one year to avoid graft rejection Autologous approach of Parkinson patient genetically mutated reprogramed as dopamine generating neuron – unknowns are present * Circuitry restoration * Microenvironment disease ameliorate symptoms – education of patients on the treatment* Q&A
10:40 AM – 10:55 AM 10:35 AM – 11:35 AM DISRUPTIVE DOZEN: 12 TECHNOLOGIES THAT WILL REINVENT GCT Nearly one hundred senior Mass General Brigham Harvard faculty contributed to the creation of this group of twelve GCT technologies that they believe will breakthrough in the next two years. The Disruptive Dozen identifies and ranks the GCT technologies that will be available on at least an experimental basis to have the chance of significantly improving health care. 11:35 AM – 11:45 AMCONCLUDING REMARKS
The co-chairs convene to reflect on the insights shared over the three days. They will discuss what to expect at the in-person GCT focused May 2-4, 2022 World Medical Innovation Forum. ALL THE TWEETS PRODUCED ON MAY 21, 2021 INCLUDE THE FOLLOWING:AVIVA LEV-ARI
@AVIVA1950
*
4h
#WMIF2021
@MGBInnovation
Erwan Bezard, PhD INSERM Research Director, Institute of Neurodegenerative Diseases Cautious on reversal@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
*
4h
#WMIF2021
@MGBInnovation
Nikola Kojic, PhD CEO and Co-Founder, Oryon Cell Therapies Autologus cell therapy placed focal replacing missing synapses reestablishmentof neural circutary
@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
4h
#WMIF2021
@MGBInnovation
Bob Carter, MD, PhD Chairman, Department of Neurosurgery, MGH William and Elizabeth Sweet, Professor of Neurosurgery, HMS Neurogeneration REVERSAL or slowing down?@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
4h
#WMIF2021
@MGBInnovation
Penelope Hallett, PhD NRL, McLean Assistant Professor Psychiatry, HMS efficacy Autologous cell therapy transplantation approach program T cells into dopamine genetating cells greater than Allogeneic celltransplantation
@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
4h
#WMIF2021
@MGBInnovation
Penelope Hallett, PhD NRL, McLean Assistant Professor Psychiatry, HMS Pharmacologic agent in existing cause another disorders locomo-movement related@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
4h
#WMIF2021
@MGBInnovation
Roger Kitterman VP, Venture, Mass General Brigham Saturation reached or more investment is coming in CGT Multi OMICS and academia originated innovations are the most attractive areas@pharma_BI
@AVIVA1950
1
3
AVIVA LEV-ARI
@AVIVA1950
4h
#WMIF2021
@MGBInnovation
Roger Kitterman VP, Venture, Mass General Brigham Saturation reached or more investment is coming in CGT@pharma_BI
@AVIVA1950
1
AVIVA LEV-ARI
@AVIVA1950
4h
#WMIF2021
@MGBInnovation
Oleg Nodelman Founder & Managing Partner, EcoR1 Capital Invest in company next round of investment will be IPO 20% discount@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
4h
#WMIF2021
@MGBInnovation
Peter Kolchinsky, PhD Founder and Managing Partner, RA Capital Management Future proof for new comers disruptors Ex Vivo gene therapy to improve funding products what tool kit belongs to@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
4h
#WMIF2021
@MGBInnovation
Deep Nishar Senior Managing Partner, SoftBank Investment Advisors Young field vs CGT started in the 80s high payloads is a challenge@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
5h
#WMIF2021
@MGBInnovation
Bob Carter, MD, PhD MGH, HMS cells producing dopamine transplantation fibroblast cells metabolic driven process lower mutation burden Quercetin inhibition elimination undifferentiated cells graft survival oxygenation increased@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
5h
#WMIF2021
@MGBInnovation
Chairman, Department of Neurosurgery, MGH, Professor of Neurosurgery, HMS Cell therapy for Parkinson to replace dopamine producing cells lost ability to produce dopamine skin cell to become autologous cellsreprogramed
@pharma_BI
@AVIVA1950
#WMIF2021
@MGBInnovation
Kapil Bharti, PhD Senior Investigator, Ocular and Stem Cell Translational Research Section, NIH Off-th-shelf one time treatment becoming cure Intact tissue in a dish is fragile to maintain metabolism to become like semiconductors@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
5h
#WMIF2021
@MGBInnovation
Ole Isacson, MD, PhD Director, Neuroregeneration Research Institute, McLean Professor, Neurology and Neuroscience, MGH, HMS Opportunities in the next generation of the tactical level Welcome the oprimism andenergy level of all
@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
5h
#WMIF2021
@MGBInnovation
Erin Kimbrel, PhD Executive Director, Regenerative Medicine, Astellas In the ocular space immunogenecity regulatory communication use gene editing for immunogenecity Cas1 and Cas2 autologous cells@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
5h
#WMIF2021
@MGBInnovation
Nabiha Saklayen, PhD CEO and Co-Founder, Cellino scale production of autologous cells foundry using semiconductor process in building cassettes by optic physicists@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
5h
#WMIF2021
@MGBInnovation
Joe Burns, PhD VP, Head of Biology, Decibel Therapeutics Ear inside the scall compartments and receptors responsible for hearing highly differentiated tall ask to identify cell for anticipated differentiation control by genomics@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
5h
#WMIF2021
@MGBInnovation
Kapil Bharti, PhD Senior Investigator, Ocular and Stem Cell Translational Research Section, NIH first drug required to establish the process for that innovations design of animal studies not donebefore
@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
5h
#WMIF2021
@MGBInnovation
Meredith Fisher, PhD Partner, Mass General Brigham Innovation Fund Strategies, success what changes are needed in the drug discoveryprocess@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
5h
#WMIF2021
@MGBInnovation
Robert Nelsen Managing Director, Co-founder, ARCH Venture Partners Manufacturing change is not a new clinical trial FDA need to be presented with new rethinking for big innovations Drug pricing cheaper requires systematization@pharma_BI
@AVIVA1950
1
AVIVA LEV-ARI
@AVIVA1950
5h
#WMIF2021
@MGBInnovation
Kush Parmar, MD, PhD Managing Partner, 5AM Ventures Responsibility mismatch should be and what is “are”@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
5h
#WMIF2021
@MGBInnovation
David Berry, MD, PhD CEO, Valo Health GP, Flagship Pioneering Bring disruptive frontier platform reliable delivery CGT double knockout disease cure all change efficiency scope human centric vs mice centered right scale acceleration@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
6h
#WMIF2021
@MGBInnovation
Kush Parmar, MD, PhD Managing Partner, 5AM Ventures build it yourself, benefit for patients FIrst Look at MGB shows MEE innovation on inner ear worthy investment@pharma_BI
@AVIVA1950
AVIVA LEV-ARI
@AVIVA1950
6h
#WMIF2021
@MGBInnovation
Robert Nelsen Managing Director, Co-founder, ARCH Venture Partners Frustration with supply chain during the Pandemic, GMC anticipation in advance CGT rapidly prototype rethink and invest proactive investor.edu and Pharma
@pharma_BI
@AVIVA1950
Posted in Cardiovascular Research,
Cell Biology
, Cell
Biology, Signaling & Cell Circuits,
Cell Processing System in Cell Therapy Process Development,
Cerebrovascular and Neurodegenerative Diseases,
Chemical Genetics
,
Clinical & Translational,
Clinical Genomics
,
Conference Coverage with Social Media,
CRISPR alternative for editing genes without cutting,
CRISPR/Cas9 & Gene Editing,
Diagnostic Immunology,
DNA repair
, Drug
Toxicity
,
Enzyme Induction
,
Epigenetics and Cardiovascular Risks,
Exosomes
,
Exosomes: Natural Carriers for siRNA Delivery,
Gene Regulation
,
Gene Therapy & Gene Editing Development,
Genetics & Innovations in Treatment,
Genetics & Pharmaceutical,
Genome Biology
,
Mass automation of plasma proteins,
mRNA Therapeutics
,
Mutagenesis
,
Origins of Cardiovascular Disease,
Proteolysis
,
Regenerative Biology and Medicine,
RNA Biology
, RNA
Biology, Cancer and Therapeutics,
Scientific & Biotech Conferences: Press Coverage,
Signaling
,
Signaling & Cell Circuits,
Technology Transfer: Biotech and Pharmaceutical,
Tissue Engineering and Regenerative Medicine,
Transformative Technologies in Healthcare,
Translational Science,
Transposon-encoded CRISPR–Cas systems direct RNA-guided DNAintegration
,
Variation in human protein-coding regions | Leave a Comment » 2021 VIRTUAL WORLD MEDICAL INNOVATION FORUM, MASS GENERAL BRIGHAM, GENE AND CELL THERAPY, VIRTUAL MAY 19–21, 2021 May 22, 2021 by 2012pharmaceuticali
Rate This
2021 VIRTUAL WORLD MEDICAL INNOVATION FORUM, MASS GENERAL BRIGHAM, GENE AND CELL THERAPY, VIRTUAL MAY 19–21, 2021 The 2021 Virtual World Medical Innovation Forum will focus on the growing impact of gene and cell therapy.Senior healthcare leaders from all over look to shape and debate the area of gene and cell therapy. Our shared belief: no matter the magnitude of change, responsible healthcare is centered on a shared commitment to collaborative innovation–industry, academia, and practitioners working together to improve patients’ lives. ABOUT THE WORLD MEDICAL INNOVATION FORUM Mass General Brigham is pleased to present the World Medical Innovation Forum (WMIF) virtual event Wednesday, May 19 – Friday, May 21. This interactive web event features expert discussions of gene and cell therapy (GCT) and its potential to change the future of medicine through its disease-treating and potentially curative properties. The agenda features 150+ executive speakers from the healthcare industry, venture, startups, life sciences manufacturing, consumer health and the front lines of care, including many Harvard Medical School-affiliated researchers and clinicians. The annual in-person Forum will resume live in Boston in 2022. The World Medical Innovation Forum is presented by Mass General Brigham Innovation, the global business development unit supporting the research requirements of 7,200 Harvard Medical School faculty and research hospitals including Massachusetts General, Brigham and Women’s, Massachusetts Eye and Ear, Spaulding Rehab and McLean Hospital. Follow us on Twitter: twitter.com/@MGBInnovation ACCELERATING THE FUTURE OF MEDICINE WITH GENE AND CELL THERAPY WHATCOMES NEXT
Click to access 2021-WMIF-White-Paper-1.0.pdf HTTPS://WORLDMEDICALINNOVATION.ORG/AGENDA/ VIRTUAL | MAY 19–21, 2021#WMIF2021
@MGBINNOVATION
LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE (LPBI) GROUP WILL COVER THE EVENT IN REAL TIME AVIVA LEV-ARI, PHD, RNFOUNDER LPBI 1.0
& LPBI
2.0
WILL BE IN VIRTUAL ATTENDANCE PRODUCING THE E-PROCEEDINGS AND THE TWEET COLLECTION OF THIS GLOBAL EVENT EXPECTING +15,000ATTENDEES
@PHARMA_BI
@AVIVA1950
LPBI’S EIGHTEEN BOOKS IN MEDICINE HTTPS://LNKD.IN/EKWGNQA AMONG THEM, BOOKS ON GENE AND CELL THERAPY INCLUDE THE FOLLOWING: TOPICS FOR MAY 19 – 21 INCLUDE: Impact on Patient Care – Therapeutic and Potentially Curative GCTDevelopments
GCT Delivery, Manufacturing – What’s Next GCT Platform Development Oncolytic Viruses – Cancer applications, start-ups Regenerative Medicine/Stem CellsFuture of CAR-T
M&A Shaping GCT’s FutureMarket Priorities
Venture Investing in GCT China’s GCT Juggernaut Disease and Patient Focus: Benign blood disorders, diabetes, neurodegenerative diseases CLICK HERE FOR THE CURRENT WMIF AGENDAPlus:
Fireside Chats: 1:1 interviews with industry CEOs/C-Suite leaders including Novartis Gene Therapies, ThermoFisher, Bayer AG, FDA First Look: 18 briefings on emerging GCT research from Mass GeneralBrigham scientists
Virtual Poster Session: 40 research posters and presenters on potential GCT discoveries from Mass General Brigham Announcement of the Disruptive Dozen, 12 GCT technologies likely to break through in the next few years Posted in Uncategorized|
Leave a Comment »
COVID VACCINES BY PFIZER, ASTRAZENECA ARE PROBED IN EUROPE AFTER REPORTS OF HEART INFLAMMATION, RARE NERVE DISORDER May 14, 2021 by 2012pharmaceuticali
8 Votes
COVID vaccines by Pfizer, AstraZeneca are probed in Europe after reports of heart inflammation, rare nerve disorder REPORTER: AVIVA LEV-ARI, PHD, RN * PRAC concludes review of signal of FACIAL SWELLING with COVID-19vaccine Comirnaty
* PRAC concludes review of unusual BLOOD CLOTS WITH LOW BLOOD PLATELETS1 WITH JANSSEN’SCOVID-19 vaccine
* PRAC continues to closely review Comirnaty and COVID-19 Vaccine MODERNA FOR UNUSUAL BLOOD CLOTS WITH LOW BLOOD PLATELETS2 * PRAC assessing reports of GUILLAIN-BARRE SYNDROME WITH ASTRAZENECA’S Covid-19 vaccine * PRAC assessing reports of MYOCARDITIS WITH COMIRNATY AND COVID-19VACCINE MODERNA
PFIZER, ASTRAZENECA COVID VACCINES PROBED IN EUROPE AFTER REPORTS OF HEART INFLAMMATION, RARE NERVE DISORDER by Noah Higgins-Dunn| May 7,
2021 11:30am
https://www.fiercepharma.com/pharma/europe-s-drug-regulator-evaluates-reports-heart-inflammation-rare-nerve-disorder-covid-19?mkt_tok=Mjk0LU1RRi0wNTYAAAF9CfvEwAx57b24DuUAcDiGVmhun4nmaK9T4RF6NqoyP7fE8IVJQ0UwroFU_tlnsRDhyPdMttTuF5GWE7PREgPwjvP4_WnKaggzqwPI3Ju6nt-1qhU&mrkid=993697 Start Quote from European Medicines Agency document MEETING HIGHLIGHTS FROM THE PHARMACOVIGILANCE RISK ASSESSMENT COMMITTEE (PRAC) 3-6 MAY 2021News 07/05/2021
This month EMA’s safety committee (PRAC) reviewed a number
of safety signals
related to
COVID-19 vaccines. The evaluation of safety signalsis a routine
part of pharmacovigilanceand is
essential to ensuring that regulatory authorities have a comprehensive knowledge of a medicine’s benefits and risks. PRAC CONCLUDES REVIEW OF SIGNAL OF FACIAL SWELLING WITH COVID-19VACCINE COMIRNATY
PRAC has recommended a change to Comirnaty’s product
information
. After
reviewing all the available evidence, including cases reported to the European database for suspected side effects (EudraVigilance) and data from
the scientific literature, PRAC considered that there is at least a reasonable possibility of a causal association between the vaccine and the reported cases of facial swelling in people with a history of injections with dermal fillers (soft, gel-like substances injected under the skin). Therefore, PRAC concluded that facial swelling in people with a history of injections with dermal fillers should be included as a side effect in section 4.8 of the summary of product characteristics(SmPC)
and in section 4 of the patient information leaflet (PIL) for Comirnaty. The benefit-risk balance of the vaccine remains unchanged. PRAC CONCLUDES REVIEW OF UNUSUAL BLOOD CLOTS WITH LOW BLOOD PLATELETS1 WITH JANSSEN’SCOVID-19 VACCINE
PRAC has now concluded its review of COVID-19 Vaccine Janssenand
confirmed, as previously communicated,
that the benefits of the vaccine in preventing COVID-19 outweigh the risks of side effects. In finalising the review, the Committee recommended on 20 April further refinement of the warning about thrombosis (formation of blood clots in the vessels) with thrombocytopenia (low blood platelets) syndrome, which was listed previously in the product informationfor
COVID-19 Vaccine Janssen. The product informationwill now
also include advice that patients who are diagnosed with thrombocytopenia within three weeks of vaccination should be actively investigated for signs of thrombosis. Similarly, patients who present with thromboembolism within three weeks of vaccination should be evaluated for thrombocytopenia. Lastly, thrombosis with thrombocytopenia syndrome will be added as an ‘important identified risk’ in the risk management planfor the
vaccine. Furthermore, the marketing authorisation holderwill
provide a plan to further study the possible underlying mechanisms for these very rare events.PRAC CONTINUES TO
CLOSELY REVIEW COMIRNATY AND COVID-19 VACCINE MODERNA FOR UNUSUAL BLOOD CLOTS WITH LOW BLOOD PLATELETS2 The PRAC is closely monitoring whether mRNA vaccines might also be linked to cases of rare, unusual blood clots with low blood platelets, a side effect that has been reported in Vaxzevriaand
COVID-19 vaccine Janssen. Following a review of reports of suspected side effects, the PRAC considers at this stage that there is no safety signalfor the mRNA
vaccines. Only few cases of blood clots with low blood platelets have been reported. When seen in the context of the exposure of people to the mRNA vaccines, these numbers are extremely low, and their frequency is lower than the one occurring in people who have not been vaccinated. In addition, these cases do not seem to present the specific clinical pattern observed with Vaxzevria and COVID-19 Vaccine Janssen. Overall, the current evidence does not suggest a causalrelation.
EMA will continue to monitor this issue closely and communicate further if necessary. TOPICS OF INTERESTS FROM ENHANCED MONITORING OF COVID-19 VACCINES Enhanced safety monitoring in the form of pandemic summary safety reports is one of the commitments required from the marketing authorisation holdersin
the context of the conditional marketing authorisation. Marketing
authorisation holdersare
required to submit pandemic summary safety reports to EMA on a monthly basis. These reports are reviewed by the PRAC and any areaof concern further investigated, if needed. PRAC ASSESSING REPORTS OF GUILLAIN-BARRE SYNDROME WITH ASTRAZENECA’SCOVID-19 VACCINE
As part of the review of the regular pandemic summary safety reports for Vaxzevria, AstraZeneca’s Covid-19 vaccine, the PRACis analysing data
provided by the marketing authorisation holderon
cases of Guillain-Barre syndrome (GBS) reported following vaccination. GBS is an immune system disorder that causes nerve inflammation and can result in pain, numbness, muscle weakness and difficulty walking. GBS was identified during the marketing authorisationprocess
as a possible adverse eventrequiring
specific safety monitoring activities. PRAChas requested
the marketing authorisation holderto
provide further detailed data, including an analysis of all the reported cases in the context of the next pandemic summary safetyreport.
PRAC will continue its review and will communicate further when new information becomesavailable.
PRAC ASSESSING REPORTS OF MYOCARDITIS WITH COMIRNATY AND COVID-19VACCINE MODERNA
EMA is aware of cases of myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the membrane around the heart) mainly reported following vaccination with Comirnaty. There isno indication at
the moment that these cases are due to the vaccine. However, PRAChas requested
the marketing authorisation holderto
provide further detailed data, including an analysis of the events according to age and gender, in the context of the next pandemic summary safety report and will consider if any other regulatory action is needed. Additionally, the PRAChas requested
the marketing authorisation holderfor COVID-19
Vaccine Moderna
– also
an mRNA vaccine – to monitor similar cases with their vaccine and to also provide a detailed analysis of the events in the context of the next pandemic summary safety report. EMA will communicate further when new information becomes available. ------------------------- 1Thrombosis with thrombocytopenia syndrome 2Thrombosis with thrombocytopenia syndromeSOURCE
https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-3-6-may-2021 Posted in Biomarkers: Inflammation,
COVID-19 ,
COVID-19 effects on Human Heart,
Mechanism of Thrombosis with AZ & J&J COVID-19 Vaccines,
Population Health Management, Genetics & Pharmaceutical,
SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus,
SARS-CoV-2
,
Vaccinology
,
Virus Infective Acute Respiratory Syndrome: SARS-CoV | Leave a Comment » NIR HACOHEN AND MARCIA GOLDBERG, RESEARCHERS AT MGH AND THE BROAD INSTITUTE IDENTIFY PROTEIN “SIGNATURE” OF SEVERE COVID-19 May 4, 2021 by 2012pharmaceuticali
5 Votes
NIR HACOHEN AND MARCIA GOLDBERG, RESEARCHERS AT MGH AND THE BROAD INSTITUTE IDENTIFY PROTEIN “SIGNATURE” OF SEVERE COVID-19 CURATOR AND REPORTER: AVIVA LEV-ARI, PHD, RN LONGITUDINAL PROTEOMIC ANALYSIS OF PLASMA FROM PATIENTS WITH SEVERE COVID-19 REVEAL PATIENT SURVIVAL-ASSOCIATED SIGNATURES, TISSUE-SPECIFIC CELL DEATH, AND CELL-CELL INTERACTIONS* Michael R. Filbin
22
* Arnav Mehta
22
* Alexis M. Schneider*
* Moshe Sade-Feldman* Nir Hacohen
23
* Marcia B. Goldberg21
, 23
* Show all authors
* Show footnotes
Open AccessPublished:April 30, 2021DOI:https://doi.org/10.1016/j.xcrm.2021.100287HIGHLIGHTS
* 16% of COVID-19 patients display an atypical low-inflammatoryplasma proteome
* Severe COVID-19 is associated with heterogeneous plasma proteomicresponses
* Death of virus-infected lung epithelial cells is a key feature ofsevere disease
* Lung monocyte/macrophages drive T cell activation, together promoting epithelial damageSUMMARY
Mechanisms underlying severe COVID-19 disease remain poorly understood. We analyze several thousand plasma proteins longitudinally in 306 COVID-19 patients and 78 symptomatic controls, uncovering immune and non-immune proteins linked to COVID-19. Deconvolution of our plasma proteome data using published scRNAseq datasets reveals contributions from circulating immune and tissue cells. Sixteen percent of patients display reduced inflammation yet comparably poor outcomes. Comparison of patients who died to severely ill survivors identifies dynamic immune cell-derived and tissue-associated proteins associated with survival, including exocrine pancreatic proteases. Using derived tissue-specific and cell type-specific intracellular death signatures, cellular ACE2 expression, and our data, we infer whether organ damage resulted from direct or indirect effects of infection. We propose a model in which interactions among myeloid, epithelial, and T cells drive tissue damage. These datasets provide important insights and a rich resource for analysis of mechanisms of severe COVID-19 disease.GRAPHICAL ABSTRACT
Image Source: DOI: https://doi.org/10.1016/j.xcrm.2021.100287 https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00115-4 THE QUEST TO IDENTIFY MECHANISMS THAT MIGHT BE CONTRIBUTING TO DEATH IN COVID-19: Why do some patients die from this disease, while others — who appear to be just as ill do not? Researchers at Massachusetts General Hospital (MGH) and the Broad Institute of MIT and Harvard have identified the protein “signature” of severe COVID-19 Interest was to develop methods for studying human immune responses to infections, which they had applied to the condition known as bacterial sepsis. The three agreed to tackle this new problem with the goal of understanding how the human immune system responds to SARS-CoV-2, the novel pathogen that causes COVID-19. HOW SCIENTISTS LAUNCHED A STUDY IN DAYS TO PROBE COVID-19’SUNPREDICTABILITY
Collecting these specimens required a large team of collaborators from many departments, which worked overtime for five weeks to amass blood samples from 306 patients who tested positive for COVID-19, as well as from 78 patients with similar symptoms who tested negative for thecoronavirus.
Credit : Alexandra-Chloé VillaniResearch associates at Mass General who worked countless hours to process blood samples for the COVID Acute Cohort Study (from left to right: Anna Gonye, Irena Gushterova, and Tom Lasalle)By Leah Eisenstadt https://www.broadinstitute.org/news/how-scientists-launched-study-days-probe-covid-19%E2%80%99s-unpredictability As the COVID-19 surge began in March, Mass General and Broad researchers worked around the clock to begin learning why some patients fare worse with the disease than others Protein signatures in the blood https://www.broadinstitute.org/news/researchers-identify-protein-%E2%80%9Csignature%E2%80%9D-severe-covid-19 The study found that most patients with COVID-19 have a consistent protein signature, regardless of disease severity; as would be expected, their bodies mount an immune response by producing proteins that attack the virus. “But we also found a small subset of patients with the disease who did not demonstrate the pro-inflammatory response that is typical of other COVID-19 patients,” Filbin said, yet these patients were just as likely as others to have severe disease. Filbin, who is also an assistant professor of emergency medicine at Harvard Medical School (HMS), noted that patients in this subset tended to be older people with chronic diseases, who likely had weakened immunesystems.
Among other revelations, this showed that the most prevalent severity-associated protein, a pro-inflammatory protein called interleukin-6 (IL-6) rose steadily in patients who died, while it rose and then dropped in those with severe disease who survived. Early attempts by other groups to treat COVID-19 patients experiencing acute respiratory distress with drugs that block IL-6 were disappointing, though more recent studies show promise in combining these medications with the steroid dexamethasone. HACOHEN, who is a professor of medicine at HMS and director of the Broad’s Cell Circuits Program:
“You can ask which of the many thousands of proteins that are circulating in your blood are associated with the actual outcome,” he said, “and whether there is a set of proteins that tell ussomething.”
GOLDBERG, who is a professor of emergency medicine at HMS: They are highly likely to be useful in figuring out some of the underlying mechanisms that lead to severe disease and death in COVID-19,” she said, noting her gratitude to the patients involved in the study. Their samples are already being used to study other aspects of COVID-19, such as identifying the qualities of antibodies that patients form against the virus.SOURCES
ORIGINAL RESEARCH
Filbin MR, Mehta A, et al. Longitudinal proteomic analysis of plasma from patients with severe COVID-19 reveal patient survival-associated signatures, tissue-specific cell death, and cell-cell interactions. _Cell
Reports Medicine_. Online April 30, 2021. DOI: 10.1016/j.xcrm.2021.100287. _Adapted from __a press release originally issued by MassachusettsGeneral Hospital_
_._
https://www.broadinstitute.org/news/researchers-identify-protein-%E2%80%9Csignature%E2%80%9D-severe-covid-19 https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(21)00115-4 Posted in Biomarkers: Inflammation,
Cancer Researchers Fighting COVID-19,
Coronavirus Gene Expression,
COVID-19 ,
COVID-19 effects on Human Heart,
Immune-Mediation (independent immunopathology: lung and reticuloendothelial system),
number of asymptomatic infections,
Population Health Management,
Population Health Management, Genetics & Pharmaceutical,
SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus,
SARS-CoV-2
,
SARS-COV2 Hijacking the Complement and Coagulation Systems,
Serology tests for coronavirus antibodies,
T-cell response to SARS-CoV-2 infection,
Treatment Protocols for COVID-19,
Virtual Drug Molecule Screening targeting SAR-CoV-2 proteins,
Virus Infective Acute Respiratory Syndrome: SARS-CoV | Tagged Longitudinal proteomic analysis of plasma,
patient survival-associated signatures,
protein “signature” of severe COVID-19,
tissue-specific cell death | Leave a Comment » MACHINE LEARNING (ML) IN CANCER PROGNOSIS PREDICTION HELPS THE RESEARCHER TO IDENTIFY MULTIPLE KNOWN AS WELL AS CANDIDATE CANCERDIVER GENES
May 4, 2021 by Dr. Patii
1 Vote
Machine Learning (ML) in cancer prognosis prediction helps the researcher to identify multiple known as well as candidate cancerdiver genes
CURATOR AND REPORTER: DR. PREMALATA PATI, PH.D., POSTDOC SEEING “THROUGH” THE CANCER WITH THE POWER OF DATA ANALYSIS — POSSIBLE WITH THE HELP OF ARTIFICIAL INTELLIGENCE. CREDIT: MPI F. MOLECULAR GENETICS/ ELLA MARU STUDIOIMAGE SOURCE:
HTTPS://MEDICALXPRESS.COM/NEWS/2021-04-SUM-MUTATIONS-CANCER-GENES-MACHINE.HTML Cancer has been characterized as a heterogeneous disease consisting of many different subtypes. The early diagnosis and prognosis of a cancer type have become a necessity in cancer research, as it can facilitate the subsequent clinical management of patients. The importance of classifying cancer patients into high or low-risk groups has led many research teams, from the biomedical and the bioinformatics field, to study the application of machine learning (ML) and Artificial Intelligence (AI) methods. Therefore, these techniques have been utilized as an aim to model the progression and treatment of cancerous conditions by predicting new algorithms. In the majority of human cancers, heritable loss of gene function through cell division may be mediated as often by epigenetic as by genetic abnormalities. Epigenetic modification occurs through a process of interrelated changes in CpG island methylation and histone modifications. Candidate gene approaches of cell cycle, growth regulatory and apoptotic genes have shown epigenetic modification associated with loss of cognate proteins in sporadic pituitary tumors. On 11th November 2020, researchers from the UNIVERSITY OF CALIFORNIA , Irvine, has established the understanding of epigenetic mechanisms in tumorigenesis and publicized a previously undetected repertoire of cancer driver genes. The study was published in “SCIENCE ADVANCES”
Researchers were able to identify novel tumor suppressor genes (TSGs) and oncogenes (OGs), particularly those with rare mutations by using a new prediction algorithm, called DORGE (DISCOVERY OF ONCOGENES AND TUMOR SUPPRESSOR GENES USING GENETIC AND EPIGENETIC FEATURES) by integrating the most comprehensive collection of genetic andepigenetic data.
The senior author Wei Li, Ph.D., the Grace B. Bell chair and professor of bioinformatics in the Department of Biological Chemistry at the UCI School of Medicine said > Existing bioinformatics algorithms do not sufficiently leverage > epigenetic features to predict cancer driver genes, even though > epigenetic alterations are known to be associated with cancer driver> genes.
THE STUDY
> This study demonstrated how cancer driver genes, predicted by DORGE, > included both known cancer driver genes and novel driver genes not > reported in current literature. In addition, researchers found that > the novel dual-functional genes, which DORGE predicted as both TSGs > and OGs, are highly enriched at hubs in protein-protein interaction > (PPI) and drug/compound-gene networks.*
FLOWCHART FOR THE ILLUSTRATION OF THE DORGE METHODIMAGE SOURCE:
https://advances.sciencemag.org/content/suppl/2020/11/09/6.46.eaba6784.DC1/aba6784_SM.pdf PROF. LI explained that the DORGE ALGORITHM, successfully leveraged public data to discover the genetic and epigenetic alterations that play significant roles in cancer driver gene dysregulation and could be instrumental in improving cancer prevention, diagnosis and treatment efforts in the future. Another new algorithmic prediction for the identification of cancer genes by Machine Learning has been carried out by a team of researchers at the MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS (MPIMG) in Berlin and the INSTITUTE OF COMPUTATIONAL BIOLOGYof Helmholtz
Zentrum München combining a wide variety of data analyzed it with “Artificial Intelligence” and identified numerous cancer genes. They termed the algorithm as EMOGI (EXPLAINABLE MULTI-OMICS GRAPH INTEGRATION). EMOGI can predict which genes cause cancer, even if their DNA sequence is not changed. This opens up new perspectives for targeted cancer therapy in personalized medicine and the development of biomarkers. The research was published in Nature Machine Intelligence on 12th April 2021. In cancer, cells get out of control. They proliferate and push their way into tissues, destroying organs and thereby impairing essential vital functions. This unrestricted growth is usually induced by an accumulation of DNA changes in cancer genes—i.e. mutations in these genes that govern the development of the cell. But some cancers have only very few mutated genes, which means that other causes lead to the disease in these cases.THE STUDY
OVERLAP
OF EMOGI’S POSITIVE PREDICTIONS WITH KNOWN CANCER GENES (KCGS) AND CANDIDATE CANCER GENESIMAGE SOURCE:
https://static-content.springer.com/esm/art%3A10.1038%2Fs42256-021-00325-y/MediaObjects/42256_2021_325_MOESM1_ESM.pdf The aim of the study has been represented in 4 main headings * Additional targets for personalized medicine * Better results by combination * In search of hints for further studies * Suitable for other types of diseases as well The team was headed by ANNALISA MARSICO. The team used the algorithm to identify 165 previously unknown cancer genes. The sequences of these genes are not necessarily altered-apparently, already a dysregulation of these genes can lead to cancer. All of the newly identified genes interact closely with well-known cancer genes and be essential for the survival of tumor cells in cell culture experiments. The EMOGI can also explain the relationships in the cell’s machinery that make a gene a cancer gene. The software integrates tens of thousands of data sets generated from patient samples. These contain information about DNA methylations, the activity of individual genes and the interactions of proteins within cellular pathways in addition to sequence data with mutations. In these data, a deep-learning algorithm detects the patterns and molecular principles that lead to the development of cancer.Marsico says
> Ideally, we obtain a complete picture of all cancer genes at some > point, which can have a different impact on cancer progression for > different patients Unlike traditional cancer treatments such as chemotherapy, personalized treatments are tailored to the exact type of tumor. “The goal is to choose the best treatment for each patient, the most effective treatment with the fewest side effects. In addition, molecular properties can be used to identify cancers that are already in the early stages. Roman Schulte-Sasse, a doctoral student on Marsico’s team and the first author of the publication says > To date, most studies have focused on pathogenic changes in > sequence, or cell blueprints, at the same time, it has recently > become clear that epigenetic perturbation or dysregulation gene > activity can also lead to cancer. This is the reason, researchers merged sequence data that reflects blueprint failures with information that represents events in cells. Initially, scientists confirmed that mutations, or proliferation of genomic segments, were the leading cause of cancer. Then, in the second step, they identified gene candidates that are not very directly related to the genes that cause cancer. CLUES FOR FUTURE DIRECTIONS The researcher’s new program adds a considerable number of new entries to the list of suspected cancer genes, which has grown to between 700 and 1,000 in recent years. It was only through a combination of bioinformatics analysis and the newest Artificial Intelligence (AI) methods that the researchers were able to track downthe hidden genes.
SCHULTE-SASSE says “The interactions of proteins and genes can be mapped as a mathematical network, known as a graph.” He explained by giving an example of a railroad network; each station corresponds to a protein or gene, and each interaction among them is the train connection. With the help of deep learning—the very algorithms that have helped artificial intelligence make a breakthrough in recent years – the researchers were able to discover even those train connections that had previously gone unnoticed. Schulte-Sasse had the computer analyze tens of thousands of different network maps from 16 different cancer types, each containing between 12,000 and 19,000 datapoints.
Many more interesting details are hidden in the data. Patterns that are dependent on particular cancer and tissue were seen. The researchers were also observed this as evidence that tumors are triggered by different molecular mechanisms in different organs.Marsico explains
> The EMOGI program is not limited to cancer, the researchers > emphasize. In theory, it can be used to integrate diverse sets of > biological data and find patterns there. It could be useful to apply > our algorithm for similarly complex diseases for which multifaceted > data are collected and where genes play an important role. An > example might be complex metabolic diseases such as diabetes.MAIN SOURCE
New prediction algorithm identifies previously undetected cancerdriver genes
HTTPS://ADVANCES.SCIENCEMAG.ORG/CONTENT/6/46/EABA6784 Integration of multiomics data with graph convolutional networks to identify new cancer genes and their associated molecular mechanisms HTTPS://WWW.NATURE.COM/ARTICLES/S42256-021-00325-Y#CITEAS OTHER RELATED ARTICLES PUBLISHED IN THIS OPEN ACCESS ONLINE SCIENTIFIC JOURNAL INCLUDE THE FOLLOWING: AI SYSTEM USED TO DETECT LUNG CANCER Reporter: Irina Robu, PhD https://pharmaceuticalintelligence.com/2019/06/28/ai-system-used-to-detect-lung-cancer/ DEEP LEARNING EXTRACTS HISTOPATHOLOGICAL PATTERNS AND ACCURATELY DISCRIMINATES 28 CANCER AND 14 NORMAL TISSUE TYPES: PAN-CANCER COMPUTATIONAL HISTOPATHOLOGY ANALYSIS Reporter: Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2019/10/28/deep-learning-extracts-histopathological-patterns-and-accurately-discriminates-28-cancer-and-14-normal-tissue-types-pan-cancer-computational-histopathology-analysis/ EVOLUTION OF THE HUMAN CELL GENOME BIOLOGY FIELD OF GENE EXPRESSION, GENE REGULATION, GENE REGULATORY NETWORKS AND APPLICATION OF MACHINE LEARNING ALGORITHMS IN LARGE-SCALE BIOLOGICAL DATA ANALYSIS Curator & Reporter: Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2019/12/08/evolution-of-the-human-cell-genome-biology-field-of-gene-expression-gene-regulation-gene-regulatory-networks-and-application-of-machine-learning-algorithms-in-large-scale-biological-data-analysis/ CANCER DETECTION AND THERAPEUTICS Curator: Larry H. Bernstein, MD, FCAP https://pharmaceuticalintelligence.com/2016/05/02/cancer-detection-and-therapeutics/ FREE BIO-IT WORLD WEBINAR: MACHINE LEARNING TO DETECT CANCER VARIANTS Reporter: Stephen J. Williams, PhD https://pharmaceuticalintelligence.com/2016/05/04/free-bio-it-world-webinar-machine-learning-to-detect-cancer-variants/ ARTIFICIAL INTELLIGENCE: GENOMICS & CANCER https://pharmaceuticalintelligence.com/ai-in-genomics-cancer/ PREMALATA PATI, PHD, POSTDOC IN BIOLOGICAL SCIENCES, MEDICAL TEXT ANALYSIS WITH MACHINE LEARNING https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/premalata-pati-phd-postdoc-in-pharmaceutical-sciences-medical-text-analysis-with-machine-learning/ Posted in Artificial Intelligence in CANCER,
Cancer - General
, CANCER
BIOLOGY & Innovations in Cancer Therapy,
Cancer Genomics
,
Cancer Screening
,
Clinical Genomics
,
CRISPR/Cas9 & Gene Editing,
Genetics & Innovations in Treatment,
Machine Learning
,
Mutant Gene Expression,
Personalized and Precision Medicine & Genomic Research,
Precision Cancer Medicine | Tagged Artificial intelligence,
Cancer , Cancer
prognosis prediction,
cancer progression
,
computational algorithm,
driver gene ,
Machine Learning
| Leave
a Comment »
THRIVING VACCINES AND RESEARCH: WEIZMANN INSTITUTE CORONAVIRUS RESEARCH DEVELOPMENT May 4, 2021 by Amandeep Kauri
1 Vote
THRIVING VACCINES AND RESEARCH: WEIZMANN INSTITUTE CORONAVIRUS RESEARCH DEVELOPMENT REPORTER: AMANDEEP KAUR, B.SC., M.SC. > In early February, Prof. Eran Segal updated in one of his tweets and > mentioned that “We say with caution, the magic has started.” The article reported that this statement by Prof. Segal was due to decreasing cases of COVID-19, severe infection cases and hospitalization of patients by rapid vaccination process throughout Israel. Prof. Segal emphasizes in another tweet to remain cautious over the country and informed that there is a long way to cover and searching for scientific solutions.*
COVID-19 Vaccine
Image source:
https://www.jhsph.edu/covid-19/articles/a-top-vaccine-expert-answers-important-questions-about-a-covid-19-vaccine.html A daylong webinar entitled “COVID-19: The epidemic that rattles the world” was a great initiative by Weizmann Institute to share their scientific knowledge about the infection among the Israeli institutions and scientists. Prof. Gideon Schreiber and Dr. Ron Diskin organized the event with the support of the Weizmann Coronavirus Response Fund and Israel Society for Biochemistry and Molecular Biology. The speakers were invited from the Hebrew University of Jerusalem, Tel-Aviv University, the Israel Institute for Biological Research (IIBR), and Kaplan Medical Center who addressed the molecular structure and infection biology of the virus, treatments and medications for COVID-19, and the positive and negative effect of thepandemic.
The article reported that with the emergence of pandemic, the scientists at Weizmann started more than 60 projects to explore the virus from different range of perspectives. With the help of funds raised by communities worldwide for the Weizmann Coronavirus Response Fund supported scientists and investigators to elucidate the chemistry, physics and biology behind SARS-CoV-2 infection. Prof. Avi Levy, the coordinator of the Weizmann Institute’s coronavirus research efforts, mentioned “The vaccines are here, and they will drastically reduce infection rates. But the coronavirus can mutate, and there are many similar infectious diseases out there to be dealt with. All of this research is critical to understanding all sorts of viruses and to preempting any future pandemics.” THE FOLLOWING ARE FEW IMPORTANT PROJECTS WITH RECENT UPDATES REPORTEDIN THE ARTICLE.
MAPPING A HIJACKER’S METHODS Dr. Noam Stern-Ginossar studied the virus invading strategies into the healthy cells and hijack the cell’s systems to divide and reproduce. The article reported that viruses take over the genetic translation system and mainly the ribosomes to produce viral proteins. Dr. Noam used a novel approach known as ‘ribosome profiling’ as her research objective and create a map to locate the translational events taking place inside the viral genome, which further maps the full repertoire of viral proteins produced inside the host. She and her team members grouped together with the Weizmann’s de Botton Institute and researchers at IIBR for Protein Profiling and understanding the hijacking instructions of coronavirus and developing tools for treatment and therapies. Scientists generated a high-resolution map of the coding regions in the SARS-CoV-2 genome using ribosome-profiling techniques, which allowed researchers to quantify the expression of vital zones along the virus genome that regulates the translation of viral proteins. The study published in Nature in January, explains the hijacking process and reported that virus produces more instruction in the form of viral mRNA than the host and thus dominates the translation process of the host cell. Researchers also clarified that it is the misconception that virus forced the host cell to translate its viral mRNA more efficiently than the host’s own translation, rather high level of viral translation instructions causes hijacking. This study provides valuable insights for the development of effective vaccines and drugs against theCOVID-19 infection.
LIKE CHUTZPAH, SOME THINGS DON’T TRANSLATE Prof. Igor Ulitsky and his team worked on untranslated region of viral genome. The article reported that “Not all the parts of viral transcript is translated into protein- rather play some important role in protein production and infection which is unknown.” This region may affect the molecular environment of the translated zones. The Ulitsky group researched to characterize that how the genetic sequence of regions that do not translate into proteins directly or indirectly affect the stability and efficiency of the translating sequences. Initially, scientists created the library of about 6,000 regions of untranslated sequences to further study their functions. In collaboration with Dr. Noam Stern-Ginossar’s lab, the researchers of Ulitsky’s team worked on Nsp1 protein and focused on the mechanism that how such regions affect the Nsp1 protein production which in turn enhances the virulence. The researchers generated a new alternative and more authentic protocol after solving some technical difficulties which included infecting cells with variants from initial library. Within few months, the researchers are expecting to obtain a more detailed map of how the stability of Nsp1 protein production is getting affected by specific sequences of the untranslated regions. THE LANDSCAPE OF ELIMINATION The article reported that the body’s immune system consists of two main factors- HLA (Human Leukocyte antigen) molecules and T cells for identifying and fighting infections. HLA molecules are protein molecules present on the cell surface and bring fragments of peptide to the surface from inside the infected cell. These peptide fragments are recognized and destroyed by the T cells of the immune system. Samuels’ group tried to find out the answer to the question that how does the body’s surveillance system recognizes the appropriate peptide derived from virus and destroy it. They isolated and analyzed the ‘HLA peptidome’- the complete set of peptides bound to the HLA proteins from inside the SARS-CoV-2 infected cells. After the analysis of infected cells, they found 26 class-I and 36 class-II HLA peptides, which are present in 99% of the population around the world. Two peptides from HLA class-I were commonly present on the cell surface and two other peptides were derived from coronavirus rare proteins- which mean that these specific coronavirus peptides were marked for easy detection. Among the identified peptides, two peptides were novel discoveries and seven others were shown to induce an immune response earlier. These results from the study will help to develop new vaccines against new coronavirusmutation variants.
GEARING UP ‘CHAIN TERMINATORS’ TO BATTLE THE CORONAVIRUS Prof. Rotem Sorek and his lab discovered a family of enzymes within bacteria that produce novel antiviral molecules. These small molecules manufactured by bacteria act as ‘chain terminators’ to fight against the virus invading the bacteria. The study published in Nature in January which reported that these molecules cause a chemical reaction that halts the virus’s replication ability. These new molecules are modified derivates of nucleotide which integrates at the molecular level in the virus and obstruct the works. Prof. Sorek and his group hypothesize that these new particles could serve as a potential antiviral drug based on the mechanism of chain termination utilized in antiviral drugs used recently in the clinical treatments. Yeda Research and Development has certified these small novel molecules to a company for testing its antiviral mechanism against SARS-CoV-2 infection. Such novel discoveries provide evidences that bacterial immune system is a potential repository of many natural antiviral particles. RESOLVING BORDERLINE DIAGNOSES Currently, Real-time Polymerase chain reaction (RT-PCR) is the only choice and extensively used for diagnosis of COVID-19 patients around the globe. Beside its benefits, there are problems associated with RT-PCR, false negative and false positive results and its limitation in detecting new mutations in the virus and emerging variants in the population worldwide. Prof. Eran Elinavs’ lab and Prof. Ido Amits’ lab are working collaboratively to develop a massively parallel, next-generation sequencing technique that tests more effectively and precisely as compared to RT-PCR. This technique can characterize the emerging mutations in SARS-CoV-2, co-occurring viral, bacterial and fungal infections and response patterns in human. The scientists identified viral variants and distinctive host signatures that help to differentiate infected individuals from non-infected individuals and patients with mild symptoms and severesymptoms.
In Hadassah-Hebrew University Medical Center, Profs. Elinav and Amit are performing trails of the pipeline to test the accuracy in borderline cases, where RT-PCR shows ambiguous or incorrect results. For proper diagnosis and patient stratification, researchers calibrated their severity-prediction matrix. Collectively, scientists are putting efforts to develop a reliable system that resolves borderline cases of RT-PCR and identify new virus variants with known and new mutations, and uses data from human host to classify patients who are needed of close observation and extensive treatment from those who have mild complications and can be managed conservatively. MOON SHOT CONSORTIUM REFINING DRUG OPTIONS The ‘Moon shot’ consortium was launched almost a year ago with an initiative to develop a novel antiviral drug against SARS-CoV-2 and was led by Dr. Nir London of the Department of Chemical and Structural Biology at Weizmann, Prof. Frank von Delft of Oxford University and the UK’s Diamond Light Source synchroton facility. To advance the series of novel molecules from conception to evidence of antiviral activity, the scientists have gathered support, guidance, expertise and resources from researchers around the world within a year. The article reported that researchers have built an alternative template for drug-discovery, full transparency process, which avoids the hindrance of intellectual property and red tape. The new molecules discovered by scientists inhibit a protease, a SARS-CoV-2 protein playing important role in virus replication. The team collaborated with the Israel Institute of Biological Research and other several labs across the globe to demonstrate the efficacy of molecules not only in-vitro as well as in analysis against live virus. Further research is performed including assaying of safety and efficacy of these potential drugs in living models. The first trial on mice has been started in March. Beside this, additional drugs are optimized and nominated for preclinical testing as candidate drug.SOURCE:
https://www.weizmann.ac.il/WeizmannCompass/sections/features/the-vaccines-are-here-and-research-abounds OTHER RELATED ARTICLES WERE PUBLISHED IN THIS OPEN ACCESS ONLINE SCIENTIFIC JOURNAL, INCLUDING THE FOLLOWING: IDENTIFICATION OF NOVEL GENES IN HUMAN THAT FIGHT COVID-19 INFECTION Reporter: Amandeep Kaur, B.Sc., M.Sc. (ept. 5/2021) https://pharmaceuticalintelligence.com/2021/04/19/identification-of-novel-genes-in-human-that-fight-covid-19-infection/ FIGHTING CHAOS WITH CARE, COMMUNITY TRUST, ENGAGEMENT MUST BE CORNERSTONES OF PANDEMIC RESPONSE Reporter: Amandeep Kaur, B.Sc., M.Sc. (ept. 5/2021) https://pharmaceuticalintelligence.com/2021/04/13/fighting-chaos-with-care/ T CELLS RECOGNIZE RECENT SARS-COV-2 VARIANTS Reporter: Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2021/03/30/t-cells-recognize-recent-sars-cov-2-variants/ NEED FOR GLOBAL RESPONSE TO SARS-COV-2 VIRAL VARIANTS Reporter: Aviva Lev-Ari, PhD, RN https://pharmaceuticalintelligence.com/2021/02/12/need-for-global-response-to-sars-cov-2-viral-variants/ MECHANISTIC LINK BETWEEN SARS-COV-2 INFECTION AND INCREASED RISK OF STROKE USING 3D PRINTED MODELS AND HUMAN ENDOTHELIAL CELLS Reporter: Adina Hazan, PhD https://pharmaceuticalintelligence.com/2020/12/28/mechanistic-link-between-sars-cov-2-infection-and-increased-risk-of-stroke-using-3d-printed-models-and-human-endothelial-cells/ Posted in Academic Publishing,
Advanced Drug Manufacturing Technology,
Biomarkers & Medical Diagnostics,
Clinical Diagnostics,
coronavirus
,
Coronavirus Gene Expression,
COVID-19 ,
COVID-19
,
Diagnostics and Lab Tests,
Disease Biology
,
Disease Biology, Small Molecules in Development of Therapeutic Drugs,
Drug Development Process,
Health in Israel
,
Human Immune System in Health and in Disease,
Infectious Disease Immunodiagnostics,
Mechanisms of infection by SARS-CoV-2,
Mutant Gene Expression,
New Drug Approval
,
Next Generation Sequencing (NGS),
number of asymptomatic infections,
Patient-centered Medicine,
Proteosome
,
SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus,
SARS-CoV-2
,
SARS-CoV-2 circulating variants,
SARS-CoV-2 Viral Variants,
SARS-COV2 Hijacking the Complement and Coagulation Systems,
Small Molecules in Development of Therapeutic Drugs,
T-cell response to SARS-CoV-2 infection,
Translational Research,
Treatment Protocols for COVID-19,
Vaccinology
,
Viral diseases
,
Virology
,
Virology
,
virology
, Virtual
Drug Molecule Screening targeting SAR-CoV-2 proteins | Tagged antiviral vaccine,
Coronavirus Vaccines,
COVID-19 SARS-CoV-2
,
Drug development
, HLA
, mapping the genome, mRNA
vaccines ,
next generation sequencing,
Nsp1 , Pandemic
, Protein
profiling
,
RT-PCR ,
Untranslated regions,
viral protein
, Virus
replication
,
Weizmann Coronavirus Research | Leave a Comment »Older Posts »
*
FOLLOW BLOG VIA EMAIL Enter your email address to follow this blog and receive notifications of new posts by email. Join 2,623 other followersEmail Address:
Follow
*
RECENT POSTS
* Developing Machine Learning Models for Prediction of Onset ofType-2 Diabetes
May 29, 2021
* Renal tumor macrophages linked to recurrence are identified using single-cell protein activity analysisMay 27, 2021
* The collaboration between National Center for Advancing Translational Sciences (NCATS) at NIH and BurstIQMay 26, 2021
* C.D.C. Reviewing Cases of Heart Problem in Youngsters After Getting Vaccinated and AHA Reassures that Benefits Overwhelm the Risksof Vaccination
May 25, 2021
* e-Proceedings for 2021 World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021May 22, 2021
* 2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021May 22, 2021
* COVID vaccines by Pfizer, AstraZeneca are probed in Europe after reports of heart inflammation, rare nerve disorderMay 14, 2021
* Nir Hacohen and Marcia Goldberg, Researchers at MGH and the Broad Institute identify protein “signature” of severe COVID-19May 4, 2021
* Machine Learning (ML) in cancer prognosis prediction helps the researcher to identify multiple known as well as candidate cancerdiver genes
May 4, 2021
* Thriving Vaccines and Research: Weizmann Institute Coronavirus Research DevelopmentMay 4, 2021
*
ARCHIVES
Archives Select Month May 2021 (10) April 2021 (8) March 2021 (15) February 2021 (17) January 2021 (20) December 2020 (10) November 2020 (12) October 2020 (26) September 2020 (17) August 2020 (22) July 2020 (27) June 2020 (33) May 2020 (26) April 2020 (42) March 2020 (22) February 2020 (11) January 2020 (7) December 2019 (20) November 2019 (13) October 2019 (11) September 2019 (3) August 2019 (8) July 2019 (25) June 2019 (47) May 2019 (40) April 2019 (27) March 2019 (29) February 2019 (17) January 2019 (50) December 2018 (14) November 2018 (17) October 2018 (18) September 2018 (17) August 2018 (8) July 2018 (20) June 2018 (22) May 2018 (17) April 2018 (12) March 2018 (20) February 2018 (26) January 2018 (16) December 2017 (6) November 2017 (20) October 2017 (13) September 2017 (16) August 2017 (16) July 2017 (19) June 2017 (20) May 2017 (32) April 2017 (21) March 2017 (10) February 2017 (24) January 2017 (21) December 2016 (43) November 2016 (8) October 2016 (40) September 2016 (67) August 2016 (59) July 2016 (75) June 2016 (37) May 2016 (95) April 2016 (152) March 2016 (175) February 2016 (196) January 2016 (139) December 2015 (90) November 2015 (287) October 2015 (237) September 2015 (115) August 2015 (96) July 2015 (63) June 2015 (44) May 2015 (53) April 2015 (76) March 2015 (95) February 2015 (83) January 2015 (75) December 2014 (75) November 2014 (88) October 2014 (135) September 2014 (117) August 2014 (88) July 2014 (88) June 2014 (109) May 2014 (60) April 2014 (85) March 2014 (58) February 2014 (72) January 2014 (107) December 2013 (104) November 2013 (136) October 2013 (62) September 2013 (32) August 2013 (46) July 2013 (74) June 2013 (110) May 2013 (112) April 2013 (86) March 2013 (92) February 2013 (63) January 2013 (63) December 2012 (46) November 2012 (71) October 2012 (84) September 2012 (82) August 2012 (122) July 2012 (59) June 2012 (34) May 2012 (46) April 2012 (2)*
CATEGORIES
Categories Select Category 3D Printing for Medical Application (213) 3D Plotting Scaffolds (42) BioInks (33) Biopolymer Blend Open Porous (17) Dental Applications (10) BioPrinting in Regenerative Medicine (65) Cell Level (10) MicroEngineering Cell-Tissue & Systems (23) Tissue Engineering (32) Cardiovascular and Vascular Systems (23) Artificial Vascular Structures (7) Cardiovascular Tissue (7) Drug Development using MultiOrgan Chip (11) Drug Development/Formulation using 3D Printing (7) MEMS (14) Bio-MEMS (10) Organ-on-a-Chip (9) Programmable Sensors (Carbon Nano Tubes) (5) 3rd Party IP: Drug DIscovery (1) 4D Printing and Meta Materials (8) Academic Publishing (214) Key Opinion Leaders in eScientific Publishing – Interviews with (6) Advanced Drug Manufacturing Technology (89) Antimalarial Preparation (7) Autologous Cell Therapy (11) Automated Cell Processing (11) Allergy and Infectious Diseases (10) Alzheimer’s Disease (154) Etiology (75) Medical Device Therapies for Altzheimer’s Disease (13) Pharmacotherapy and Cell Activity (48) Anticancer Resistance (27) Aortic Valve: TAVR (4) Art Exhibits on the Human Condition (1) Art Inspires Science (3) Artificial Heart (2) Artificial Intelligence – General (129) An executive’s guide to AI (8) Artificial Intelligence – Breakthroughs in Theories and Technologies (64) Artificial Intelligence Applications in Health Care (63) Artificial Intelligence in CANCER (17) Artificial Intelligence in Health Care – Tools & Innovations (36) Artificial Intelligence in Medicine – Application for Diagnosis (40) Artificial intelligence applications for cardiology (20) AI-assisted Cardiac MRI (8) Artificial Intelligence in Psychiatry (5) Deep Learning in Pathology (10) Artificial Intelligence in Medicine – Applications in Therapeutics (30) Machine Learning (9) Natural Language Processing (NLP) (5) Machine learning in predicting type 2 diabetes (1) Auditory and vision (11) Autism Spectrum Disorders (10) Autoimmune Inflammatory DIseases (17) Crohn’s disease (4) Tolerance-inducing Autoimmune Disease Therapeutics (2) Ulcerative Colitis (3) Autophagosome (2) Bacterial Resistance (23) Behavior (22) Behavioral Genetics (19) Big Data (62) Intelligent Information Systems (38) Bio Instrumentation in Experimental Life Sciences Research (359) Analytical Instruments Industry (3) Microfuidics (6) Bio-Ethics (8) BioBanking (29) Biodegradable Drug-eluting Material (7) Bioengineering & reverse engineering design (40) BioIT: BioInformatics (117) BioIT: BioInformatics, NGS, Clinical & Translational, Pharmaceutical R&D Informatics, Clinical Genomics, Cancer Informatics (95) Advanced Computing Platform (10) Blockchain Transactions System (2) Pancreatic adenocarcinoma classifier (3) Simulation Modeling in NGS (1) Biological Engineering (35) Biological Networks (175) Biological Networks, Gene Regulation and Evolution (462) Virology (8) Biomarkers & Medical Diagnostics (553) VOC – Volatile Organic Compounds as BioMarkers (1) Biomedical Measurement Science (168) BioSimilars (107) BioTechnology – Venture Creation (120) Foundations for supporting Science and Education (12) Philanthropy to Academic Institution (2) BioTechnology – Venture Creation, Venture Capital (101) Seeking Talent (3) BiVAD (1) Blindness (6) Bone Disease and Musculoskeletal Disease (78) Brain Basis of Emotion (4) Business Career Consideration (1) Ca2+ triggered activation (58) Calcium (17) Calcium Signaling (66) Calmodulin Kinase and Contraction (33) Cancer – General (162) Cancer and Current Therapeutics (382) interventional oncology (39) Breast Cancer – impalpable breast lesions (17) Prostate Cancer: Monitoring vs Treatment (7) CANCER BIOLOGY & Innovations in Cancer Therapy (1,061) Anaerobic Glycolysis (51) Cachexia (18) Cancer Genomics (54) Circulating Tumor Cells (CTC) (15) Liquid Biopsy Chip detects an array of metastatic cancer cell markers in blood (12) mRNA (4) MagSifter chip (1) KRAS Mutation (3) Li-fraumeni syndrome. (2) TP53 – Germline mutations (3) cancer metabolism (15) Funding Opportunities for Cancer Research (10) Genomic Expression (135) Glioblastoma (6) Hexokinase (14) Loss of function gene (14) Metabolic Immuno-Oncology (11) Metastasis Process (8) Methylation (29) Microbiome and Responses to Cancer Therapy (5) Monoclonal Immunotherapy (26) mtDNA (13) Oxidative phosphorylation (55) Pancreatic cancer (9) Pyruvate Kinase (27) The NCI Formulary (1) tumor microenvironment (11) Warburg effect (49) Cancer Informatics (88) Cancer Prevention: Research & Programs (124) Cancer Screening (99) Cancer Vaccines: Targeting Cancer Genes for Immunotherapy (23) Engineering Enhanced Cancer Vaccines (3) Cardiac and Cardiovascular Surgical Procedures (289) Aortic Valve: TAVR, TAVI vs Open Heart Surgery (81) Prosthesis-Patient Mismatch (PPM) in TAVI vs SAVR (1) TAVI vs Open Heart Surgery (4) Valve-in-Valve Procedure (3) Atrial Fibrilation (a-Fib), Cardiac Pacing and Arrhythmias (12) BackBeat’s Cardiac Neuromodulation Therapy (CNT) bioelectronic therapy (1) CABG (43) Cancer Surgery of the Heart (10) Cardiovascular Fluid Management: algorithms (1) Heart Transplant (13) Heart-Lung Transplant (8) Implantation (1) Left Main Coronary Artery Disease (LMCAD) (3) Mechanical Assist Devices: LVAD, RVAD, BiVAD, Artificial Heart (19) Mitral Valve: Repair and Replacement (58) TMVR – Transcatheter Mitral Valve Repair (2) PCI (94) Bioresorbable Vascular Scaffold (BVS) (3) Robotic-assisted percutaneous coronary intervention (1) Stent Retriever in endovascular thrombectomy (1) Peripheral Arterial Disease & Peripheral Vascular Surgery (57) Abdominal Aorta (19) Carotid Artery (15) Thoracic Aorta (15) Pulmonary Valve Replacement and Repair (1) Renal Denervation (20) Replacement (1) Tricuspid Valve Repair (5) Vena Caval Filters: Device for Prevention of Pulmonary Embolism and Thrombosis (1) Cardiovascular Pharmacogenomics (168) Cargo (3) Cell Biology (304) Cell Biology, Signaling & Cell Circuits (639) Apoptosis (11) Autophagy-Modulating Proteins (3) “Antibody–enzyme conjugates” (3) Cell Processing System in Cell Therapy Process Development (17) Endoplasmic reticulum (2) Enzymatic mechanism underlying the synthesis of adenosine triphosphate (ATP) (1) Ubiquitin (5) Cerebrovascular and Neurodegenerative Diseases (112) Stroke (3) Chemical Biology and its relations to Metabolic Disease (454) #BIGAxisSummit (1) Gut Microbiome and Obesity (7) Chemical Genetics (346) Child and Adolescent Psychiatry (13) Childhood cancer (12) Childhood malnutrition (3) Circulating Progenitor Cells (27) Bone marrow derived cells (17) Endothelial cells (7) Umbilical cord cells (6) Clinical & Translational (232) Clinical Diagnostics (211) Mass automation of plasma proteins (13) Clinical Genomics (131) Coagulation Therapy and Internal Bleeding (80) Cognition (41) Commercialization (19) Components and IRB related issues (4) Computational Biology/Systems and Bioinformatics (460) Computational Histopathology (1) Meta-analysis of transcriptome data (8) Conference Coverage with Social Media (452) MassBio (3) coronavirus (13) COVID-19 (14) CRISPR/Cas9 & Gene Editing (180) CRISPR alternative for editing genes without cutting (13) CAST – Alternative to CRISPR/Cas9 (3) Transposon-encoded CRISPR–Cas systems direct RNA-guided DNA integration (4) CRISPR applied to Human Germ Line (9) Gene Editing Impact on Longevity (4) CT (18) Cytokines (19) Cytoskeleton (83) Developmental biology (104) Diabetes Mellitus (139) Artificial Pancreas for Type1 Diabetes (4) Gestational diabetes (2) Diagnostic Immunology (54) Diagnostics and Lab Tests (119) Liquid Biopsy: Circulating Tumor Cells in Urine and Blood (8) Digital HealthCare – biotech & internet joint ventures (37) Disease Biology (318) Disease Biology, Small Molecules in Development of Therapeutic Drugs (477) DNA repair (58) Apoptosis (11) Autophagy (10) Cell death pathways (15) Proteolysis (7) Proteosome (6) Drug Delivery Platform Technology (147) Drug Carrier Design (15) Medication Remote Compliance Monitoring (3) Exosomes: Natural Carriers for siRNA Delivery (8) Drug Toxicity (74) Ecosystems & Industrial Concentration in the Medical Device Sector (172) Cardiac & Vascular Repair Tools Subsegment (128) Exec Compensation in the Cardiac & Vascular Repair Tools Subsegment (14) Massachusetts Niche Suppliers and National Leaders (20) Electronic Health Record (8) Embryology (24) Empathy (6) Endocrine Diseases (58) Enzyme Induction (42) ion-transporting enzyme (1) K + -ATPase. (1) Na + (1) Epigenetics and Environmental Factors (22) Ethics and Leadership (9) Executive Compensation – Big Pharma (3) Fat soluble vitamins (4) FDA (64) FDA Regulatory Affairs (350) FDA, CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP, GLP, ISO 14155 (50) ISO 10993 for Product Registration: FDA & CE Mark for Development of Medical Devices and Diagnostics (30) Fetal Ultrasound (1) Fiction and medicine (4) Frontiers in Cardiology and Cardiovascular Disorders (822) Acute Myocardial Infarction (48) Cardiogenic Shock (3) Anemia in CVD Patients (6) Cardio-Oncology (3) Cardiomyopathy (53) Cardiovascular Research (163) Myocardial metabolism, Myocardial ischemia, Myocardial adenine nucleotide metabolism (43) Pre-Clinical Animal Model Development (23) Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Pulmonary Arterial Hypertension (PAH) (19) Cost of Inpatient Stay for Cardiovascular Diagnosis for Admission (1) Electrophysiology (99) Ablation Procedure vs Drug Therapy (1) Arrhythmia Detection with Machine Learning Algorithms (5) Cardiotoxic Risks of Immune Checkpoint Inhibitors (1) Genomic Analysis of EKG Electrophysiology Genomics (2) implantable cardioverter defibrillator (ICD) and External Defibrillation (1) implantable pacemaker (2) Rare heart rhythm disorders and Long QT syndrome (LQTS) (5) Epigenetics and Cardiovascular Risks (55) Heart Failure (HF) (33) Acute coronary syndrome (5) congestive heart failure (17) Medical Devices R&D and Inventions (201) Assist Devices: LV (3) RV (1) Stents & Tools (87) Valves & Tools (63) Origins of Cardiovascular Disease (402) Atherogenic Processes & Pathology (166) Congenital Heart DIsease (34) Genetic Mutations in Congenital Heart DIsease (4) inflammation independent of lipid levels (10) Systemic Inflammatory Diseases as CVD Risk (9) Pharmacotherapy of Cardiovascular Disease (328) HTN (155) HTN in Youth (7) Resident-cell-based (42) Subarachnoid Hemorrhage (SAH) (1) Transthyretin amyloid cardiomyopathy (ATTR-CM) (1) Spontaneous Coronary Artery Dissection (SCAD) (6) Stroke (6) endovascular thrombectomy (2) Vascular Diseases (11) Future Pandemics Inform-graphics (1) Gastroenterology (36) Gene Regulation (219) Gene Regulation and Evolution (130) Genetics & Innovations in Treatment (163) Genetics & Pharmaceutical (193) Genome Biology (929) Exosomes (22) Gene Therapy & Gene Editing Development (32) mRNA Therapeutics (15) Mutagenesis (25) Single Cell Genomics (20) Single-cell sequencing (15) Variation in human protein-coding regions (23) Genomic Endocrinology (38) Genomic Testing: Methodology for Diagnosis (408) Genomics Pharmacy (36) Global Market of Medical Devices Technology (1) Global Medical Publishers by Country (1) Global Partnering & Biotech Investment (43) GLP (4) Glycobiology: Biopharmaceutical Production (12) Glycobiology: Biopharmaceutical Production, Pharmacodynamics and Pharmacokinetics (25) Health Care System by Country (35) AI Models in Healthcare (1) Centers for Medicare & Medicaid Services (6) Health in Israel (2) United States (17) Hospital-based Medical Innovations (7) Medical Recertification and Maintenance of Certification (MOC) (1) Health Economics and Outcomes Research (369) Women Health (10) Heart and Brain Disease in Women (3) Health Law & Patient Safety (154) and Bioethics (10) Biotechnology (8) Health Law Policy (5) HealthCare IT (127) Healthcare Reform (104) Accountable Care Organizations (24) Affordable Care Act (28) Repair (1) Repeal ACA (1) Replace (1) Federal Budget Appropriations (23) Healthcare costs and reimbursement (52) Indigent Nutrition (13) Medicare and Medicaid (20) Prescription Drugs Costs (19) Skilled Nursing Facilities (6) Technology Capital Expenses (14) Uninsured and Underinsured (19) Hematology (96) Acute lymphocytic leukemia (18) Acute myelocytic leukemia (21) Hematopoiesis (48) Lymphoma (21) History and physical exam (6) Human aging (26) Human Immune System in Health and in Disease (233) Human Sensation and Cellular Transduction: Physiology and Therapeutics (20) Image Processing/Computing (40) Imaging-based Cancer Patient Management (116) Immuno-Oncology & Genomics (120) mRNA platform in Drug DIscovery (5) Immunodiagnostics (121) Cancer-Immune Interactions (16) CNS-Immune Interface (3) Neuronal Circuits (4) Immunology (98) Adaptive Immune Response to Biomaterials and Tissue Repair (8) Antibody Responses Predict Antigen Exposure (10) Cytokine Receptor Structure (6) Human Antibody Response (13) Human Circulating Antibody Repertoire (9) Human Naive B Cell Repertoire (8) MHC Repertoires for Antigen Prediction (8) Protection Against Autoimmune Disease (7) Synthetic Immunology: Hacking Immune Cells (12) Immunotherapy (110) CAR-T (13) combination immunotherapies. (10) Efficacy of Anti-Tumor T Cells (8) Engineering Better T Cells (7) Immune Engineering (12) Immune Modulatory (11) Integrin-targeted Combination Immunotherapy (5) Modulating Macrophages in Cancer Immunotherapy (10) NK Cell-Based Cancer Immunotherapy (14) Synergistic Innate and Adaptive Immunotherapy (12) Income Disparity (2) Infectious Disease & New Antibiotic Targets (151) Antibiotic resistance (4) Viral diseases (30) Myocarditis (1) Infectious Disease Immunodiagnostics (48) Virology – Vector-borne DIsease (12) Inflammasome (26) Anti-tumor necrosis factor drugs (TNF inhibitors) (2) Innovation in Immunology Diagnostics (102) Universal Immune Cell Therapies (uICT) (8) Innovations (174) R&D Expenditure (2) Innovations in Neurophysiology & Neuropsychology (131) Age and Life Expectancy (1) autism spectrum disorder (1) Circadian Rhythm and Sleep (6) hNPCs (1) Nervous System Function (1) Relapsing Multiple Sclerosis (1) Intellectual Property (72) Disputes and Settlements (8) IP Valuation Models – Pricing Intangible Assets (3) Patent Law in Biotech (11) Intellectual Property, Innovations, Commercialization, Investment in technological breakthrough (102) International Global Work in Pharmaceutical (187) Interventional Oncology: Radiofrequency Ablation, Transarterial Chemoembolization, Microwave Ablation and Irreversible Electroporation (IRE) (12) Interviews with Scientific Leaders (283) Albany Medical Center Prize in Medicine and Biomedical Research (1) Annual Breakthrough Prize (2) Annual Lewis S. Rosenstiel Award (1) Awards in Cardiology and Cardiovascular Medicine (3) CEOs of Biotech Companies (1) Gerald D Aurbach Award for Outstanding Translational Research (1) Interviews with Key Opinion Leaders (KOLs) (6) James Prize in Science and Technology Integration (1) Jessie Stevenson Kovalenko Medal – Medical Sciences (1) Lemelson-MIT Prize (1) Life Sciences Breakthrough Prize (2) Mosteller Statistician of the Year Award (1) Mourning the Loss of a Scientific Leader (2) National Academy of Sciences AWARDS (2) Nobel Prize WInners (15) Noble Prize (Not Nobel Prize) (1) Paul Marks Prize for Cancer Research (1) Russ Prize recognizes bioengineering achievements worldwide (1) The Dan David Prize (5) Warren Alpert Foundation Prize Recipients (3) Wolf Prize (1) Wolf Prize in Medicine (1) women in science (3) Investment in Technological Breakthrough (56) Ionic Transporters Na+ (25) IP Development by LPBI Group Team (8) IP Development by LPBI Group Team & Other Organizations (5) ISO 14155 (3) Joint Venture – SBH & M3DP: SOP and Arrangements (1) Justice & Law (1) K (15) Lab-on-a-chip (2) Landscape (1) Lasers and photonics (18) Midrange IR spectroscopy (1) Law and Medicine Conflicts (12) Leadership, Power, Social Interlocking Connections (12) Lipid metabolism (108) Fatty acids (37) Lipids (37) PCSK9 Inhibitor Therapy (19) Lipidomics (10) Liposome (3) Liver & Digestive Diseases Research (117) LPBI Group, e-Scientific Media, DFP, R&D-M3DP, R&D-Drug Discovery, US Patents: SOPs and Team Management (109) Award Nominations (5) BioMed e-Books e-Series by LPBI Group (6) Feedback from Investors: LPBI Portfolio of Five Businesses (2) LPBI Group Founder – Aviva Lev-Ari (16) PhD (1) RN (1) LPBI Management (5) Massachusetts Academy of Sciences (MAS) (2) Materials Science & Engineering (31) Math (13) Great Discoveries (7) Mechanical Assist Devices: LVAD (4) Medical and Population Genetics (190) Medical Devices R&D Investment (235) 21st Century Cures Act (2) CE Mark & Global Regulatory Affairs: process management and strategic planning – GCP (13) Rhythm management device hardware: dual-chamber pacemakers (1) Systolic HTN (1) Medical Imaging Technology (51) Medical Imaging Technology, Image Processing/Computing, MRI, CT, Nuclear Medicine, Ultra Sound (151) Circumferential-Intravascular-Radioluminescence-Photoacoustic-Imaging (CIRPI) (2) Echocardiography (1) Invasive FFR for PCI (2) MRI (15) Noninvasive Diagnostic Fractional Flow Reserve (FFR) CT (4) Ultra Sound (7) Melatonin & Circadian Regulation (7) Metabolism (229) Biochemical pathways (137) Enzymes and isoenzymes (69) Dehydrogenase (14) Kinase (27) Phosphatase (8) Phosphorylase (21) tyrosine decarboxylases (2) Inosine nucleotides (8) Leloir pathway (6) microbiome (6) Pentose monophosphate shunt (14) Pyridine nucleotides (28) Pyridine nucleotide transhydrogenase (7) Metabolomics (315) Methods (37) Mg++ (10) Microbiologial genetics (31) Microbiology (60) Virology (12) Micronutrients (15) Microvesicle (6) Microwave Ablation and Irreversible Electroporation (IRE) (1) Mobile Healthcare (1) Molecular Genetics & Pharmaceutical (371) Organoids (3) Monoclonal antibody therapy (7) Mutant Gene Expression (41) Myocardial adenine nucleotide metabolism (5) Myocardial Ischemia (24) Myocardial Metabolism (34) Na-K transport (39) Na-K-ATPase (26) Nanotechnology for Drug Delivery (89) Nephrology (45) Nephrology & Regenerative medicine (8) Neurodegenerative Diseases (81) hNPCs (3) MS (4) Neurohumoral Transmission (64) Ca2+ triggered activation (18) Calmodulin (11) Parkinson’s disease dyskinesia levodopa (2) PKC (13) Synaptic vesicle (19) Neurological Diseases (115) Neuroscience (119) Next Generation Sequencing (NGS) (19) Nanopore sequencing (1) NIH Common Fund (1) Nitric Oxide in Health and Disease (135) Nuclear Medicine (11) Nutrigenomics (67) Nutrition (192) Nutritional Supplements: Atherogenesis, lipid metabolism (47) Nutrition and Phytochemistry (59) Minerals in Medicine (4) Plant extract (21) Nutrition Disorders (29) Nutritional Supplements: Atherogenesis (30) Obesity (17) Oligonucleotide Therapeutics & Delivery (5) Oncolytic virus & OncoViro-Therapy (18) Synthetic Virology (1) Organ-on-a-Chip & 3D Printing in Life Sciences (7) Pain: Etiology, Genetics & Innovations in Treatment (22) Parasitology (5) Malaria (4) Tropical diseases (1) Patents (32) Patient Experience (61) Art therapy (1) Hospital reputation (6) Humor (1) Music therapy (2) Pain Alleviation (7) Patient Outlook (27) Reputation of Interventionist (4) Support Staff (12) Supportive therapies (6) laughfter (1) Surgical Procedure (7) Patient Experience: Personal Memories of Invasive Medical Intervantion (30) Patient’s Voice: Personal Experience with Invasive Medical Procedures (18) Perioperative Statins at Noncardiac Surgery (1) Personal Health Applications: Tech Innovations serves HealhCare (31) Personalized and Precision Medicine & Genomic Research (703) Longevity (1) New Drug Approval (2) Patient-centered Medicine (29) cell-based therapy (6) stem cell biology and patient-specific (6) Personalized Medicine Coalition (6) Precision Cancer Medicine (15) Phagophore (1) Pharmaceutical Analytics (258) Pharmacologic toxicities (61) Pharmaceutical Discovery (100) Rapid automation of plasma protein pools (16) Pharmaceutical Drug Discovery (181) Drug Development Process (40) Drug Discovery Chemistry (19) drug repurposing (7) Pharmaceutical Industry Competitive Intelligence (331) Pharmacovigilance (5) Value-based Drug Pricing (7) Pharmaceutical R&D Informatics (41) Pharmaceutical R&D Investment (297) Pharmacodynamics and Pharmacokinetics (20) Pharmacogenomics (154) Photography Collection (1) Physics (12) Placenta (6) Population genetics (25) Population Health Management (179) Evolution of Biology Through Culture (12) U.S. Employment-to-Population Ratio (7) Population Health Management, Genetics & Pharmaceutical (598) COVID-19 (142) Biomarkers: Inflammation (34) Cancer Researchers Fighting COVID-19 (13) COVID-19 effects on Human Heart (15) COVID-19: Pandemic Surgery Guidance (17) Economic Impact of Coronavirus Pandemic (41) number of asymptomatic infections (26) Treatment Protocols for COVID-19 (56) SARS-CoV-2 (124) Coronavirus Gene Expression (54) SARS-CoV-2 circulating variants (6) SARS-CoV-2 Viral Variants (8) Glycosylation and its Role in SARS-CoV-2 Viral Pathogenesis (1) Immune-Mediation (independent immunopathology: lung and reticuloendothelial system) (25) Mechanisms of infection by SARS-CoV-2 (12) SAR-Cov-2 a vasculotropic (blood vessels) RNA Virus (32) SARS-COV2 Hijacking the Complement and Coagulation Systems (17) Seasonality & Environmental Factors in Resurgence (26) Serology tests for coronavirus antibodies (43) T-cell response to SARS-CoV-2 infection (9) Vaccinology (43) Mechanism of Thrombosis with AZ & J&J COVID-19 Vaccines (3) Virtual Drug Molecule Screening targeting SAR-CoV-2 proteins (6) Virus Infective Acute Respiratory Syndrome: SARS-CoV (86) Population Health Management, Nutrition and Phytochemistry (149) Preimplantation Genetic Diagnosis and Reproductive Genomics (9) Protein-energy malnutrition (11) Proteomics (352) Amino acids (49) Proteins (128) Pulmonary diseases (14) Lung and pulmonology (13) Pulmonary pathology (6) Radio Frequency (RF)-based Surgical Solutions (2) REAL TIME Conference Coverage Twitter’s Hashtags and Handles per Presentation/session (28) Regenerative Biology and Medicine (83) Regulated Clinical Trials: Design, Methods, Components and IRB related issues (263) Reproductive Andrology, Embryology, Genomic Endocrinology, Preimplantation Genetic Diagnosis and Reproductive Genomics (102) Reproductive Biology & Bio Instrumentation (68) RNA Biology (73) RNA interference (RNAi) therapeutic (4) RNA Biology, Cancer and Therapeutics (58) RVAD (1) SBIR, SBA, NIH, NSF (2) Schizophrenia (14) Scientific & Biotech Conferences: Press Coverage (171) Scientific Publishing (601) Curation (581) Curation methodology (37) De novo synthesis (15) Dialectic (17) Discovery process (69) Evolutionary cognition (53) Experimental validation (90) Explanatory (92) Historical relevance (71) Technology Advance Assessment of (68) Theoretic convergence (27) Open Access Journals (31) Scientist: Career considerations (191) Big Data & Analytics (13) Data Science (10) Women in Life Sciences (10) Scoop.it (18) Sensors & Analytics (16) Sepsis (2) Severe Autism (3) Signaling (95) Phosphorylation (40) S-nitrosylation (11) Ubiquitinylation (30) Signaling & Cell Circuits (124) Small Molecules in Development of Therapeutic Drugs (66) Social Development (15) Specialized 3D BioPrinters (Cornea (1) Statistical Methods for Research Evaluation (136) Stem Cells for Regenerative Medicine (171) Cardiac muscle regeneration (17) Competition in regenerative stem cell science (17) Human neural progenitor sells (6) Skeletal muscle regeneration (8) STORM (2) Stress Disorders (18) Substance Abuse (4) Systemic Inflammatory Response Related Disorders (156) Inflammatory Pathophysiology (4) Technology Transfer: Biotech and Pharmaceutical (348) Tissue Engineering and Regenerative Medicine (21) Tissue Microenvironment (3) Transarterial Chemoembolization (2) Transcriptomics (41) Transformative Technologies in Healthcare (10) Translational Science (217) Best evidence (52) Bias measurement tools (2) Evidence-based decision-making (26) Inferential analysis (25) Intra-rater error (1) Quality Assurance (8) Random Error (2) Systematic Error (Bias) (5) Total error (2) Translational Effectiveness (49) Translational Research (85) Trends in Global Economy (3) Uncategorized (1,328) Unfolded Protein Response (UPR) (4) US and Global Economy: Trends and Findings (6) Venture Capital (41) Income Geographic Distribution (2) Institutional Capital Raised by Female Founders (4) virology (4) Vision (6) Voices of Patients and Healthcare Providers (19) Water Transporters (7) Wearable Tech + Digital Health (3) Anemia (21) Neutropenia (8) Neutrophilia (9) Platelet count disorder (9) Folate and B12 (7) Iron deficiency (5) Myelodysplasia (12) Myelofibrosis (10)*
META
* Register
* Log in
* Entries feed
* Comments feed
* WordPress.com
*
* 2012PHARMACEUTICAL* AMANDEEP KAUR
* AASHIR AWAN, PHD
* ADINA HAZAN
* ALAN F. KAUL, PHARMD., MS, MBA, FCCP* ALEXCRYSTAL6
* ANAMIKASARKAR
* APRECONASIA
* AVIRALVATSA
* DAVID ORCHARD-WEBB, PHD* DANUTDAAGMAILCOM
* DEMET SAG, PH.D., CRA, GCP* DANIEL MENZIN
* DROR NIR
* DSMOLYAR
* EVELINACOHN
* GAIL S THORNTON
* IRINA ROBU
* JAYZMIT48
* JDPMD
* JSHERTOK
* KELLYPERLMAN
* ED KISLAUSKIS
* LARRYHBERN
* MADISON DAVIS
* MARZANKHAN
* MEGBAKER58
* OFERMAR2020
* DR. PATI
* PKANDALA
* ROSALIND CODRINGTON, PHD* RITUSAXENA
* RICK MANDAHL
* SJWILLIAMSPA
* STUARTLPBI
* DR. SUDIPTA SAHA
* TILDABARLIYA
* ZRAVIV06
* ZS22
Blog at WordPress.com.WPThemes.
Leaders in Pharmaceutical Business Intelligence (LPBI) Group Blog at WordPress.com.Write a Comment...
Email (Required) Name (Required) WebsiteLoading Comments...
Comment
×
* FollowFollowing
* Leaders in Pharmaceutical Business Intelligence (LPBI) Group*
Already have a WordPress.com account? Log in now.*
* Leaders in Pharmaceutical Business Intelligence (LPBI) Group* Customize
* FollowFollowing
* Sign up
* Log in
* Report this content * Manage subscriptions* Collapse this bar
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0